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1. General Properties of Cancer 
Cancer is considered one of the leading cause of morbidity and mortality 
worldwide, with 14 million new cases and 8.2 million cancer-related deaths registered in 
2012 (1). The 5 most common cancers diagnosed in women in 2012 were breast, 
colorectal, lung, cervix and stomach cancer while in men these include lung, prostate, 
colorectal, stomach and liver cancer.  
Carcinogenesis is a complex multi-step process that usually proceeds over 
several years and starts from one single cell. It progressively drives normal cell evolution 
into a cell with an increasingly abnormal neoplastic phenotype. This process is the 
result of a combination of genetic and epigenetic factors determined by individual 
variability caused by hereditary predisposition, life style and other variables like 
environmental influences, infectious agents, nutritional factors, hormonal and 
reproductive factors, and exposure to physical, chemical and biological carcinogens (2). 
Tumor formation and progression is driven by a sequence of essential alterations in cell 
physiology, cell homeostasis, randomly occurring mutations and epigenetic alterations 
of DNA. These events affect genes controlling different processes, such as cell 
proliferation, differentiation and survival, and bring cancer to acquire different 
malignant capabilities that together lead to malignant growth. The genetic 
abnormalities that contribute to cancer pathogenesis generally involve two main 
mechanisms: the inactivation of negative mediators of cell proliferation (tumor 
suppressor genes) and the activation of positive mediators of cell proliferation (proto-
oncogenes) (3). 
The definition of cancer, as established nowadays by the last advances in the tumor 
biology, includes multiple characteristics and aspects, that surprisingly are already 
present in the etymology of the word itself. The word “Cancer” originates from the 
ancient Greek word “καρκίνος” (Karkìnos, “crab”) credited to the Greek physician 
Hippocrates (460-370 BC). This word was probably chosen to describe the similarities of 
solid tumors with swollen veins and spreading projections reminding the shape of a 
“crab”. Strikingly, this description includes exactly all the elements that the modern 
biology of tumors ascribe to cancer; a primary tumor mass, the presence of new vessels 
and the spreading and invasion of the neighboring tissues. Today we learned that the 
biology of tumors should be investigated not only focusing on the traits of single cancer 
cells, but also considering the contributions of the tumor microenvironment, the 
interactions between tumor cells and the supportive stroma, the role of the immune 
system and the preferential tropism of spreading tumor cells for specific metastatic 
sites. These interactions are fundamental to understand the mechanisms that lead to 
the switch from a contained disease to the aggressive spreading and metastatic phase 





by Hanahan and Weinberg as “Hallmarks of Cancer” (4) and more recently updated to 
include the supportive cellular and non-cellular microenvironment (5,6). 
 
1.1. Hallmarks of Cancer 
There is a certain series of events that have to occur to drive the transformation 
from a normal cell to a cancer cell. These events are part of a multistep process and all 
the steps involved in this process contribute progressively to the generation and 
development of cancer. The fundamental characteristics of cancer or the hallmarks of 
cancer represent the set of properties that a cell or a group of cells in general have to 
acquire to become a tumor and to interact with the surrounding stroma (5,6) (Fig. 1): 
 
Sustaining Proliferative Signaling: normal cells are constantly proliferating as part of the 
physiological turnover present in every normal tissue. However, their proliferation is 
finely tuned and regulated by multiple growth factors to maintain a proliferative rate 
appropriate for the maintenance of the homeostasis of the tissues where they home. 
These growth factors are part of a paracrine signaling and their availability or signaling 
efficacy depends also on the capability of the “receiving” normal or tumor cells to 
properly react to these stimuli. In cancer, the tumor cells can instruct the supportive 
tumor-stroma to supply growth factors (7) or acquire a “self-sustained proliferative 
signaling” resulting in an autocrine and abnormal proliferative stimulation.  
 
Evading Growth Suppressors: part of the regulation of the maintenance of the 
homeostasis of cells and tissue is determined by the suppression of the proliferation. 
Normal cells have to proliferate to generate new tissues and maintain the tissue 
integrity but also have to stop their growth to prevent abnormal hyper-proliferation. In 
cancer, tumor cells have to escape these suppressive mechanisms and have to 
circumvent the programs that negatively regulates cell proliferation. Typical alterations 
in tumor suppressor genes include the loss of function of critical “gatekeeper” of cell-
cycle progression such as pRb (Retinoblastoma 1) and p53 which regulates apoptosis 
and is a stress responsive sensor.  
 
Resisting to Cell Death: Programmed cell death, apoptosis, is one of the mechanisms in 
normal physiology that prevents cancer development and the afore mentioned p53 is 
one of the key player in this process. There are two main circuits that orchestrate 
apoptosis: one receives and process extracellular death-inducing signals (e.g. Fas and 
Fas ligand mechanism) and the other sense intracellular signals (intrinsic program). 
Both the machineries converge on the activation of a cascade of proteolytic cleavage 





strategies to avoid this programmed death. The most common feature of tumor cells 
evading apoptosis is the loss of p53; other strategies include the suppression of pro-
apoptotic factors (e.g. Bax, Puma, Bim) or the upregulation of anti-apoptotic genes (e.g. 
Bcl-2, Bcl-XL). 
 
Enabling Replicative Immortality: normal cells in healthy tissues are capable of pass 
through only a limited number of division cycles. The mechanisms that limit the number 
of growth-and-division cycles are essentially two: senescence (nonproliferative but 
viable state) and crisis (cell death). Both are linked to the length of telomeric DNA that in 
a cell dictates how many cycles of division are still available before the cell enters in a 
phase of DNA instability (i.e. crisis). It is a remarkable properties of cancer cells their 
ability to proliferate indefinitely, escaping from this control. One of the mechanisms that 
drive immortalization in tumor cells is the presence of telomerase activity, responsible 
for the integrity of telomeric DNA, detected in up to 90% of spontaneously immortalized 
cells. 
 
Inducing Angiogenesis: in every normal tissue, nutrients and oxygen are provided by a 
fully functional network of vessels, responsible also for the elimination of wastes and 
other products of the metabolism. In normal physiology, in an adult organism these 
vessels remain mostly stable and quiescent. In malignant tumors, vessel remodelling 
and new vessel formation occurs after the so-called “angiogenic switch” which cause 
the normal quiescent vasculature to sprout and produce new branches 
(neovascularization). This abnormal angiogenesis produces vessels that are 
histologically different from those formed during the physiological process. Moreover, 
highly invasive tumor cells can form fluid-conducting channels in a process defined as 
“vasculogenic mimicry” (8). The new vessels in the tumor have an aberrant morphology 
and are characterized by abnormal level of endothelial cells proliferation and apoptosis. 
In addition, the leakiness that characterize these vessels is one of the major effectors for 
the low efficiency in the delivery of therapies specifically to the tumor.  
 
Activating Invasion and Metastasis: the invasion of the surrounding tissues, the 
intravasation in blood and lymphatic vessels and the formation of distant metastasis 
represent one of the critical problem in tumor progression. In this context transformed 
epithelial cells acquire a motile mesenchymal phenotype in a process referred to as 
“epithelial to mesenchymal transition” (EMT) (9). However, cancer cell migration is not 
restricted to singly migrating cells. Different patterns of cell migration include single-cell 
migration, multicellular streaming and collective cell migration, (reviewed in (10)). The 





establishment of therapy resistance will be discussed more in details in the next 
paragraphs. 
 
Interaction with the tumor stroma: tumor cells do not behave independently from the 
rich microenvironment where they are localized and that represents an important 
component during tumor initiation, growth and progression. During cancer progression 
the stroma co-evolves with the tumor and create a dynamic signaling network of 
paracrine signals that promotes cancer. The different stromal components involved in 
this process include: cancer-associated fibroblasts (CAFs), pericytes, endothelial cells, 
immune cells and the extracellular matrix (reviewed in (6)). 
 
Metabolic reprogramming: In addition to the above mentioned specific characteristics, 
tumor cells can also adapt their metabolism and switch to the so called “aerobic 
glycolysis” converging their metabolism largely to glycolysis (i.e. Warburg-effect) (11). 
This is one of the basis of the non-invasive visualization of tumors based on positron 
emission tomography (PET) with radiolabelled analog of glucose as reporter. In 
proliferating (cancer) cells the mitochondrial metabolism is reprogrammed toward 
macromolecular synthesis to sustain multiple cell divisions, (reviewed in (12)). 
Moreover, oncogenic mutations in metabolic enzymes such as the cytosolic NADP+-
dependent isocitrate dehydrogenase 1 gene (IDH1) and the mitochondrial homolog 
IDH2 responsible for converting α-ketoglutarate to 2-hydroxyglutarate (2HG), a 
metabolite found only in reduced amounts in mammalian cells under normal conditions 
have been reported (12,13). Interestingly this has also effects on epigenetic 
mechanisms, resulting in altered histone methylation marks, hypermethylation at CpG 
islands and dysregulated cell differentiation(12). 
Moreover, it is important to note the pro-inflammatory and immunosuppressive 
properties of cancer cells. Inflammation can sustain proliferative signaling and 
inhibiting cell death, activate extracellular matrix-modifying enzymes and support 
invasion and angiogenesis (14,15). Tumor cells can also secrete immunosuppressive 
factors or recruit immunosuppressive cells, blocking the action of cytotoxic 
lymphocytes or recruit tumor associated macrophages that can enhance tumor 
progression and metastasis and suppress antitumor immunity (16-18).  
All the aspects discussed above depend, to a large extent, on genomic alterations 
in neoplastic cells. Different cells can gain different alterations and the combination of 
several alteration together will produce a cancer cell, capable of outgrow and gain a 
local dominance over other neoplastic and/or normal cells. In this perspective, tumor 
progression is characterized by the expansion of different heterogeneous clones. In this 





generating a malignant tumor. The issue of intra-tumor and inter-tumor heterogeneity 




Figure 1. Schematic representation of the hallmarks of cancer, their correlation with cancer 








1.2. Tumor Heterogeneity 
There are two main levels of complexity in tumor heterogeneity. If we consider 
the tumor mass as an independent entity, one level consists of the differences between 
different cancer types or different patients affected by the same cancer and is defined as 
inter-tumor heterogeneity (Fig. 2). Another level of heterogeneity encompasses the 
cellular differences within the same tumor (e.g. multiple cell clones with different 
properties, dispersed within the same tumor mass of the same patient) and is defined as 
intra-tumor heterogeneity (Fig. 2). Despite the fact that, overall, the evolution and 
progression of these tumor can be similar (e.g. onset of primary tumor, progression from 
benign to malignant growth, neo-angiogenesis, invasion of surrounding tissues, and 
formation of distant metastasis) there are intrinsic differences that distinguish one 
cancer from the other and, within the same cancer family, one cancer subtype to 
another (e.g. hormone-naïve or androgen-independent prostate cancer). These 
differences are part of the so-called inter-tumor heterogeneity and reflect the 
differential responsiveness to specific therapeutics and not to others. Additionally, the 
tropism for specific metastatic sites (e.g. osteotropism in prostate cancer), is also 
characteristic of certain malignancies and can be ascribed to the inter-tumor 
heterogeneity.  
The second level of complexity comprises intra-tumor heterogeneity. As already 
discussed, cancer formation is a multistep process that starts from one single cell; on 
the other hand, tumors are tissues and therefore are constituted by a variety of different 
tumor- and other-cell types. As established in the last decade by high-resolution 
genome-wide studies, the formation and progression of tumors is characterized by a 
continuous “Darwinian-like” evolution of branches of specific clones (19). This process 
of “clonal evolution” results also in the construction of a supportive tumor 
microenvironment, which is continuously being remodelled during the tumor 
progression. Different cell types contribute to increase the complexity and the 
heterogeneity of this environment. As previously mentioned, these cell types include, 
among the others, also non-malignant cells, such as immune and inflammatory cells, 
endothelial cells, pericytes, and cancer-associated fibroblast. For the purpose of this 
thesis we will mainly focus on the cancer cells and discuss the different cell types and 
subpopulation that are represented within the tumor. Macroscopic tumors are 
constituted of different subpopulation of malignant cells. Depending on environmental 
stimuli and stochastic processes, or depending on their alterations, such as mutations 
and epigenetic changes, these clones can acquire a dominant phenotype with clinically 
relevant characteristics (e.g. resistance to therapy). In this respect, the intra-tumor 
heterogeneity is one of the relevant problems in the identification of therapeutic 





and clones that maintain the cancer. Similarly, this also has an impact on studies that 








Molecular- and genetic-profiles of cancerous “bulk” tissues indeed cannot discriminate 
between the aggressive subsets of cancer cells responsible for tumor maintenance, 
growth & the development of therapy resistance and less aggressive, more 
differentiated cancer cell subpopulations. This raises the question whether the different 
clones and subpopulations present in the tumor are properly represented also in a 
transcriptional analysis between “bulk” tumor and “normal” tissues. One of the aspects 
of tumor heterogeneity, that has revolutionized the tumor biology in the last years, is 
indeed the discovery of a subpopulation of cancer cells with tissue stem-like properties, 
the cancer stem cells (CSCs). The contribution of these cells to the tumor formation and 
maintenance, metastasis, therapy resistance and their clinical relevance for the 







2. Anatomy of the Prostate 
The prostate is a walnut-sized exocrine gland, well encapsulated and positioned 
in the pelvic cavity inferior of the bladder (it surrounds the first tract of the urethra) and 
anterior of the rectum (20) (Fig. 3). The function of the prostate is to secrete a slightly 
alkaline milky white fluid, that constitutes about the 30% of the volume of the semen 
and that contains carbohydrates, phospholipids, and enzymes (e.g. prostate specific 












The prostate can be divided in four “zones” (mainly used in pathology, (22,23)) (Fig. 4) 
or in four lobes (mainly used in anatomy): 
1) Central zone: it surrounds the ejaculatory ducts and constitutes about 20% of 
the whole gland and it presents large and irregular ducts. Approximately 1 – 5% 
of prostate cancer originates from this region and tend to invade the seminal 
vesicles (24). This part roughly corresponds to the median lobe. 
2) Peripheral zone: accounts for the majority of the gland and it originates from 
the mesoderm. Up to 70% of prostate cancer originates from this part. Roughly 
corresponds to the posterior lobe. 
3) Transition zone: it surrounds the prostatic urethra and it originates from the 
endoderm. About 20% of prostate cancer originates from this zone which is also 
responsible for the formation of benign prostatic hyperplasia (BPH, discussed 
later (25)). Roughly corresponds to the anterior lobe. 
4) Anterior fibromuscular stroma: it consists of muscular and fibrous tissue. 




Figure 4. Structure of the prostate. The four zones are indicated: transition zone, central zone, 
peripheral zone and anterior fibromuscular stroma. From Baylor College of Medicine 1990. 
 
The growth of the prostate is regulated by androgens like testosterone. Testosterone is 





and its synthesis is controlled by luteinizing hormone (LH) and the follicle stimulating 
hormone (FSH). The secretion of LH from the pituitary gland is regulated by the 
hypothalamic luteinizing hormone-releasing hormone (LHRH) (26). When testosterone is 
converted to 5α-dihydrotestosterone (DHT) by 5α-reductase, it can stimulate the growth 
of the prostate (for example during puberty) (27). DHT in the blood is associated with 
the sex hormone-binding protein (SHB), responsible for its transportation into the 
vasculature and to the target cells, where androgens bind and activate the androgen 
receptor (AR). Activation of the AR by androgens results in the transcription of androgen-
responsive genes like PSA or the prostate-specific gene TMPRSS2 (28,29).  
 
2.1. Architecture of the prostate 
The prostate has a glandular structure characterized by several ducts constituted 
by three major cell types: luminal, basal and neuroendocrine cells (30) (Fig. 5). These 
cells are different in morphology, function and significance for tumorigenesis. 
Luminal cells: these cells are located along the glandular lumen and have a 
secretory function. They are terminally differentiated and express specific 
differentiation markers such as AR and cytokeratin 8/18 (31,32). Additionally, they are 
androgen regulated and produce PSA and PAP. Cells with self-renewal properties have 
been identified within the luminal compartment in mice and humans (33,34) and 
proposed as the cell-of-origin of castration resistant prostate cancer (CRPC, discussed 
later). 
Basal cells: these cells are located between the luminal cells and the basal layer 
that separates the epithelium from the stroma, which consists of fibroblasts, blood 
vessels, nerve cells, smooth muscles cells, infiltrating immune cells and connective 
tissue. The contribution of these cells and components to prostate cancer is crucial, 
especially during the progression of the disease (35,36). Basal cells are proliferative and 
characterized by the expression of cytokeratin 5 and 14 (37,38). Experimental evidence 
have shown the presence of stem-like cells within the basal compartment (39,40) which 
could maintain basal cells or differentiate into luminal cells and neuroendocrine cells 
(41,42). 
Neuroendocrine cells: these cells are dispersed within the basal layer and are 
androgen independent; they express different neuropeptides like serotonin and 
chromogranin A (43). It is hypothesized that their function is to participate in the 







Figure 5. Histology of the prostate. The epithelial layer that characterizes the prostate consists of 
basal cells (Cytokeratin 5 positive, bottom left), separated from the stroma by the basal lamina; 
neuroendocrine cells, dispersed within the basal cells (Chromogranin A positive cells, top right) and 
luminal cells (Cytokeratin 18 positive cells, bottom right). Source: www.proteinatlas.org. 
 
3. Diseases of the Prostate 
Due to its high blood perfusion and connection with the urethra, the prostate 
gland is susceptible to acute and chronic bacterial infection (i.e. prostatitis) typically 
treated with antibiotics (46). Moreover, during aging, the prostate increases 
physiologically in size and this can result in benign prostatic hyperplasia (BPH), 
classified in two types: histologic BPH, characterized by microscopic evidence of 
epithelial and stromal hyperplasia, and macroscopic BPH, characterized by an 
enlargement of the prostate (25). Three main theories have been proposed to explain 
the etiology of BPH (47): 1) the enlargement of the prostate could be caused by a shift in 
the prostatic androgen metabolism occurring with age, which lead to abnormal 
accumulation of dihydrotestosterone; 2) changes in epithelial-stromal interaction 
induce prostatic growth; 3) an expansion in epithelial stem cells. Clinical manifestations 
of an enlargement of the prostate include lower urinary tracts symptoms such as 
bladder outlet obstruction and chronic urinary retention which results in additional 
complications (e.g. infections). Treatment options include pharmacologic agents 





inhibitors) or transurethral resection (48,49). Additionally, there are some similarities 
between BPH and prostate cancer as both require androgens for growth and 
development and therefore might respond to antiandrogen treatments (50).  
 
4. Prostate Cancer 
4.1. Epidemiology 
Prostate cancer is the second leading cause of death from cancer in males in 
western countries with 220,800 new cases estimated for 2015 (51). The incidence of 
prostate cancer increases with age (prostate cancer is a rare event in men under the age 
of 50), and it is higher in the western world compared to less developed countries, due 
to differences in life-style, eating habits, environmental agents and ethnicity (52). 
However, there is homogeneity in the age-dependent prevalence of prostate cancer in 
different countries.  
 
4.2. Prostate Cancer Initiation 
Prostate cancer is considered a multifocal disease. The primary tumor often 
presents multiple histologically independent foci that can be genetically identified for 
their properties and are relevant for understanding the distinction between latent and 
clinical disease (30). Although prostate cancer is commonly considered a disease of 
older men, analysis of specimen collected from younger healthy individuals revealed 
the presence of histologic foci of prostate cancer also in men in their 20s to 40s, 
suggesting an early onset of cancer (53). In the majority of the cases, these multifocal 
lesions will result in a latent disease that will not progress to clinically detectable and 
relevant prostate cancer. This can be explained by two hypothesis: there is a critical 
difference between the initiation of the pathogenic program of latent and clinical 
prostate cancer, or the critical events that are needed to generate a clinical disease do 
not occur in the latent foci. In the initiation phase, the normal prostate gland present a 
ductal-acinar histology, characterized by an organized epithelium with luminal 
secretory cells, basal and neuroendocrine cells and a basal lamina (Fig. 5). This 
organized structure is altered during the “initiation stage”, where histological changes 
of the luminal epithelium occur and lead to luminal epithelial hyperplasia defined as 
prostatic intra-epithelial neoplasia (PIN) (54). PIN lesions are classified between low-
grade and high-grade, they are multifocal and, at this stage, the cancer is contained by 
the intact basal layer which prevents the invasion of the surrounding tissues. The 
morphological integrity of the glandular structures prevents also an increased release of 
PSA into the blood stream. For this reason PIN lesions are usually detected by biopsy 





lesions are characterized by high expression of proliferation markers (56) and by the 
histological presence of basal cells (30).  
A number of genomic alterations such as copy number variations and 
chromosomal rearrangements (insertions, deletions) associated with prostate cancer 
and hereditary prostate cancer have been identified with multiple genome analysis 
studies (30). 
Among the most common copy number alterations, those occurring at 8p21 (Nkx3.1), at 
10q23 (PTEN) and at 8q24 (MYC) involve key regulatory genes (30,57-59). In addition, 
genome-wide association studies have shown the involvement of HPC1 and HPC2 
(mapped in 1q24-25 and 17p11 respectively) in hereditary prostate cancer (60,61). The 
down regulation of Nkx3.1 is one of the critical events in prostate cancer initiation and is 
detected in up to 80% of the prostate tumors (also in PIN lesions and early invasive 
carcinoma). Nkx3.1 has a critical role in prostate morphogenesis and differentiation and 
mutant mice for Nkx3.1 develop PIN lesions that resemble closely those detected in 
human.  
Another frequent chromosomal loss detected in a high percentage of prostate cancer 
cases is represented by PTEN (tumor suppressor gene). Loss of PTEN leads to 
hyperactive PI3K-AKT-mTOR signaling, which results in aberrant cell proliferation and 
metabolism (62). Recent studies have shown that the allelic loss of PTEN represents an 
early event in prostate carcinogenesis and correlates with progression of the disease 
(59). As for Nkx3.1, also loss of PTEN in mice results in PIN lesions and/or 
adenocarcinoma (63).  
 Besides the aforementioned chromosomal losses, genetic studies have identified 
also gene amplifications in prostate tumors. The oncogene MYC is amplified during 
initiation of prostate tumors and upregulation of MYC has been registered in PIN lesions 
(64). Similarly, transgenic mice overexpressing human MYC undergo rapid formation of 
PIN lesions, followed by progression to invasive adenocarcinoma (65). Another set of 
genetic alterations is represented by chromosomal rearrangements. Among these, the 
most common alteration regards the family of transcription factors (ERG, ETV1 and 
ETV4) and the prostate specific gene TMPRSS2 (66). The most frequent rearrangement 
produces the fusion gene TMPRSS2-ERG, where the N-terminally truncated ERG protein 
is expressed under the control of the promoter of the androgen-regulated TMPRSS2 
gene (66). This alteration usually occurs in cancer initiation and is also detected as early 
event during cancer progression.  
 
4.3. Prostate Cancer Detection 
The oldest known case of prostate cancer diagnosed reliably by morphological 





described that a well preserved skeleton of a 40 to 50-year-old Schythian king who lived 
during the Iron Age in the Southern Siberia (Arzhan) suffered from macroscopically 
visible osteoblastic and osteolytic lesions throughout the entire skeleton (67). This 
diagnosis is based on microscopic imaging of the lesions and detection of prostate-
specific-antigen (PSA) complexed with α1-antichymotrypsin (PSA/ACT) in the 
extracellular matrix (ECM) proteins extracted from the compact cortical bone of the 
skeleton from Arzhan (68,69). 
The blood test for PSA, nowadays routinely used in the clinic, has revolutionized the 
clinical practice over the past four decades and has represented the standard for 
prostate cancer detection and monitoring. PSA is a glandular kallikrenin-related 
peptidase produced by the gene KLK3 and its transcription is regulated by androgens 
which make its expression a main characteristic of the prostate epithelium (70). PSA is 
continuously produced by the healthy prostate. In the normal prostate, the 
morphological structure of the glands contains PSA tightly confined and only a reduced 
amount is released into the blood (0.6 ng/ml in a healthy adult male) where it exits in 
multiple forms: as pro-protein or mature protein and free or associated with different 
protease inhibitors (70). In BPH or prostate cancer, the disruption of the normal prostate 
architecture often results in a massive release of PSA into the blood (>100 ng/ml) that is 
measured almost exclusively in males with advanced prostate cancer (70). Altered PSA 
levels in blood are also commonly detected during the occurrence of other alterations of 
the prostate such as inflammation (prostatitis) and its’ levels are also influenced by age. 
For this reason, PSA is considered as a prostate-specific marker but not a cancer-specific 
marker. In this perspective, two more specific and clinically-promising markers for 
prostate cancer detection are represented by the non-coding messenger RNA for the so 
called Prostate Cancer Antigen 3 (PCA3), identified in 1999 (71) and the fusion gene 
TMPRSS2-ERG described in 2005 (66). However, although PCA3 and TMPRSS2-ERG (also 
as combined biomarkers) displayed higher specificity and diagnostic accuracy for 
prostate cancer outcome, PSA is still the most widely used biomarker in prostate cancer 
diagnosis (72). Importantly, the expression of KLK3 at molecular level in the prostate 
epithelium and the increase of PSA level in the blood of men affected by prostate cancer 
are not directly correlated (73). The detection of augmented PSA level into the blood is 
indeed determined by an increased release of PSA from the prostatic gland as a 
consequence of disruption of normal prostate architecture and not by an increase of its 
transcription. This leads to the documented paradox that during development and 
progression of prostate cancer, KLK3 expression might slightly decrease (74).  
The typical clinical practice for men with high PSA levels schedules biopsy to 
assess the possible presence of prostate cancer. The prostate tissue collected is then 





in the 1960s and recently updated in 2005 (75-77). The Gleason scale describes the 
primary and secondary architectural pattern of the tissue obtained from prostate 
biopsies and classifies tumors according to their differentiation, from 1 to 5, based on 
the morphological architecture of the prostate (76,78). Briefly, Gleason 1 corresponds to 
a transformed prostate epithelium that resembles a normal prostatic epithelial tissue; 
from Gleason 2 to Gleason 4, the infiltration of cells at the margin of the gland is 
progressively increasing; Gleason 5 corresponds to a cancerous prostate which has 
completely lost its epithelial structure and is filled with invading mesenchyme-like 
cancer cells. The final Gleason score is obtained upon mathematical addition of primary 
and secondary score and can range from 2 to 10 (79). In addition, the status of the 
primary tumor is also graded, from organ-confined to fully invasive (T1-4), with or 
without involvement of lymph nodes (N0 or N1) and with or without presence of distant 
metastasis (M0 or M1 a-c) (80). These together constitute the so called Tumor-Node-
Metastasis (TNM) system of grading.  
 
4.4. Treatment of Localized Disease 
There are several options for treating prostate cancer patients with localized 
disease, depending on the stage and the patient condition.  
As previously mentioned, due to improved screening methods, prostate cancer can be 
detected already at the very initial stage. Active surveillance is considered a logical 
approach for those men with localized prostate cancer and associated low-risk to 
prevent overtreatment (81-83). The clinical criteria to define an active surveillance 
strategy are: confined disease with T1-T2 stage, maximum PSA level of 10 ng/mL and 
Gleason score <7 (84). Additionally, watchful waiting is considered an alternative for old 
men with less aggressive disease (85). 
Surgical approaches like the removal of the entire prostate are applied to men with high 
life expectancy and localized disease with the aim to completely eradicate the tumor 
(86). In these patients, given the low risk of lymph node involvement, the removal of 
pelvic lymph nodes remains controversial (86,87).  
Another therapeutic approach for the localized disease is radiotherapy which employs 
x- and gamma-rays or alpha emitting radio isotopes (88) to kill tumor cells by causing 
DNA damage. Two applications are possible: external beam radiotherapy and internal 
radiotherapy (also called brachytherapy, which consists of implantation near the 
cancerous region of radioactive plugs which will release slowly the radiation). Recently, 
also image guided intensity-modulated radiotherapy has been developed to deliver high 
dose particles to specific regions reducing the impact on the surrounding tissues (89). It 





similar outcome, they have a different impact on the quality of life of the patient (e.g. 
urinary and sexual function) (90).  
 
4.5. Prostate Cancer Progression and Bone metastasis 
When the cancer enters into the “progression phase”, the loss of the basal lamina 
occurs and results in the switch from high-grade PIN to adenocarcinoma with an 
invasive phenotype, macroscopically characterized by the lack of basal cells as shown 
by p63 and cytokeratin 5/14 staining (91). However, whether prostate cancer is 
originated from luminal or basal prostate cancer stem cells is still under debate (33,92). 
The majority of prostate adenocarcinomas present with an acinar morphology while 
ductal and mucinous adenocarcinomas are more rare. In less than 2% of the cases the 
adenocarcinomas are classified as neuroendocrine variants and mainly occur during 
recurrence after androgen deprivation therapy (93). This can partially be explained by 
the fact that neuroendocrine cells lacking of AR expression survive ADT and prevail 
producing relapse (94). 
 The terminal phase of prostate cancer progression encompasses systemic 
metastasis, which coincides with the development of therapy resistance, e.g castration 
and chemotherapy resistance (95). The majority of aggressive prostate cancers is 
characterized by their osteotropism leading to the development of predominantly 
osteoblastic/osteosclerotic lesions and, thus, represent one of the major clinical 
challenges in uro-oncology. The first explanation for the bone tropism of prostate 
cancer metastasis was provided in 1940 when Oscar Batson suggested that the venous 
network that drains the prostate and connect the pelvic veins to the paravertebral 
venous plexus could explain the dissemination (96). However, another study 
demonstrated that the venous network does not represent the major driver in the 
dissemination of prostate cancer cells to the bones (97). Alternatively the interactions 
between cancer cells and the endothelium was also suggested to underlie organ-
specific dissemination (98). Furthermore, the interaction between the chemokine (C-X-C 
motif) receptor (CXCR) 4 (CXCR4) and its ligand stromal derived factor 1 (SFD1, also 
known as CXCL12) may be critically important (99). Prostate cancer cells express CXCR4 
and experimental evidence has shown that neutralization of CXCR4 reduces prostate 
cancer bone metastasis in preclinical models (100). Moreover, prostate cancer cells also 
express various integrins, e.g. integrin αvβ3, which correlates with prostate cancer bone 
metastasis and is responsible for the interaction with fibronectin, vitronectin and 
osteopontin (101-104). The notion that molecular factors might be involved in the 
specific bone tropism of certain cancer cells was for the first time postulated by Sir 
Stephen Paget who introduced the “Seed and Soil” hypothesis in which he compared 





a fertile soil, the bone marrow (105). Today we know that the formation of distant 
metastasis is a complex process, characterized by multiple bi-directional interactions 
between the tumor cells and the supportive stroma (106). This process starts at the level 
of the confined primary tumor where factors systemically released contribute to the 
conditioning of the metastatic “soil” and provide the establishment of the so called 
“pre-metastatic niche” (107). The “pre-metastatic niche” is defined as a fertile 
microenvironment induced in the metastatic target organs that facilitates the future 
invasion, colonization and the proliferation of metastatic tumor cells (107). During the 
establishment of the “pre-metastatic niche”, bone marrow-derived hematopoietic 
progenitor cells expressing VEGF receptor 1 (VEGFR1) are recruited to metastatic target 
organs by specific factors released by the primary tumor (108). Among these factors, 
LOXL enzymes, VEGFA, VEGFC, TNFα and TGF-β produced by the primary tumor 
stimulate inflammation, attachment and recruitment of, for example, myeloid cells and 
the expansion of lymphatic vessels in the proximity of the sentinel lymph nodes (109-
112). Interestingly it has been proposed that extracellular vesicles and exosomes 
released from the primary tumor represent the mechanism of communication between 
the primary cancer cells and the metastatic sites during the induction of the “pre-
metastatic niche” (113) also in prostate cancer (114). 
Additionally, in primary and metastatic cancers, tumor cells interact with 
different cell types that constitute the stroma. Such cells include tumor-associated 
macrophages (TAMs), cancer associated fibroblasts (CAFs), endothelial cells, pericytes 
and mesenchymal stem cells (MSCs) reviewed in (6,115). Tumor cells produce several 
factors that “activate” the surrounding stromal cells and induce remodelling of the EMC. 
These factors include fibroblast growth factor 2 (FGF2), vascular endothelial growth 
factor (VEGF), platelet-derived growth factor (PDGF), epidermal growth factor (EGF), 
interleukins colony-stimulating factors and TGF-β (116) and proteolytic enzymes (117) 
that remodel ECM, enabling cell migration. In the progression and castration resistant 
phase of prostate cancer, cancerous polarized-epithelial cells localized at the site of the 
primary tumor undergo biochemical changes and acquire an invasive and often 
mesenchymal phenotype (118,119) which confers them enhanced migratory ability, 
invasiveness, resistance to apoptosis and resistance to therapy, which are all properties 
resulting in a clinically-relevant phenotype (120,121). Together these events result in the 
invasion of the surrounding stroma and in the intravasation and circulation of 
cancerous cells in the blood stream. Tumor cells which possess stem cell-like 
characteristics, that survive in the circulation can extravasate at those distant sites 
where the “pre-metastatic niche” has previously prepared a fertile “soil” for future 
colonization. Recent research has highlighted the clinically relevant properties of the so 





distant metastatic sites (122). Once that these CTCs have colonized the metastatic site 
(e.g. the bone), they may activate a reverse program of mesenchymal-to-epithelial 
transition (MET) and remain dormant for years (123). Therefore it appears that these 
disseminating tumor cells (DTCs) can perpetuate in the bone the malignant progression 
and establish a “metastatic niche”. 
Typically, the “metastatic niche” is located at perivascular locations (124). CTCs 
and DTCs may, potentially, establish a metastatic niche through competition with 
hematopoietic stem cells (HSCs) for their niche at a perivascular location (124-127). 
Moreover it has been hypothesized that tumor cells can also create their own niche 
(125,128). PCa cells amplify the existing hematopoietic niche and induce de novo an 
ectopic epithelial tissue-of-origin niche which together with the amplified 
hematopoietic niche generates a hybrid niche, supportive for cancer cell growth (106) 
and reviewed in (129). DTCs can survive in the bone microenvironment as non-
proliferating (dormant) cells that originate microscopic lesions (classified as 
micrometastasis) (130,131). The mechanisms that induce exit from dormancy are still 
largely unknown (131). However, it has been shown that a collagen-I enriched fibrotic 
environment plays a crucial role in the cytoskeletal reorganization in dormant cells and 
in their awakening from dormancy (132). Once that these cells escape from dormancy, 
they induce local inflammation, followed by vascular and bone remodelling and 
establishment of a distant secondary tumor (bone metastasis) (120,133). Recently, it 
was revealed that the molecular signature of the stroma response in prostate cancer-
induced osteoblastic bone metastasis highlights the amplification of hematopoietic and 
prostate epithelial stem cell niche (106). This observation supports the notion that 
angiogenesis and osteogenesis are crucial processes involved in the formation and 
growth of osteoblastic bone metastasis. Moreover, a recent report described the 
presence of two different type of microvessels: type “H” (CD31high and endomucinhigh) 
and type “L” (CD31low and endomucinlow) (134). Interestingly, angiogenesis and 
osteogenesis have been coupled to the type “H” vessels, that provide also signals for 
HSCs and where osteoblasts also reside (135). Moreover, the kinetic of type “H” vessels 
in mice shows a peak at week 4 and loss of type “H” endothelium during ageing has 
been documented (134). Together this support the involvement of angiogenesis in the 
homing of metastatic cells in the bones in preclinical mouse models.  
The bone remodelling induced by metastatic cancer cells results in either bone 
formation (osteoblastic bone metastasis) or bone resorption (osteolytic bone 
metastasis) and interferes with hematopoiesis (133). In prostate cancer, the bone 
lesions are typically osteoblastic (133,136), however the co-existence of osteobastic and 





Factors inducing osteoblast recruitment and activity in prostate cancer are: BMP6 (138), 
and BMP modulators, such as Noggin (NOG) (139); IGF1 (140) VEGFs (141), wnt signaling 
(142) and modulators of Wnt signaling such as dickkopf (DKK) and Sclerostin (SOST) 
(139). On the other hand, factors modulating osteoclast recruitment and activity in 
prostate cancer are: MMP-7, which promotes osteolysis via cleavage of RANKL that 
stimulates osteoclastogenesis (143); Noggin which antagonizes bone morphogenetic 
proteins (BMPs) and impairs bone formation (139,144);  
It has been hypothesised that osteolytic cancer cells produce PTHrP that stimulates 
osteoblasts to secrete RANKL. This in turn stimulates ostecolasts progenitor cells and 
leads to osteoclastogenesis therefore bone resorption. During this process, many 
factors such as TGF-β, IGF-1 and calcium are released from the mineralised matrix to 
further feed cancer cell growth, thus perpetuating this “vicious cycle” (133,145). In 
prostate cancer for example, the expression of the calcium sensing receptor by tumor 
cells makes them responsive to the release of calcium during bone resorption and leads 
to increased proliferation and PTHrP release (146,147). However, the inhibition of bone 
resorption as strategy to impair bone metastasis with agents such as bisphosphonates 
revealed no effect on cancer cell proliferation in animal studies (148,149) and clinical 
trials also in prostate cancer (150) suggesting that other mechanisms support tumor cell 
growth in the bone. In this perspective, the recent identification of the molecular stroma 
response in osteoblastic prostate cancer (106) supports the coupling of angiogenesis 
and ostegenesis in bone metastasis (134) and suggest that anti angiogenesis might 
impact on the growth of osteotropic prostate cancer cells in the bone.  
 
4.6. Treatment of Advanced Disease 
As previously described, PSA testing allows an early detection of many cases of 
the disease when the cancer is still confined and may therefore be successfully resolved 
by surgery or radiotherapy. However, after local treatment, 20-40% of the cases, 
biochemical relapse will occur (PSA > 0.2 ng/ml) (Fig. 6) (95). Typically these patients 
will be treated with androgen deprivation therapy (ADT, which consists of chemical or 
surgical castration and/or treatment with anti-androgens) which will lead to regression 
of prostate tumors (151). 
A strategy consists in the modulation of the testosterone biosynthesis via interference 
with LH and LHRH. This can be achieved in two ways: employment of LH agonists to 
produce in the long term a downregulation of the LH receptor thus resulting in a 
decrease of the testosterone biosynthesis (152); employment of LH antagonists which 
result in a rapid decrease of testosterone levels (152). Another strategy consists of 





Despite these therapies, 30-70% of the patients treated with androgen deprivation 
therapy will inevitably display increased PSA levels, acquire resistance to androgen 
suppression and develop incurable metastatic disease (154). This situation is commonly 
defined as castration resistant prostate cancer (CRPC) or hormone refractory prostate 
cancer (HRPC). Although similar, these two terms refer actually to two different clinical 
situations. Patients who are traditionally identified as HRPC are highly heterogeneous 
depending on: 1) the clinical status, 2) the level of PSA, 3) the applicability of hormone 
therapy and 4) the eventual presence of metastasis (95).  
 
 
Figure 6. Overview of prostate cancer progression combined with diagnosis and treatment 
options. Prostate cancer is initially treated with prostatectomy or radiotherapy and in almost 80% of 
the cases, patients will be cured. In 20-30% of the cases, prostate cancer relapses and these patients 
will be typically treated with androgen deprivation therapy. However, the development of castration 
resistance prostate cancer (CRPC) will inevitably occur. Although these patients will be treated with 
therapies such as docetaxel, cabazitaxel, enzalutamide and abiraterone, the development of incurable 
metastasis, typically in the bone will occur. 
 
Interestingly, there are documented cases in which the androgen receptor (AR) signaling 
remains active after androgen deprivation therapy probably through escape 
mechanisms (30). Such mechanisms include amplification of the AR gene (155-157), 
gain-of-function mutations of AR (158-162), expression of alternative splice variants 
(163-165) and endogenous expression of enzymes involved in DHT synthesis by tumor 





the clinic to indicate a condition where response to hormonal therapy is still possible, 
therefore reveals a different condition from HRPC (95).  
Once that tumor acquires resistance to androgen suppression and patients develop 
metastasis mainly in the bones, treatment options are limited and include symptomatic 
care with analgesics or radiotherapy to reduce bone pain, treatment with bone-seeking 
isotopes (e.g. Strontium-89 and the recently FDA-approved Radium-223 chloride) and 
chemotherapy (170). Typical therapeutic treatments consist of agents targeting the 
androgen pathway (abiraterone acetate and enzalutamide) and taxanes (docetaxel and 
cabazitaxel), which target microtubules and result in the arrest of the cell cycle (170-
174). Current first-line treatments consist of combination therapy with docetaxel and 
prednisone, while second line combination treatments are cabazitaxel and prednisone, 
abiraterone acetate and prednisone and enzalutamide (171-174). Recent studies 
revealed that simultaneous treatment of ADT and docetaxel significantly increases 
patient survival (175,176). However, longer follow up of these studies is needed to 
assess whether this benefit translates also into metastatic-free survival.  
 
4.7. Prostate Cancer Stem Cells 
According to what is commonly known as the “cancer stem cell hypothesis”, CSCs 
appear to be strongly involved in tumor formation, therapy resistance, recurrence and 
metastasis. As we already mentioned in a previous paragraph, cancer is a disease that 
originates from a single normal cell after a series of specific genomic and non-genomic 
alterations. As a result it was hypothesized that cells with self-renewal ability represent 
good candidates for oncogenic transformation and cancer formation (47). There are two 
putative sources of cells with self-renewal properties that are believed to generate 
cancer: adult stem cells (SCs) and non-stem cells that acquire self-renewal properties 
after de-differentiation and transformation. The majority of prostate cancer have a 
luminal phenotype and the absence of basal cells is a diagnostic feature of prostate 
adenocarcinoma (91,177). One could, therefore, speculate that prostate tumors 
originate from luminal progenitor cells or stem cells within the basal layer that after 
transformation differentiate into a luminal progeny. However, the histological 
compartment where the putative cell of origin of prostate cancer resides is still under 
debate. In hormone-naïve cancer, experimental evidence in rodents and humans 
support the existence of cells with self-renewal properties and tumorigenic ability in the 
basal compartment of the prostate (α2β1 integrinhi and CD133+ cells (178,179)) (Fig. 7). 
Other common markers include ALDHhigh, CD44+ and CD24- (39,40,180). On the other 
hand, in CRPC, cells with self-renewal properties exhibit a luminal phenotype. These 
cells have been identified in castrated mice and are known as castration-resistant 





phenotype (CARN-like cells) were also identified in humans (34). CARNs are 
characterized by low AR expression, and display the stem-cell marker ALDH1A1 or 
NANOG and express the luminal marker NKX3.1 and CK18 (34). Interestingly, the 
experimental observation in favour of the luminal hypothesis suggest the presence of a 
residual and dormant subpopulation of cancer cells which are castration-resistant for 
survival but castration-sensitive for growth (34). Recently the field has been additionally 
complicated by the experimental evidence that murine luminal (CD49f positive (181)) 
and basal (CD24 positive (182)) cells and human luminal (CD26 positive (182)) and basal 
(CD49f positive (182)) cells are capable of generating prostate organoids (183). However, 
the debate about the localization of the cell of origin of human prostate cancer and its 
role in the progression to a castration resistant phase is still controversial.  
 
Figure 7. Hierachical model of tumorigenesis: role of normal and transformed tissue 
stem/progenitor cells. Cells within the different epithelial compartments can be distinguished by their 
phenotypic characteristics. 
 
In addition to haematological malignancies, the presence of a subpopulation of 
epithelial cells with self-renewal properties is generally recognized in solid tumors 
including those of the human prostate. Furthermore accumulating experimental and 
clinical evidence suggest that such cells are highly tumorigenic and may play a key role 





The assumed role of CSCs in tumor maintenance represents one of the major problems 
for the identification of new, targeted therapies capable of eradicating the disease. 
Current therapies are indeed very effective in the treatment of the primary tumor mass 
(186). However, the relapse that is commonly observed (even after many years) in 
patients, suggests the presence of subpopulation of cells, resistant to therapy, which 







5. Pathways Involved in Prostate Cancer Progression and Bone 
Metastasis  
The notion that genes involved in developmental process are also likely to be 
altered in cancer is known and established. Molecular analysis revealed that a wide 
range of genes, commonly expressed during prostate organogenesis and developmental 
processes, are also abnormally expressed in prostate cancer. 
 
Wnt pathway: the Wnt signaling pathway is an evolutionarily conserved pathway 
that regulates crucial aspects of development and cell behaviour, such as 
differentiation, migration and cell polarity. The Wnt signaling is characterized by two 
branches: a canonical pathway (Wnt/β-catenin dependent) and a non-canonical 
pathway (β-catenin independent).  
The canonical Wnt signaling is activated upon the interaction between a ligand (Wnt) 
and its receptor (Frizzled, Fz) and co-receptor (low-density-lipoprotein-related protein 










In the absence of Wnt, a complex of Axin, APC, GSK3-β, CK1 and β-catenin is localized in 
the cytoplasm. CK1 and GSK3-β phosphorylate β-catenin which is subsequently 
degraded by the proteasomal machinery. In presence of Wnt, LRP6 is phosphorylated by 
CK1 and GSK3-β, thus recruiting to the plasma membrane a complex containing Axin 
and Dishevelled (Dsh), which is sequestered or degraded. This results in stabilization of 
β-catenin which subsequently translocates into the nucleus and mediates transcription 
of downstream target genes via interaction with LEF/TCF family members. Canonical 
Wnt signaling regulates process such as cell fate decision and anteroposterior 
organization in embryogenesis, as well as important function in organogenesis and 
stem cell renewal. 
Many studies have documented alterations of the Wnt signaling pathway during 
prostate cancer progression, reviewed in (30,188-191). More specifically, elevated 
canonical Wnt signaling seems to play a role in the onset of castration resistance in 
prostate cancer (192). Additionally, alterations or interferences with canonical Wnt 
signaling, such as modulation of DKK (142) or mutation in sclerostin (SOST), which 
inhibits LRP5, contribute to disrupt bone formation, a process also regulated by Wnt 
signaling (193). In addition to the well-established effects of Wnt-signaling on enhanced 
osteogenesis, Wnt-signaling also induces bone-active factors, such as OPG which 
prevents the binding of RANKL to RANK thereby inhibiting osteoclast function (194). 
The non-canonical Wnt signaling, comprise two branches of signaling 
transduction: the Wnt/Ca2+ signaling and the Wnt/planar cell polarity (PCP) pathway 
(195) (Fig. 8B). In Wnt/Ca2+ signaling, the interaction between Wnt and Fz activates 
phospholipase C via G proteins and lead to increase intracellular Ca2+. This can induce, 
for example, EMT and invasion, therefore promoting cancer progression. In Wnt/PCP, 
the non-canonical Wnt (Wnt5a and Wnt11) bind their receptor Fz which recruits Dsh at 
the plasma membrane. This lead to a cascade of interactions which converge on 
common regulators of cytoskeletal remodelling and actin organization such as RhoA, 
Rac1 and JNK, which also impact on cell motility. 
Wnt/PCP and canonical-Wnt signaling are both part of a negative feedback-loop where 
Wnt/PCP negatively regulates canonical-Wnt signaling and vice versa (196). In cancer, 
due to aberrant alterations in tumor cells, cancer cells can escape from these control 
mechanisms and as tumors progress, Wnt/PCP gets activated and promote cell motility, 
invasion and metastasis (195). Interestingly, β-catenin and GSK3-β have indeed been 
shown to be decreased in prostate cancer cell lines with high invasive and metastatic 
potential, such as PC3 (197). Therefore one could speculate that there is a misbalance in 
these cells between canonical and non-canonical Wnt signaling which results in 






 Notch pathway: the Notch signaling pathways exerts also a crucial role during 
embryogenesis and organogenesis. In cancer, an aberrant activation of this pathway 
produces abnormal cell proliferation, increase in self-renewal properties and induction 
of therapy resistance (198,199). Conversely from Wnt signaling, the Notch signaling 
pathways requires a direct cell-to-cell contact for its activation. Typically, a signal-
sending cell expressing on its plasma membrane the ligand (JAG1/2 or Delta-like 1, 3 
and 4, in mammals) stimulates a signal-receiving cell expressing on its membrane the 
receptor (Notch1/2/3/4). This interaction produces a series of proteolytic cleavages 
operated by ADAM10 and γ-secretases that convert the full-length transmembrane 
Notch receptor into a transcriptional activator (Notch intracellular domain, NICD). 
Subsequently, NICD translocates into the nucleus, where it interacts with RBPjk/CBP 
transcription factors, resulting in the transcription of downstream target genes (e.g. 
Hairy and enhancer of split, HES and Hairy/enhancer-of-split related with YRPW motif, 




Figure 9. Schematic representation of Notch signaling.  
 
Notably, Notch plays a crucial role during prostate organogenesis and is involved in its 





signaling pathway is characterized by multiple cross-talk with other major signaling 
pathways involved in prostate cancer progression and bone metastasis formation (e.g. 
TGF-β, AR and PI3K/AKT) (Fig. 9) (200-205). Members of TGF- β superfamily can control 
Notch signaling: for example, Bone morphogenetic protein 7 (BMP7) can inhibit the 
branching morphogenesis of the prostate during development via down-regulation of 
Notch signaling (206). Notch can also suppress AR signaling which is crucially involved in 
prostate growth and disease. Upon binding of androgen to the AR, the receptor 
undergoes a homodimerization and traslocates into the nucleus where it can recruit 
coactivators such as p300/CBP and steroid receptor coactivator 1 (SRC1). The 
downstream target of Notch, HEY1 can directly bind the N-terminal activation domain of 
AR thus preventing androgen signaling, supporting a role of Notch in the acquisition of a 
castration resistant phenotype (204). Finally, Notch can also suppress the PI3K/AKT 
pathway that is fundamental for prostate growth and cell migration (207). The 
activation of this pathway triggers a cascade of sequential phosphorylation that can be 
suppressed by PTEN (198). It appears that NICD contributes to induction of PTEN 
expression, therefore suppressing indirectly PI3K/AKT pathway (208). This has led to the 
paradox that Notch signaling (particularly when triggered by Notch1) can exert a tumor 
suppressive role in the prostate. The complexity of the interaction between the Notch 
signaling and AR and PI3K/AKT pathways is further increased by a reciprocal feedback 
mechanism between PI3K/AKT and AR signaling: recently it was indeed demonstrated 
that inactivation of PI3K/AKT induces activity in AR signaling, while suppression of AR 
pathway induces increase in PI3K/AKT (209). Given the established increased in 
PI3K/AKT in advanced prostate cancer (59,210), one could speculate that an increase in 
Notch signaling (as documented during prostate cancer progression), through its 
downstream target HEY1, produces a decrease in the AR pathway (castration resistant 
phase) which results in increased PI3K/AKT signaling (increase migration and 
metastasis). Notch signaling has also been shown to critically be involved in prostate 
cancer progression and bone metastasis formation and JAG1 has been found to be 
elevated in metastatic prostate cancer compared to primary tumor (211). Additionally, 
in the bone microenvironment, tumour-derived JAG1 activates the Notch pathway in 
osteoblasts and osteoclasts and the activation of the pathway in osteoblasts results in a 
growth advantage to bone metastatic tumour cells (212). Interestingly, mechanistic 
studies showed that the proliferative effect was dependent on osteoblast-secreted IL-6, 
which was transcriptionally regulated by the Notch signaling in breast cancer (213). The 
Notch signaling pathways represents a promising target for therapy against tumor 
growth (214) and bone metastasis (213). However, the presence of studies addressing 






TGF-β superfamily signaling pathways: during the early phase of prostate 
tumor growth, TGF-β acts as tumor suppressor by reducing proliferation and inducing 
apoptosis (215). However, during tumor progression, TGF-β switch gains a tumor 
promoter role and facilitates EMT and therefore metastasis (9,216). The transforming 
growth factor (TGF)-β superfamily of ligands includes more than 30 factors such as Bone 
morphogenetic proteins (BMPs), Growth and differentiation factors (GDFs), activins, 
inhibins, nodal and Anti-müllerian hormone (AMH). For the purpose of this thesis we will 
mainly focus on TGF-β members and BMPs. TGF-β is a pleiotropic cytokine that 
regulates many biological processes such as tissue growth and morphogenesis, cell 
proliferation and apoptosis, adhesion, differentiation, migration and metastasis (217). 
The TGF-β cytokine family consists in different members (TGF-β1, β2 and β3) whose 
bioactive cytokine molecule is a dimer consisting in a polypeptide chain which is 
cleaved from a latent precursor into the biologically active product (218). 
BMPs include approximately twenty members and these are less homologous compared 
to the TGF-β isoforms (219). They are functionally involved in skeletal and joint 
morphogenesis, bone remodeling and in different cellular processes including 
osteogenesis, cell differentiation, anterior/posterior axis specification, growth, and 
homeostasis (220). In normal tissues, basal release of TGF-β by local sources is enough 
for the maintenance of homeostasis. In case of tissue injury, TGF-β is abundantly 
released by blood platelets and stromal components to prevent aberrant regenerative 
cell proliferation and inflammation. This occurs also in tumor microenvironment, where 
TGF-β is frequently present initially as factor to prevent premalignant progression, and 
eventually as factor that cancer cells may use to their advantage (218).  
TGF-β superfamily members bind to type I and type II serine/threonine kinase receptors 
(Fig. 10). In human, seven different human type I receptors have been identified (ALK1-
7) and five type II receptors, namely, TGF-β receptor II (TβRII), BMP receptor II (BMPRII), 
activin receptor II (ActRII), ActRIIB and AMH receptor type II. TGF-β binds TβRII and ALK5 
and in endothelial cells it signals also via ALK1. BMP signaling occurs via BMPRII, ActRII 
and ActRIIB in association with ALK1,2,3 or 6 depending on the molecular context (221-
231).  
Binding of TGF-β and BMPs to their heterodimeric transmembrane receptors induces 
phosphorylation of type I receptor threonine/serine kinases. The signal is then 
transduced via Smad intracellular proteins, which later translocate into the nucleus and 
regulate transcription. The Smad pathway is also named canonical signaling pathway. 
TGF-β type I receptor propagates the signal by phosphorylating receptor-regulated 
Smad proteins (R-Smads) Smad-2 and -3. On the other hand, BMPs induce 





by activated type I receptor occurs at the C-terminal SXS domain that is shared by all 
Smad proteins and that represent a nuclear localization signal (218,233).  
 
 
Figure 10. Schematic representation of the TGF-β and BMP signaling.  
 
Depending on their phosphorylation state, Smad-2 and Smad-3 linked to Smad-4 
undergo constant nucleo-cytoplasmic shuttling, in a sort of rapid activation-
deactivation cycle, determined by repeated cycles of dephosphorylation and 
rephosphorylation, involving direct interactions with both nuclear pore proteins and 
importins and exportins, a protein family of transport factors (233). 
TGF-β also regulates alternative pathways via Smad-independent signaling (non-
canonical Smad signaling). These signaling include the extracellular-signal- regulated 
kinase (ERK1 and ERK2), p38, MAPKs, c-Jun N-terminal Kinase (JNK), PI3K-Akt and small 
GTPases. The non-canonical Smad signaling pathways have been extensively reviewd in 
(234-236). 
Each step in the TGF-β signaling pathways is controlled by specialized factors. These 
factors include encapsulation of the extracellular ligand by binding proteins, inhibition 
of activation of latent TGF-β, receptor-interacting partners (BAMBI, SARA and FKBP12), 
inhibitory Smads (Smad6 and Smad7) and post-translational modification by E3 






Integrins: integrins belong to a family of heterodimeric transmembrane 
glycoprotein receptors which consist of an α and a β subunit and which play important 
roles in tissue development and cancer (238,239). To date 18 α and 8 β subunits have 
been identified from which 24 different functional heterodimers can be generated (240). 
Integrins regulate many processes such as cell adhesion, migration, proliferation, neo 
angiogenesis (241) and have been shown to undergo changes in their expression during 
the transition to neoplastic phase (242,243). Integrins establish the connection between 
the cell and the extracellular environment (mostly the extracellular matrix molecules) 
and the cytoskeleton and transduce signals from the outside and into the cells and vice 
versa (reviewed in (238,240,244-246)) (Fig. 11). In addition, integrins can modulate the 
signaling cascade of multiple growth factor receptors via RasGTP, such as the epidermal 
growth factor (EGF), platelet-derived growth factor (PDGF) and fibroblast growth factor 
(FGF) receptors, thereby lowering the threshold level in different signaling pathways 
(247). Moreover, ligation and clustering of integrins can lead to the activation of focal 
adhesion kinase (FAK) and extracellular signal-related kinase kinase (MEK) (248) which 
have been implicated in prostate cancer progression and metastasis (249,250). Previous 
studies have shown that specific integrins (such as αvβ3 (101,102)) correlate with poor 
survival and are involved in the formation of bone metastasis (251-254). Furthermore, 
targeting of αv integrin (knockdown or selective drug targeting) in human prostate 
cancer cells, abolished the formation of bone metastasis in preclinical mouse model 
(255,256).  
 





Additionally, αv integrins appear to be up-regulated in tumor- and metastasis-initiating 
prostate cancer cells (ALDHhigh (39,257)) and these integrins are involved in the 
activation of latent TGF-β, thereby modulating TGF-β signaling (and vice versa in a 
feedforward loop (244,258-260)) (Fig. 8). As previously outlined, high bone turnover 
provides a significant contribution to the development and the relapse of bone 
metastasis (261). Interestingly, it has been reporter that increased expression of integrin 
alpha-v enhanced the TGF-β mediated osteoclastogenesis (262). Therefore it appears 
that changes in integrin expression play an important role in malignat disease and 
impact not only on primary tumor growth and invasion but also on the bone 
microenvironment. 
 
 Cripto pathway: Cripto (TDGF1, CRIPTO-1) is a small, GPI-anchored/secreted 
fetal-oncoprotein that plays important roles in regulating stem cell differentiation, 
embryogenesis, tissue growth and remodelling (263). An essential mediator for the 
Cripto signaling is the Glucose-regulated protein 78 (GRP78) (264). As for Wnt and Notch, 
Cripto represents one of those embryonic signaling pathways that when corrupted can 
drive tumor initiation and progression. The Cripto pathway modulates the signaling of 
multiple TGF-β ligand that transduce the signal via Smad2 and 3 such as Nodal, GDF1 
and GDF3 (265-267) (Fig. 12). Interestingly, Cripto has also been shown to negatively 
regulate the activation of Smad by Activin-A (268,269), Activin-B (270) and TGFβ-1 
(269,271) leading to suppression of the cytostatic effect of these ligands (271,272). These 
cross-talk with the TGFβ pathway, also crucially involved in prostate cancer bone 
metastasis, highlight the interest of elucidating the role of Cripto signaling in the contest 
of bone metastasis. Additionally, even though the soluble vs. secreted effects regulated 
by Cripto are not yet been entirely elucidated (273), Cripto has also signaling activities 
that are independent from the TGF-β pathway. Relevant for the purpose of this thesis, 
soluble Cripto can activate and promote signaling routes of extreme relevance in 
prostate cancer formation and progression, such as the already discussed PI3K/AKT. In 
this context, blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto 
signaling via MAPK/PI3K and Smad2/3 signaling routes (270). Moreover, Cripto is also 
known to modulate Wnt and Notch signaling pathways (274-277). The interaction 
between Cripto and PI3K/AKT pathway is mediated via Glypican-1, a GPI-anchored 
heparan sulphate proteoglycan, that activates a cascade of phosphorylation in which 
MAP Kinase are involved. This lead to the subsequent activation of PI3K/AKT pathway 
which promotes proliferation and motility (278). Cripto has also been shown to cross-
talk with Wnt signaling; it can bind LRP5/6 facilitating the interaction with Wnt3a, 
therefore stimulating Wnt pathway through cytoplasmic stabilization of β-catenin (279). 





cleavage from the plasma membrane, thereby potentiating Notch signaling (277). 
Finally, Notch signaling can also modulate the expression of Nodal, further complicating 
the cross-talk between Notch and Cripto /Nodal signaling (280). As we previously 
mentioned, one of the key processes that characterize the switch from non-invasive to 
invasive disease in prostate cancer is represented by EMT. Interestingly, Cripto exerts an 
important role in this process in prostate cancer, where its overexpression produces 
increase in the mesenchymal marker Vimentine, decrease in the epithelial marker E-
Cadherin and augment PI3K/AKT and FGFR1 activity, thus inducing migration (281).  
 
 
Figure 12. Schematic representation of the multiple interactions of Cripto signaling.  
 
 The genetic alterations and the signaling pathways discussed in this paragraph 
obviously do not cover the entire complexity of aberrant genetic events and 
abnormalities that characterize multiple pathways and molecules from the onset to the 
progression of prostate cancer. Among these, we have focused our interest on the 
alteration and the role of a class of small non coding RNA, namely microRNA, that 
regulate gene expression. The properties of these molecules, the mechanism of action 





cancer cells during prostate cancer progression and metastasis are presented in the 









5.1. The involvement of microRNA in prostate cancer 
microRNAs (miRs) are a class of small non-coding RNAs that derive from larger 
precursor (pri-miRNA) folded into a stem-loop configuration. miRs are transcribed by 
RNA polymerase II (Pol II) and subsequently processed into the ~70-nucleotide 
precursors (pre-miR) (282,283). The pre-miR is then cleaved to generate a ~21-25-
nucleotide mature miR. miRs localized within Alu-repetitive element, can be transcribed 
by RNA polymerase III (284). miRs can be positioned at different genomic locations; for 
example, they can map within introns of both protein-coding or non-coding genes (285). 
These are transcriptionally regulated through the promoters of these genes (286,287). 
The transcription of miRs held in the same cluster is regulated by the same promoter 
and all the miRs from that cluster are transcribed at the same time. 
The processing of miR is catalyzed by different multiprotein complexes (Fig. 13) 
(reviewed in (288)). A complex localized in the nucleus and composed by an RNase III 
enzyme Drosha and the double-stranded RNA-binding domain (dsRBD) protein 
DGCR8/Pasha, process the pri-miR (289). This enzymatic reaction produces a 2-
nucleotide-long 3’ overhangs at the cleavage site. The processing of the pri-miR into 
~70-bp pre-miRs by Drosha depends on the terminal loop size and the flanking sequence 
of the Drosha cleavage site. Shortening of the terminal loop, disruption of 
complementariety within the sequence, or mutations of flanking sequence at the 
Drosha cleavage site, can significantly reduce, if not abolish the processing of the pri-
miR.  
After the pri-miR is cleaved by Drosha, the resuting pre-miR is exported from the nucleus 
into the cytoplasm by Exportin 5 (Exp5), a nucleo/cytoplasmic cargo transporter Ran-
GTP dependent (290-292). In the cytoplasm, another RNase III enzyme (Dicer) cleaves 
the hairpin into a small imperfect dsRNA duplex that contains both the mature miR 
strand and its complementary strand (293-295). The ability of Dicer to recognize the pre-
miR molecules is due to the presence of a PAZ (Piwi-Argonaute-Zwille) domain that 
allows a low-affinity interaction with the 3’ end of ssRNAs (296-298). For this reason, the 
pre-miR that presents 2-nucleotide 3’ overhangs resulting from Drosha cleavage, can be 
easily recognized and processed by Dicer. 
Dicer cleavage generates mature miRs ~21-25-nucleotide long. After the dsRNA duplex is 
formed, the target specificity and the functional efficiency of a miR, requires that the 
mature miR strand is incorporated into the RNA-induced silencing complex (RISC) 
(reviewed in (288)). In human cells, transactivating response (TAR) RNA-binding 
protein (TRBP), recruits the Argonaute protein Ago2 and together with Dicer they form a 
trimeric complex that initiates the assembly of the RISC complex (reviewed in (288)). 
The mechanism by which the RISC complex incorporates the mature miR strand of the 





mature miR strand can reside on either strand of the hairpin, but, because of 
thermodynamic reasons, it mostly derives from the strand with the less stable 5’. 
 
 
Figure 13. Schematic representation of the microRNA processing pathway. 
 
The detection of microRNA in blood and urines represent an interesting and non-
invasive approach to diagnose prostate cancer (299). Independent studies have shown 
that miR-141 and miR-375 are significantly elevated in the blood of prostate cancer 
patients with bone metastasis and in the respective exosomes (300,301). Interestingly 
elevated levels of the two microRNAs are also associated with higher Gleason score, 
positive lymph nodes and were also detected in the urine of prostate cancer patients 
(302,303). miR-375 has also been identified as prognostic marker in castration-
resistance prostate cancer together with miR-1290 in exosomes (304). Additional 
microRNA that have been measured in the urine and associated with prostate cancer 
are miR-107, miR-574-3p and miR-200b (303). Interestingly, the last has also been 
associated by an independent study with docetaxel resistance (305). In the same study, 
miR-429, miR-200a, miR-21, miR-200c, miR-375, miR-132 and miR-20 have been 
associated with lower survival (305). A recent report investigated the expression of 





benign prostatic hyperplasia, Gleason 7 treatment-naive prostate cancer, and CRPC and 
identified miR-548c-3p as functional biomarker involved in prostate cancer progression 
(306). 
 
5.2. Mechanisms of microRNA Post-Transcriptional Repression 
After incorporation into the RISC complex, the miR interact with its target mRNA 
by base-pairing interactions. If mRNA/miR complementarity is perfect or near-perfect, 
the target mRNA can be cleaved and degraded; otherwise the translation is repressed 
(294). 
The target complementarity is determined by base-pairing of nucleotides in the so 
called “seed sequence” of the miR (307). This sequence is essential for the binding of the 
miR to the mRNA. The seed sequence is an heptametrical sequence located at positions 
2-7 from the miR 5´-end and has to be perfectly complementary to the target mRNA 
complementary sequence. The miR seed sequence is exploited to develop 
computational approaches for target prediction.  
The microRNA target site is positioned at the 3’UTR region, probably because the 
movement of ribosomes that occur during translation will contrast RISC binding and 
interaction (308). Different and “non-canonical” miR-mediated mechanisms of mRNA 
expression modulation are also emerging. In fact some miRs can bind to the open 
reading frame (ORF) sequences or to the 5’UTR region of the target genes, determining 
gene activation rather than repression (309). The RISC action on target mRNA is 
modulated by the Ago protein that is incorporated in the complex and by the grade of 
complementarity between the miR strand and its mRNA target. Ago2, for example, is 
able to cleave RNA, but this event requires extensive base pairing between the miR 
strand and the mRNA target (310,311). 
 
To date, six models have been proposed for the miR translational repression:  
 
1)  the RISC complex induces de-adenylation determining a decrease of 
translational efficiency by blocking target mRNA circularization (312);  
2)  RISC complex blocks cap function by interacting with both the cap or eIF4E 
(313);  
3)  Argonaute proteins recruit eIF6, which blocks the recruitment of 60s ribosomal 
subunit (314);  
4)  RISC complex blocks the translation elongation or promotes premature 
dissociation of ribosomes (ribosome drop-off) (315);  
5)  RISC complex induces the proteolysis of nascent peptides during translation (in 





6)  RISC complex recruits target mRNAs to processing bodies, where the mRNA is 
degraded or stored in an inactive state for translation (317,318). 
 
5.3. microRNA and Cancer Stem Cells 
microRNAs regulate multiple biological process, such development and cell 
growth and have been proposed as one of the important players during pathogenesis 
and cancer. In human prostate cancer, several studies in patient samples and 
xenografts have revealed their characteristic pattern in benign vs. aggressive disease 
and highlighted their role in castration-resistant prostate cancer and their implication in 
bone metastasis formation (see microRNAs described in paragraph 3 and reviewed in 
(299,300,302)).  
However, the number of studies addressing the role of specific miRs in the 
regulation of stem-like properties in bulk prostate cancer cells lines is limited. 
Remarkably, there is an even lower number of studies, that investigated the expression 
of miRs directly in selected subpopulation of cells, characterized by stem-like properties 
and capable of maintaining the tumor and producing metastasis. In these studies new 
miRs have been identified using expression profiling of subpopulation of cells enriched 
for cancer stem cells isolated from bulk prostate cancer cell lines. For example, 
prostaspheres from PC3 cells have been compared to adherent PC3 cells and miR-143 
has been identified as promoter of prostate cancer metastasis (319). In other 
approaches, a fraction of prostate cancer stem cells (PCSCs, described as CD44+/CD133+) 
has been isolated by viable cell sorting from culturedLNCaP cells and miR-101 has been 
found to inhibit cell growth and promote apoptosis in PCSCs (320). With a similar 
approach, miR-409-3p/5p has been identified in embryonic stem cells and then studied 
in prostate cancer, where it was found to promote bone metastasis (321). Other studies 
have also employed cell sorting of various stem/progenitor cell population, including 
CD44+, CD133+, integrin α2β1+ and side population of cells isolate from bulk cell lines and 
found multiple tumor-suppressive microRNA down-regulated, including miR34a, let-7, 
miR-106a and miR141 (322). Interestingly, a ‘near-patient’ approach highlights that a 
population of CD44+ cells isolated from xenografts led to the identification of miR-34a as 
master regulator of metastasis (323) and, as a consequence, this was subsequently 
validated in CD44+ cells isolated from primary prostate tumors. Moreover, in patient-
derived stem like cells (CD133+, α2β1high), it was recently found that miR-548c-3p can be 
considered as functional biomarker involved in prostate cancer progression (306) as 
enforced overexpression of this miR in differentiated cells induced stem-like properties 
and radioresistance. Finally other studies have used Hoechst 33342-based flow 
cytometry to isolate a CSC-like side population and confirmed the tumor suppressive 





Strikingly, there is lack of microRNA expression profiles of cancer-stem 
like/progenitor cells obtained from clinical prostate cancer specimens. The molecular 
characterization of this subpopulation of highly tumorigenic cells, could indeed provide 
novel insights in tumor progression and facilitate the identification of new therapeutic 







6. Outline of the thesis 
Cancer is a heterogeneous disease and the presence of multiple genetically 
distinct foci in the primary prostate cancer supports this notion. The identification of the 
molecular properties of highly aggressive and metastatic subclones might facilitate the 
identification of new targets for therapy and putative markers for monitoring the 
progression of the disease. 
In Chapter 2 of this thesis, we established a microRNA signature common to 
three key signaling pathways in prostate cancer progression and bone metastasis 
formation (i.e. TGF-β, Wnt and Notch). With this approach we identified a signature of 
validated microRNA targeting the process of epithelial-to-mesenchymal transition (EMT) 
that may be critically involved in the spreading of many aggressive cells from the 
primary tumor and the formation of distant metastases. 
Chapter 3 is focused on a candidate tumor suppressor microRNA that is 
downregulated in highly metastatic, stem-like ALDHhigh cells vs. non-metastatic, more 
differentiated ALDHlow prostate cancer cells. We studied the functional role of miR-25 in 
the maintenance of aggressive behaviour of ALDHhigh compared to ALDHlow 
subpopulation of cells in vitro and in vivo. Our analysis revealed that miR-25 represents 
an important player in the regulation of invasiveness in human prostate cancer through 
the interaction with at least three signaling pathways.  
Chapter 4 describes a follow-up study for the regulatory role of miR-25 in human 
prostate cancer biology, in particular its role in the cross-talk between the TGF-β and 
Wnt signalling in prostate carcinogenesis and progression.  
In Chapter 5 we show that the soluble chimeric protein ALK1Fc reduces BMP-9 
induced activation of Notch signaling and proliferation in human prostate cancer cells. 
Alk1Fc is capable of reducing tumor growth in an orthotopic model of human prostate 
cancer in vivo.  
Chapter 6 contains a study about the role of Cripto and GRP78 in the 
maintenance of an aggressive behaviour in human prostate cancer cells in vitro and 
their role in metastatic dissemination in two different preclinical models of prostate 
cancer invasion and metastasis in vivo. The general conclusions are included in Chapter 
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Epithelial to mesenchymal transition (EMT) is a reversible process by which 
cancer cells can switch from a sessile epithelial phenotype to an invasive mesenchymal 
state. EMT enables tumor cells to become invasive, intravasate, survive in the 
circulation, extravasate and colonize distant sites. Paracrine heterotypic stroma-derived 
signals as well as paracrine homotypic or autocrine signals can mediate oncogenic EMT 
and contribute to the acquisition of stem/progenitor cell properties, expansion of 
cancer stem cells, development of therapy resistance and often lethal metastatic 
disease. EMT is regulated by a variety of stimuli that trigger specific intracellular 
signaling pathways. Altered microRNA (miR) expression and perturbed signaling 
pathways have been associated with epithelial plasticity, including oncogenic EMT. In 
this review we analyse and describe the interaction between experimentally-validated 
miRs and their target genes in TGF-β, Notch and Wnt signaling pathways. Interestingly, 
in this process, we identified a “signature” of 30 experimentally-validated miRs and a 
cluster of validated target genes that seem to mediate the cross-talk between TGF-β, 
Notch and Wnt signaling networks during EMT and reinforce their connection to the 



















In the last decade the amount of data regarding microRNAs (miRs) and their 
target genes described in the literature has expanded tremendously. The volume of 
information on this new group of regulators (i.e. miRs) has complicated attempts to 
integrate this data within existing metabolic and signaling networks. As regulators of 
gene expression, miRs have indeed added a new level of interaction between different 
networks. In addition, a single miR can potentially regulate multiple different genes at 
the same time, leading to complex functional outcomes. However, from another 
perspective, the identification of groups of genes targeted by the same miR and the 
clustering of these genes within individual signaling pathways represents a means to 
understand the cross-talk between multiple signaling networks and their role in a 
common biological process. 
The focus of this review is to summarize the validated groups of miRs functionally 
linked to the cross-talk between TGF-β, Notch and Wnt signaling during the common 
biological process of Epithelial-to-Mesenchymal Transition (EMT). In particular, this 
review will address whether the documented cross-talk between these three important 
EMT-associated pathways, could be further reinforced by the identification of a 
“signature” of miRs, already depicted in the literature but not yet “sharpened” or clearly  
 
          
 
 
Figure 1. A) Venn diagram showing number of overlapping, experimentally validated miRs targeting 
KEGG pathway genes from the TGF-β, Wnt and Notch pathways. B) Venn diagram showing number of 
overlapping KEGG pathway genes from the TGF-β, Wnt and Notch pathways. 
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defined in this role. In the past years, many studies have elegantly described the role of 
TGF-β, Notch and Wnt pathways in promoting EMT and EMT-associated disorders 
including fibrosis and metastatic dissemination in cancer (1-6).  
 
Here we identify published and validated interactions between miRs and genes 
involved in TGF-β, Notch and Wnt signaling. This led to the discovery of a signature of 30 
miRs each regulating all three pathways. We then searched for additional validated 
genes targeted by these 30 miRs and then further clustered these into the TGF-β, Notch 
and Wnt signaling pathways. Interestingly, in our attempt to identify miRs that were 
common to all three of these signaling pathways, we found that the 30 miR signature 
strongly reinforced existing evidence supporting cross-talk between these three 
pathways during EMT. 
 
Data sources and analysis 
In this review we used TarBase v6.0, the largest currently available manually 
curated miR-target gene database, which includes targets derived from specific and 
high throughput experiments (7). Using TarBase v6.0 we searched the collection of 
manually curated, experimentally validated miR-gene interactions for TGF-β (hsa04350), 
Wnt (hsa04310) and Notch (hsa04330) signaling KEGG pathways in Homo sapiens (8).  
Using DIANA-miRPath (9), a miR pathway analysis web-server, we clustered the 
validated miRs using experimentally validated miR interactions derived from DIANA-
TarBase v6.0. Results were merged using a union of genes and analysed with A Priori 
Analysis Methods (overrepresentation statistical analysis). This statistical analysis 
identified pathways significantly enriched with targets belonging to a union of genes. A 
p-value threshold of 0.05 was applied with False Discovery Rate (FDR) correction to the 
resulting significance levels. 
 
A network of experimentally-validated microRNA highlights the 
cross-talk between TGF-β, Wnt and Notch signaling in EMT 
Using TarBase v6.0 we explored the collection of manually-curated, 
experimentally-validated miR interactions with genes in the TGF-β, Wnt and Notch KEGG 
pathways. We identified 84 experimentally validated miRs interacting with genes 
involved in the TGF-β signaling pathway, 104 miRs in the Wnt pathway and 48 miRs 
interacting with genes involved in Notch signaling. We clustered the miRs identified in 





three pathways focusing first on clusters of two out of three pathways (i.e. 
experimentally validated miRs shared between only TGF-β and Notch, TGF-β and Wnt or 
Notch and Wnt) (Fig. 1). We identified 2 experimentally validated miRs shared between 
the TGF-β and Notch pathways (Fig. 1 and Suppl. Table 1); 10 miRs shared between the 
Notch and Wnt pathways (Fig. 1 and Suppl. Table 2); 39 miRs shared between the TGF-
β and Wnt pathways (Fig. 1 and Suppl. Table 3). We further identified a signature of 30 
experimentally validated miRs targeting all three pathways (Fig. 1 and Table 1, 2 and 
3). Within this 30 miR signature, 4 miRs (miR-103a, miR-132, miR-30a and miR-10a) had 
validated target genes not ascribable to the manually annotated interactions within the 
KEGG pathways. 
DIANA-miRPath was used to collect the complete list of manually-annotated, 
experimentally-validated and published target genes for the 30 miRs identified. This was 
done in order to get better insight into the experimental data and understand the 
functional relevance of our analysis. Of all validated target genes 48 genes could be 
ascribed to the TGF-β pathway (p-value=6.9e-09), 30 to the Notch pathway (p-
value=4.7e-05) and 88 to the Wnt signaling pathway (p-value=5.07e-14). Using the same 
approach as for the miRs, a cluster of genes was found to be shared between only two of 
the three pathways (i.e. experimentally validated miR-gene interactions from TGF-β and 
Notch, TGF-β and Wnt or Notch and Wnt KEGG pathways). With this procedure, we 
identified 8 manually annotated and validated target genes shared by TGF-β and Wnt 
KEGG pathways (SMAD2, SMAD3, SMAD4, ROCK2, RHOA, MYC, PPP2R1A and PPP2R1B) 
and 5 manually annotated and validated target genes shared by Notch and Wnt KEGG 
pathways (CTBP1, CTBP2, DVL2, DVL3, PSEN1). Interestingly, no genes were shared 
between TGF-β and Notch KEGG pathways (Fig. 1B). Finally, we determined whether a 
new cluster of experimentally validated target genes coupled to our signature described 
above could be connected to a common biological process among TGF-β, Notch and 
Wnt signaling pathways. Strikingly, only 2 validated target genes, the transcriptional co-
activator cAMP-response element-binding protein (CREB)-binding protein (CBP) and the 
adenovirus E1A-associated cellular p300 transcriptional co-activator protein p300 
(EP300), were shared exclusively between the TGF-β, Notch and Wnt signaling KEGG 
pathways (Fig. 1B). These results indicate the relevance of the 30 identified miR 
signature thus suggesting a possible link between these miRs and cross-talk between 
TGF-β, Notch and Wnt pathways during EMT. 
 
  





Table I. List of experimentally validated miRNA-gene interactions for TGf-β signaling pathway. 








Table II. List of experimentally validated miRNA-gene interactions for Wnt signaling pathway. 
Interaction with Notch and TGF-β signaling are also indicated (genes among those in Wnt pathway). 
  





Table III. List of experimentally validated miRNA-gene interactions for Notch signaling pathway. 









Identification of a signature of miRs targeting genes linked to TGF-β-, 
Notch- and Wnt-dependent EMT 
1.1. Identification of miRs that regulate canonical and non-canonical TGF-β 
signaling during EMT 
TGF-β signaling plays complex roles during tumor progression and can either 
inhibit or promote tumor growth depending on the cellular context. The complexity of 
TGF-β signaling derives in part from the capability of its receptors to activate distinct 
canonical and non-canonical signaling pathways. In the SMAD-dependent canonical 
pathway, TGF-β ligands assemble their specific type II and type I transmembrane serine 
kinase receptors, allowing the constitutively active type II receptor kinase to 
phosphorylate the type I receptor, thereby activating its kinase.  
The active type I receptor then phosphorylates its cognate cytoplasmic SMAD proteins 
which then enter the nucleus to regulate the transcription of target genes. By contrast, 
the non-canonical pathway is SMAD-independent and includes TGF-β signaling via the 
Rho family of GTPases and MAPK/PI3K pathways. In this context, TGF-β has been shown 
to rapidly activate the Rho-GTPases and its activation of RHOA in epithelial cells leads to 
induction of stress fibers and acquisition of mesenchymal characteristics, thus 
promoting EMT (10). Additionally, RHOA is a crucial regulator in the signal transduction 
events that link activation of latent TGF-β by plasma membrane receptors (e.g. 
integrins) to the assembly of focal adhesions and sites of F-actin fiber organization (11).  
Interestingly, we have identified interactions between RHOA and a group of 5 
validated miRs (miR-155, miR-124, miR-375, miR-122 and miR-31) (12-17) (Fig. 2). More 
specifically, in endothelial cells, miR-155 was shown to block the acquisition of the 
mesenchymal phenotype induced by TGF-β by directly targeting RHOA (17). Similar 
observations were made in osteoclast precursor cells, where overexpression of miR-124 
decreased RHOA expression and reduced cell migration (18). miR-375 also interferes 
with cytoskeletal organization by indirectly targeting RHOA during neuronal 
development (12). Dramatic effects on migration and cytoskeleton disruption have also 
been reported for miR-122 in hepatocellular carcinoma (HCC). In this context, miR-122 
and RHOA interact directly and over-expression of RHOA reverts miR-122-induced 
mesenchymal to epithelial transition (MET) and inhibition of migration (16). Finally, in 
breast cancer cells it was demonstrated that overexpression of miR-31 decreases 
invasion and metastasis via downregulation of RHOA (15) (Fig. 2). Together, these 
findings highlight the relevance of these miRs in interfering with RHOA mediated EMT.  
 




Modulation of stress fibers and cytoskeletal rearrangements are key events in the 
acquisition of a mesenchymal phenotype and in the modulation of cellular motility. Two 
key players in this process are the Rho-serine/threonine kinases ROCK1 and ROCK2 
which regulate smooth muscle contraction, formation of stress fibers and focal 
adhesions (19). ROCK1 and ROCK2 are two major downstream effectors of RHOA that 
constitute additional important mediators of TGF-β-induced EMT. Interestingly, among 
the 30 miRs in our signature, we found 2 validated miRs (miR-335 and miR-124) that 
regulate expression of ROCK1 and ROCK2 (20, 21). Low levels of miR-335 were correlated 
with poor overall patient survival in neuroblastoma while overexpression of this miR 
strongly reduced cell migration and impaired F-actin organization (20). Further analysis 
revealed that miR-335 directly targets ROCK1 providing an explanation for its ability to 
reduce cell invasion (20). Low levels of miR-124 have been associated with poor 
prognosis in aggressive HCC while overexpression of miR-124 in HCC cell lines strongly 
decreased ROCK2 expression and inhibited EMT, formation of stress fibers, filopodia and 
lamellipodia (21). Taken together these experimental data highlight an important role 
for miR-335 and miR-124 in SMAD-independent, non-canonical TGF-β effects on 
cytoskeletal rearrangements via RHOA-dependent signaling pathways (Fig. 2). 
TGF-β also induces mesenchymal characteristics via canonical signaling, i.e. via 
SMAD2 and SMAD3. In the previous paragraph we described the ability of miR-155 to 
directly decrease RHOA expression and thereby inhibit cell motility and EMT 
characteristics (17). Interestingly, miR-155 has also been shown to interfere with the 
canonical TGF-β pathway by directly affecting the formation of the SMAD2/3 signaling 
complex. Louafi et al. have demonstrated that miR-155 directly targets SMAD2, leading 
to a reduction of TGF-β-induced SMAD2 phosphorylation and blocking SMAD2-
dependent activation of a TGF-β-inducible, SMAD-dependent CAGA reporter plasmid 
(22). Additionally, miR-155 targets presenilin 1 (PSEN1), a catalytic subunit of the 
gamma-secretase complex which catalyzes the cleavage of membrane proteins 
including Notch receptors (23). In this regard, Gudey et al. have shown that PSEN1 plays 
a crucial role in mediating the interaction between TGF-β and Notch signaling by 
promoting the association between the TGF-β type I receptor intracellular domain 
(TβRI-ICD) and the Notch intracellular domain (NICD) which in turn triggers cell-invasive 
behaviour in prostate cancer (24). Altogether, these data suggest that miR-155 can 
disrupt both the canonical and non-canonical TGF-β pathways and might represent an 










Figure 2. Interaction between miRs from the 30 miR signature and their predicted target genes 
overlaid on KEGG TGF-β, Notch and Wnt pathways. 
 
1.2. Identification of miRs regulating the cross-talk between TGF-β and Wnt 
signaling during EMT 
The observation that TGF-β alone can be sufficient to induce EMT in epithelial 
cells (10) while other cell types may not be sensitive to this effect of TGF-β (25) suggests 
that induction of EMT by TGF-β requires cooperation with other signaling pathways. 
Indeed, several studies indicate that TGF-β acts together with the Notch and Wnt 
pathways to promote EMT (4, 6, 26, 27). Remarkably, in our analysis we could not 
identify any validated miR target genes shared exclusively between the TGF-β and Notch 
pathways. However, Notch is able to antagonize TGF-β via sequestration of EP300, a 
factor that in turn acts as transcriptional co-activator for Notch1 (28). The interaction 
between the cluster of miR target genes ascribable to Notch signaling and their 




interactions with miR target genes associated with both TGF-β and Wnt signaling 
pathways is discussed below. 
Concerning Wnt signaling, two interesting genes highlighted in our analysis are 
PPP2R1A and PPP2R1B. These are the catalytic subunits of the PP2A holoenzyme, a 
protein phosphatase that reverts the action of protein kinases in many signaling 
cascades, including Wnt signaling (29). Several reports support the notion that PP2A 
plays a dual role in Wnt signaling and can act as either a positive or negative regulator of 
the pathway (30). On one hand, in the absence of Wnt, β-catenin forms a complex with 
APC, AXIN and GSK3β. This allows GSK3β to phosphorylate β-catenin that is then 
ubiquitinated and targeted for proteasomal degradation. In this context, different PP2A 
subunits bind to AXIN and APC, decreasing β-catenin levels and thereby negatively 
regulating Wnt signaling. On the other hand, in the presence of Wnt, PP2A seems to exert 
a positive role in β-catenin stabilization (30). In this situation, the complex of APC, AXIN 
and GSK3β is degraded by Dishevelled (DSH) leading to nuclear β-catenin accumulation 
and activation of Wnt target genes. Stabilized β-catenin can subsequently localize at 
plasma membrane in complex with E-Cadherin and PP2A, thus reducing EMT. 
Recently, we have demonstrated that activation of Wnt signaling via GSK3β 
inhibition in metastatic and androgen independent prostate cancer cells (PC3, DU145 
and C4-2B) induces dramatic changes in their morphology, blocks their migration, 
reduces their metastatic growth and strongly affects their mesenchymal phenotype (31). 
This highlights the ability of Wnt signaling to stabilize E-Cadherin and interfere with EMT 
in prostate cancer suggesting that PP2A may act as a negative regulator of EMT. 
Consistent with this possibility, it has been shown that restoring expression of a 
catalytic subunit of PP2A can revert EMT and suppress tumor growth and metastasis in 
an orthotopic mouse model of human prostate cancer (32). Interestingly, we identified 
two miRs in our signature (miR-16 and miR-124) that directly block the expression of 
catalytic subunits of PP2A (PPP2R1A and PPP2R1B) and that have been positively 
validated by proteomics and microarray, respectively (13, 23). Strikingly, homozygous 
deletion (HD) of the miR-16 locus was observed in androgen independent prostate 
cancer in xenograft models (33). The HD of miR-16 in a subset of androgen independent 
prostate cancer xenograft might suggest that, in this context, PP2A is present and 
stable. In turn, this might also suggest that activation of Wnt signaling in androgen 
independent prostate cancer cells could act synergistically with PP2A to promote 
stabilization of β-catenin and E-Cadherin leading to reduced EMT. Taken together, these 
data might identify a subset of androgen independent prostate cancers in which 
restoration of Wnt signaling reduces the aggressiveness of tumor cells and abolishes 





The involvement of miR-16 in EMT in the context of prostate cancer is further 
reinforced by an interesting observation regarding its role in the tumor-supportive 
capacity of stromal cells. Musumeci et al. have shown that miR-16 is downregulated in 
fibroblasts surrounding prostate tumors in patients (34). Additionally, they have 
demonstrated that miR-16 restoration considerably impairs the tumor-supportive 
capability of stromal cells in vitro and in vivo (34). From this perspective, it is important 
to note that the prostate tumor microenvironment is rich in TGF-β superfamily members 
including TGF-βs, bone morphogenetic proteins (BMPs), growth/differentiation factors 
(GDFs), activins, inhibins, Nodal and anti-müllerian hormone (AMH) (35). Among them, 
miR-16 has been suggested to regulate activin/Nodal signaling via direct interaction 
with teratocarcinoma-derived growth factor 1 (Cripto, TDGF1). Chen et. al. have indeed 
shown using luciferase reporter assays that miR-16 (together with miR-15a) directly 
interacts with the 3’UTR of Cripto (36). 
Cripto is a small, GPI-anchored protein that functions as a secreted growth factor 
and as an obligatory cell surface co-receptor for a subset of TGF-β superfamily ligands 
including Nodal (37). Cripto regulates both cell movement and EMT during embryonic 
development and cancer (38) and, strikingly, Nodal, which has been implicated in 
enhancing tumor cell plasticity and aggressiveness, is expressed in cancerous but not 
normal human prostate specimens (39). Although it is required for Nodal signaling, 
Cripto suppresses TGF-beta signaling in multiple cell types (40), reinforcing the inclusion 
of miR-16 in our signature. Therefore, the reduced expression of miR-16 in the tumor 
microenvironment in prostate cancer is predicted to facilitate Cripto-dependent Nodal 
signaling which together with Cripto’s other tumor promoting effects could trigger 
invasiveness, bone metastasis and EMT.  
Similar to miR-16, overexpression of miR-124 in androgen independent prostate 
cancer cell lines (DU145) strongly reduces aggressiveness and invasion (41). This further 
supports the hypothesis that the increased PP2A stability caused by low levels of miR-16 
and miR-124 in a subset of androgen independent prostate cancer cell lines could 
explain reduced cell migration and invasion, an effect that we also documented upon 
GSK3β inhibition (31). miR-124 is also likely to be an important player in Wnt signal 
transduction since proteomics and microarray analyses have revealed that it interacts 
with DVL2 (a member of DSH protein family) (13, 42). DVL2 binds the cytoplasmic C-
terminus of the frizzled family of Wnt receptors and transduces the Wnt signal to down-
stream effectors. Interestingly, DVL2 also interacts with insulin receptor substrates 
(IRS1/2) and thereby promotes canonical Wnt signaling (43). Moreover, IRS1/2 have 
been identified as key players in the regulation of E-Cadherin expression during EMT (44, 
45). IRS1/2 have also been implicated in the progression and etiology of prostate cancer. 
The IRS1/2 ratio has been shown to be significantly lower in malignant prostate tumors 




than in benign prostatic tissue and functional polymorphisms in IRS1 has been 
associated with a more advanced Gleason score (46, 47). Also reduced migration was 
documented after miR-124 overexpression in androgen independent prostate cancer 
suggesting a mechanism in which low levels of miR-124 boost DVL2. This, in turn, would 
be predicted to lead to GSK3β blockade with subsequent β-catenin and E-Cadherin 
stabilization. Additionally, low levels of miR-124 strengthen PP2A, which further 
contribute to stabilize β-catenin and E-Cadherin, therefore reducing EMT. 
Another miR in our signature, miR-324, has also been shown to regulated 
expression of DVL2. Ragan et al. used a luciferase reporter plasmid to demonstrate that 
miR-324 directly targets DVL2 (48). Interestingly, dysregulation of miR-324 has been 
linked to macrophage dysfunction in colorectal cancer, where altered Wnt signaling is 
known to play a pivotal role (49). More specifically, miR-324 was found to be highly 
expressed in infiltrated macrophages in fresh colon cancer tissues isolated immediately 
after surgical removal (49). Additionally, in the same work, the oncogene c-Myc was 
identified as a candidate transcription factor capable of regulating miR-324. This, 
combined with the identification of miR-324 in our analysis, suggests a fascinating role 
for miR-324 in the cross-talk between TGF-β and Wnt signaling in EMT and colorectal 
cancer. The role of TGF-β as a “double edged sword” during colon cancer progression 
has been extensively documented in the literature. In its tumor suppressive role, TGF-β 
inhibits progression of the cell cycle by inducing the tumor suppressors p15 (INK4B) and 
p21 (CDKN1A) and inhibiting expression c-Myc (50). At the same time, c-Myc is also a 
crucial downstream target of altered Wnt signaling in colon cancer (51) and has been 
shown to cause loss of E-Cadherin, which is a hallmark of EMT (52). Therefore, miR-324 
could be involved in a feedback loop between Wnt, TGF-β and c-Myc. More specifically, 
altered Wnt signaling during colorectal cancer development could modulate c-Myc 
levels and therefore miR-324 expression. In turn, abnormal miR-324 levels can interfere 
with DVL2 expression leading to alteration in the Wnt signaling pathway that further 
alter c-Myc and E-Cadherin levels (Fig. 2).  
 
We have identified a group of 6 miRs (miR-335, miR-34a, miR-21, miR-98, miR-24 
and miR-145) directly linked to c-Myc, reinforcing the role of c-Myc as common 
downstream target between TGF-β and Wnt mediated EMT. Among them, we have 
already discussed the role of miR-335 in EMT induced by TGF-β, particularly its 
interaction with ROCK1 and ROCK2 (20). Interestingly, Tavazoie et al. have shown by 
microarray that miR-335 also interacts with c-Myc (53), suggesting a more 
comprehensive role for miR-335 in TGF-β and Wnt mediated EMT. Additionally, Sampson 
et al. have suggested that miR-98 (from let-7/miR-98 family) might regulate c-Myc 





inhibits MYC, strongly increases the expression of miR-98 and other let-7 family 
members (54). Strikingly, treatment of melanoma cells with 10058-F4 efficiently 
diminished EMT mediated by TGF-β and S-phase kinase-associated protein 2 (SKP2) 
(55). Taken together, these data suggest that miR-98 could represent an important 
mediator in the cross-talk between TGF-β and Wnt and their effect in modulating of 
EMT. 
Deregulated expression of c-Myc has been reported in a wide variety of human 
cancers and among several key regulators of c-Myc expression, an important role is 
exerted by p53. Interestingly miR-145 has been reported to repress c-Myc in response to 
the p53 pathway (56) reinforcing its identification in our EMT signature. Similarly, 
members of miR-34 family are known to be direct transcriptional targets of p53 and p53-
binding sites are localized on the miR-34 gene promoter (57). However, Christoffersen et 
al. demonstrated that miR-34a is capable of repressing c-Myc in a p53 independent 
manner (58). This suggests that beside the cross-talk between p53 and c-Myc, there are 
additional mechanisms that contribute to fine tuning the role of c-Myc in TGF-β and Wnt 
dependent EMT. From this perspective, a crucial outcome of deregulated MYC signaling 
is represented by E-Cadherin repression. Lal et al. have shown that miR-24 directly 
targets MYC, suggesting that this miR could potentially play an interesting role in EMT 
modulation (59). To support this hypothesis, miR-24 has also been recently shown to 
regulate the EMT program in response to TGF-β in breast cancer cells. Papadimitriou et 
al. have demonstrated that miR-24 is capable of modulating TGF-beta-induced breast 
cancer cell invasiveness through regulation of RhoA-specific guanine nucleotide 
exchange factor Net1 isoform2 (Net1A), a protein that is necessary for TGF-beta-
mediated RhoA activation (60). Together, these findings reinforce the identification of 
miR-24 in our EMT signature. 
The last miR included in the group of those targeting c-Myc is miR-21. Singh et al. 
have suggested that miR-21 regulates self renewal in mouse embryonic stem (ES) cells 
and could potentially interact with MYC and other self renewal markers (Oct4, Nanog 
and Sox2) (61). They have shown that enforced expression of miR-21 in ES cells 
downregulates renewal markers, including c-Myc (61). This suggests that in specific 
contexts modulation of miR-21 could potentially affect c-Myc expression and therefore 
modulate E-Cadherin levels and affect EMT. 
Finally, in the previous paragraphs we have described the role of miR-155 as an 
interesting player capable of disrupting the tumor-promoting effects of SMAD-
dependent and SMAD-independent TGF-β signaling (22). Interestingly, in our analysis we 
identified another group of 4 miRs linked to TGF-β signaling and belonging to the miR-
17-92 cluster (i.e. miR-19a, miR-19b and miR-92a) and to its paralog cluster miR-106b-25 
(i.e. miR-93). Interestingly, c-Myc has been reported to upregulate the miR-17-92 cluster, 




providing further evidence of cross-talk between Wnt and TGF-β signaling (62). Dews et 
al. performed a detailed study to elucidate the mechanism of interaction between the 
miR-17-92 cluster and TGF-β signaling, particularly with SMAD4 (63). Using qPCR and 
microarray analyses they provide evidence suggesting that miR-19a, miR-19b and miR-
92a regulate SMAD4 indirectly, i.e. without interacting with the SMAD4 3’UTR (63).  
 
1.3. A group of miRs targeting the CREBBP/EP300 interaction highlight the 
cross-talk between TGF-β, Wnt and Notch signaling during EMT 
As mentioned above, EP300 (p300) and CREBBP (CREB binding protein, CBP) are 
the only two KEGG pathway genes shared among all three pathways (i.e. TGF-β, Wnt and 
Notch). EP300 and CREBBP are functionally related transcriptional co-activator proteins 
that play many important roles in in processes including cell proliferation, 
differentiation and apoptosis. In the context of Wnt signaling, EP300 has been shown to 
act synergistically with β-catenin and T cell factor (TCF) during neoplastic 
transformation (64). Similarly, in the context of TGF-β signaling, it has been reported 
that phosphorylated Smad3 interacts with the CREBBP/EP300 complex to augment 
transcriptional activation (65). Additionally, the Notch intracellular domain (NICD) can 
recruit the complex CREBBP/EP300 to interact with the transcription factor CSL 
(CBF1/Su(H)/Lag-1) which, in turn, activates the transcription of two known Notch 
related basic-helix-loop-helix transcription factor families, Hey and Hes (66).  
EP300 regulates transcription and remodels chromatin by acting as histone 
acetyltransferase. It regulates p53 dependent transcription and binds specifically to 
phosphorylated CREBBP (67). EP300 and CREBBP were originally identified in protein 
interaction assays through their association with the transcription factor CREB and with 
the adenoviral-transforming protein E1A respectively (68-70). The roles of CREBBP and 
EP300 and their interaction during EMT have been extensively studied. However, the 
large degree of cellular heterogeneity within different organs and tissues makes the role 
of EP300 in EMT difficult to define with precision (71).  
Strikingly, some reports have linked the expression of wild-type EP300 in 
colorectal and prostate cancer with the degree of intravascular dissemination of cancer 
cells (probably affected by ongoing EMT) and poor prognosis (72-74). In this context, 
EP300 seems to promote cancer cells EMT. In support of this, elevated expression of 
EP300 in hepatocellular carcinomas (HCC) correlates with enhanced vascular invasion, 
intrahepatic metastasis, shortened survival and, strikingly, low E-Cadherin expression 
(75). EP300 knockdown strongly increased E-Cadherin expression and significantly 
decreased migration and invasion in a hepatoma cell line (HLE) that is otherwise highly 





In the context of cancerous hepatocytes, TGF-β is one factor that plays a major 
role in the induction of EMT, causing type I collagen induction and formation of liver 
fibrosis. In this situation, EP300 interacts with Smad3 and function as signal integrator 
for mediating regulation of collagen synthesis by TGF-β (76). Treatment with HDAC 
inhibitor strongly decreases EP300 levels and restores E-Cadherin distribution to the 
hepatocytes cell membrane therefore reducing TGF-β induced EMT (77). 
As outlined above, targeting the expression of EP300 and/or CREBBP can 
simultaneously affect TGF-β, Wnt and Notch pathways. In this regard, miR-9, which is 
represented in our 30 miR signature, was shown to target EP300 as determined by 
microarray analysis (78) (Fig. 2). Remarkably, miR-9 has also been shown to be involved 
in the modulation of E-Cadherin levels via c-Myc. More specifically, Ma et al. have shown 
that MYC acts as transcriptional activator of miR-9 and that miR-9, in turn, directly 
targets E-Cadherin (79). Therefore, miR-9 is not only one of the common miRs linking 
TGF-β, Wnt and Notch signaling it also has the ability to target E-Cadherin which links it 
directly to EMT. Thus, it appears that miR-9 might represent an interesting regulator of 
the cross-talk between TGF-β, Wnt and Notch signaling pathways in both normal cells 
and cancer cells. On one hand, through its effect on E-Cadherin and EP300, miR-9 may 
maintain the balance between epithelial and mesenchymal cell state in normal cells. On 
the other hand, in cancer cells that have lost the tumor suppressive effect of TGF-β, the 
disruption of the TGF-β cytostatic program could cause c-Myc induced up-regulation of 
miR-9 leading to loss of E-Cadherin and subsequent EMT. Bonev et al. have further 
shown that in the context of Notch signaling, in addition to its connection with EP300, 
miR-9 also interacts directly with Hes1 (80). This reinforces the hypothesis that miR-9 
represents an interesting regulator of the Notch signaling pathway with a role in the 
cross-talk between TGF-β, Wnt and Notch.  
Regulation of the CREBBP/EP300 complex by miR-9 represents an interesting 
mechanism of co-regulation of TGF-β, Wnt and Notch signaling pathways. In this regard, 
it is interesting to note that we identified another group of 5 miRs (miR-26b, miR-194, 
miR-182, miR-374 and miR-324) that also were shown to interact with EP300 and 
CREBBP by microarray (81). Among these, notable observations have been reported for 
miR-26 and miR-324. Cai et al. have shown that miR-26 is strongly downregulated in HT-
29 colon cancer cells undergoing TGF-β induced EMT, whereas Ragan et al. have 
described an interaction between miR-324 and CREBBP by transcriptomic analysis (48, 
82). Moreover, interestingly in our analysis we have also identified miR-1, that has been 
shown to interact with CTBP1/2, two proteins that binds to the C-terminus of adenovirus 
E1A protein (13) and act as corepressors of Notch target genes (83). (Fig. 2).  
As discussed above, there is a connection between miR-324 and DVL2 in the 
context of Wnt signaling and colon cancer (48, 49). Interactions between TGF-β and Wnt 




are important in many biological processes. In particular, in the context of colon cancer, 
the cascade of events that drives tumor progression is characterized by series of genetic 
modifications involving components of the Wnt and TGF-β signaling pathways. In colon 
cancer, the adenoma-carcinoma sequence is initiated by alteration in Wnt signaling (i.e. 
inactivation of APC). Subsequently, the late stage adenoma shows loss of 18q-arm, 
where maps the best candidate tumor suppressor gene DPC4/MADH4, which encodes 
SMAD4, involved in the TGF-β pathway (84). This event drives the progression from the 
intermediate adenoma stage to late adenoma, resulting in loss of the cytostatic effect of 
TGF-β. Strikingly, the interaction between β-catenin and the TGF-β pathway depends on 
the transcriptional co-activator CREBBP as demonstrated by Zhou et al. who used 
chromatin immune precipitation to show that a complex forms between Smad3, β-
catenin and CREBBP (85). These findings together with the identification of EP300 and 
CREBBP in our analysis suggest that miR-26 and miR-324 may link TGF-β and Wnt 
signaling with EMT in colon cancer progression.  
 
1.4. Interaction between CREBBP/EP300 and miR-200 family  
Recent studies have indicated that the switch in tumor cells from a sessile, 
epithelial phenotype towards a motile, mesenchymal phenotype is accompanied by the 
acquisition of stem/progenitor cell characteristics (86). In particular, cells undergoing 
EMT acquire chemoresistance, a key property attributed to cancer stem cells (CSCs) (86). 
In this context, the miR-200 family is particularly interesting. The miR-200 family 
includes miR-200c-3p, miR-200b-3p and miR-429 (all identified in our analysis) and 
inhibits EMT and cancer cell migration by directly targeting the E-Cadherin 
transcriptional repressors ZEB1 and ZEB2 (87). Additionally, downregulation of miR-200 
family has been described in docetaxel resistant prostate cancer cells, reinforcing the 
link between EMT and resistance to chemotherapy (88).  
Interestingly, our analysis revealed a connection between miR-200 family 
members and EP300 regulation. Mizuguchi et al. have shown that acetyltransferase 
EP300 regulates expression of miR-200c-3p overcoming its transcriptional suppression 
by ZEB1 (89). The same authors showed that treatment with an HDAC inhibitor 
significantly increased miR-200c-3p levels causing a decrease in Vimentine and ZEB1 
and upregulation of E-Cadherin. Strikingly, miR-200c-3p, miR-200b-3p and miR-429 have 
also been shown to interact with EP300 by microarray and protein analysis (81). These 
observations enhance the complexity of the regulatory mechanisms governing the 
interplay between EP300 and E-Cadherin and suggest a positive feedback loop between 





by EP300 which upregulates miR-200 expression. Furthermore, higher levels of miR-200 
could decrease ZEB1, suggesting that the positive effect of EP300 on E-Cadherin 
expression could also be mediated via miR-200 family (Fig. 2). 
 
Conclusion 
In this review, we discussed and summarized the known interactions between 
miRs and genes involved in TGF-β, Notch and Wnt signaling pathways and highlighted a 
signature of 30 validated miRs linking these pathways to the process of EMT. Our novel 
approach led to the identification of cluster of validated and known miRs involved in 
different pathways in an attempt to reduce the extraordinary volume of information 
related to the interaction between miRs and different target genes. We believe that the 
identification of groups of genes targeted by the same miR and the clustering of these 
genes in different pathways could potentially represent an interesting strategy to better 
understand the cross-talk between multiple signaling networks, thus facilitating the 
understanding of their connections and their role in a common biological process. 
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Supplementary Table I. List of experimentally validated miRNA – gene interactions for Notch signaling 
and TGF-β signaling pathway. 
 
 
Supplementary Table II. List of experimentally validated miRNA – gene interactions for Notch signaling 












Supplementary Table III. List of experimentally validated miRNA – gene interactions for Wnt signaling 
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Altered microRNA (miR) expression is associated with tumor formation and 
progression of various solid cancers. A major challenge in miR expression profiling of 
bulk tumors is represented by the heterogeneity of the subpopulations of cells that 
constitute the organ, as well as the tumor tissue. Here we analyzed the expression of 
miRs in a subpopulation of epithelial stem/progenitor-like cells in human prostate 
cancer (PCSC) and compared their expression profile to more differentiated cancer cells. 
In both cell lines and clinical prostate cancer specimens we identified that miR-25 
expression in PCSCs was low/absent and steadily increased during their differentiation 
into cells with a luminal epithelial phenotype. Functional studies revealed that 
overexpression of miR-25 in prostate cancer cell lines and selected subpopulation of 
highly metastatic and tumorigenic cells (ALDHhigh) strongly affected the invasive 
cytoskeleton causing reduced migration in vitro and metastasis via attenuation of 
extravasation in vivo. Here we show, for the first time, that miR-25 can act as a tumor 
suppressor in highly metastatic PCSCs by direct functional interaction with the 3’UTR of 
pro-invasive αv- and α6 integrins. Taken together, our observations suggest that miR-25 
is a key regulator of invasiveness in human prostate cancer through its direct 



















Prostate cancer is the second most frequently diagnosed cancer and the sixth 
leading cause of death from cancer in males worldwide (1). Despite the progress in the 
pathogenesis, detection, and treatment of primary tumor, the main problem for 
prostate cancer patients remains the risk of metastasis formation and tumor recurrence 
after surgical removal and/or treatment of the primary tumor.  
From a hierarchical point of view, normal and transformed epithelial tissues are indeed 
characterized by a cellular heterogeneity, in which different cell types contribute to the 
maintenance of the complexity of tissues (2). One of the major challenges in the field of 
new therapy development for advanced cancer is to specifically target “driver” cancer 
cell subpopulations, that seem to be involved in tumor maintenance, metastasis and 
therapy resistance (3). Accumulating evidence shows that prostate cancer 
stem/progenitor-like cells play key roles in tumor initiation, local and distant relapse, 
metastasis, and castration- & chemotherapy resistance (4,5). One of the driving forces of 
oncological transformation of normal epithelial stem cells (SC) into cancer stem cells 
(CSCs), is the deregulated gene expression of tumor suppressors and oncogenes (6). 
Furthermore, oncological research has highlighted an emerging role for microRNAs 
(miRs) as crucial regulators of such oncogenes and tumor suppressors in cancer (7). 
miRs are a class of small non-coding RNA molecules (18-25 nucleotides long), which 
modulate gene expression by binding to the 3’-untranslated regions (3’-UTR) of target 
mRNAs and promoting mRNA degradation or translational repression (8). Several 
studies have delineated and compared the expression of miRs in bulk tissues from 
human prostate cancer and normal prostate and have shown significant correlations 
between miRs levels, prostate cancer progression and response to chemotherapy (9,10). 
In addition, these studies have highlighted the diagnostic and prognostic value of miRs 
detection in blood and urine, suggesting the possible relevance of the use of miRs as 
prostate cancer biomarkers.  
Most attempts to decipher the miRs signatures have been performed in clinical samples 
of bulk tumor tissues or heterogeneous prostate cancer cell lines. In these heterotypic 
and heterogeneous cell populations, this strategy cannot clearly discriminate between 
the “driver” subpopulation and other, non-tumorigenic and more differentiated cancer 
cell subpopulations. In bulk tumor tissues, it is even more difficult to discriminate 
between tumor-derived and stroma-derived miR expression profiles.  
Here we examined the expression of miRs in the “driver” subpopulation of human 
stem/progenitor-like prostate cancer cells (cell lines, patient samples) that was 
previously shown to drive tumorigenesis and metastasis in preclinical prostate cancer 
models of bone metastasis in vivo (11). Based on the list of differentially expressed miRs, 




miR-25 was selected because a number of its putative target genes are predicted to be 
involved in the stimulation of cancer invasiveness. In both clinical prostate cancer 
specimens and prostate cancer cell lines we found that miR-25 is low/absent in the 
α2β1hi /CD133+ compartment, also referred to as stem-like cells (SC) in recent 
publication (12). and steadily increases during differentiation into luminal epithelial 
cells in clinical samples. Here we validate, for the first time, the direct functional 
interaction between miR-25 and αv- and α6 integrins linked to the cytoskeletal 
organization and invasive behavior in vitro. In line with these observations, we further 
demonstrate that miR-25 targeted αv- and α6 integrins in selected ALDHhigh 
subpopulation of cancer stem/progenitor cells and reduced invasion by blocking the 
extravasation of human prostate cancer cells in the intact organism.  
 





Materials and Methods 
 
ALDEFLUOR® assay and real time PCR-based microRNA expression profiling 
Aldehyde Dehydrogenase (ALDH) activity of the cells was measured using the 
ALDEFLUOR® assay kit (StemCell Technologies, Durham, USA) according to the 
manufacturer's protocol (11). ALDH substrate was added to the cells and converted by 
intracellular ALDH into a fluorescent product. For FACS sorting cells were labelled with 
ALDEFLUOR® kit and sorted using FACS ARIA cell sorter (BD Bioscience, Breda, The 
Netherlands) (ALDHhigh = highest 10% ALDH+; ALDHlow = lowest 10% ALDH- cells). 
microRNA expression profiling was performed using RT2 miRNA PCR array (SA-
biosciences, Frederick, USA) according to the manufacturer’s protocol. Data were 
normalized using SNORD48 and U6 RNA housekeeping genes. Inclusion criteria were Ct 
value <35, fold induction >2 and <-2 and similar data in 2 independent experiments. 
 
Prostate cancer cell lines and transfection with miR-25 precursor molecule 
Human osteotropic prostate cancer cell lines PC-3M-Pro4Luc2 and C4-2B cells 
were maintained in DMEM with 10% FCII, 1% Penicillin-Streptomycin (Life Technologies, 
USA ) and 0.8 mg/ml Neomycin (Santacruz, USA) and T-medium DMEM (Sigma-Aldrich, 
The Netherlands) with 20% F-12K nutrient mixture Kaighn’s modification (GibcoBRL), 
10% FCS, 1% Insulin-Transferin-Selenium, 0.125 mg/ml biotin, 12.5 mg/ml adenine, 
6.825 ng/ml T3 and 1% penicillin/streptomycin respectively. Cells were maintained at 
37°C with 5% CO2 .  
For transient transfection, Lipofectamine® 2000 (Invitrogen, USA) was used according to 
manufacturer's protocol with Pre-miR-25 (ID: PM10584; Life Technologies) and pre-
miRNA negative control (scramble) (ID: AM17110; Life Technologies). Total RNA was 
collected after 72 hours. 
 
Collection of samples from patient, isolation of subpopulation from 
primary prostate epithelial cells and expression array 
Prostate epithelial tissue was collected with ethical permission from York District 
Hospital (York) and Castle Hill Hospital (Cottingham, Hull). Primary epithelial prostate 
cells were expended in culture and selected for α2β1 integrin expression using rapid 
adhesion to type collagen-I coated plates (13). α2β1hi cells were subsequently enriched 
for CD133- and CD133+ fraction using MACS cell sorting according to the manufacturer’s 
protocol (Milteny Biotec) (5,12,14). Cultured cells were harvested at passage 2 and total 
RNA was extracted using miRVana kit (Life Technology, Paisley, UK). Agilent V3 arrays 




were used to perform miR microarray analysis and the data was processed using Agilent 
Feature extraction software. The data were quantile normalized, and RMA summarized. 
 
miRNA target prediction and bioinformatic analysis of cluster of genes 
Targetscan v6.2, miRDB (15) and microT-CDS (16) were used to identify novel 
miR-25 predicted targets. Functional annotation was performed using DAVID 
Bioinformatics Resources 6.7 (17,18) and KEGG database (19). 
 
RNA isolation and real-time qPCR 
Total RNA was isolated using Trizol (Invitrogen, USA), cDNA was synthesized by 
reverse transcription (Promega, USA) according to manufacturer’s protocol and qRT-
PCR performed with Biorad CFX96 system (Biorad, The Netherlands). Expression was 
normalized to GAPDH. (Primer sequences in supplementary table I).  
 
Migration assay 
Cells were starved overnight in medium containing 0.3% serum and then seeded 
in medium containing 0.3% serum in Transwell chamber (Corning 8-µm pore size). The 
lower chamber was filled with medium containing 10% serum. After 18 hours of 
incubation, cells on the upper side of the filters were removed and cells migrated to the 
lower side were fixed with 4% paraformaldehyde, stained with 0.1% crystal violet 
(Sigma-Aldrich, USA) and counted. 
 
Proliferation assay 
Cells were seeded at density of 2,000 cells/well 24 hours and allowed to grow for 
24, 48, 72. After incubation, 20 µl of 3-(4,5 dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium was added and 
mitochondrial activity was measured after 2 hours incubation at 37°C. (CellTiter96 
Aqueous Non-radioactive Cell proliferation assay, Promega, USA). 
 
FACS analysis 
Protein expression was measured with flow-cytometry. 1 x 105 cells were 
incubated for 45 min at 4°C in FACS wash buffer containing PBS + 1% FCS + 0.1% 
Natriumazide NaN3 and 10 µl antibody (αV-PE, α2-FITC, α6-APC, Milteny). Cells were 
washed with PBS, protein measured with FACS Calibur (BD Biosciences, USA) and data 








PC-3M-Pro4luc2 transfected with Pre-miR-25 and scramble negative control were 
seeded onto glass slides, fixed with 4% paraformaldehyde and stained with 0.25 µM 
Phalloidin (Life technologies, USA). TOPRO (Life technologies) was used for nuclei 
visualization. Images were acquired with confocal microscope leica SP5 (Leica, 
Germany) and analysed with ImageJ (NIH). 
 
Reporter constructs and luciferase assay 
497 bp and 485 bp nucleotide sequences corresponding to portion of the 3’ UTR 
of ITGA6 and ITGAV respectively, including the conserved predicted binding site (seed 
sequence) for miR-25 were cloned downstream of the firefly Luciferase2 sequence in a 
PGL4.10 vector (Promega, USA) using XbaI (Promega) and FseI (New England Biolabs, 
USA) restriction enzymes. 1184 bp sequence of human elongation factor 1α (hEF1α) 
promoter was inserted into the multiple cloning site (MCS) of the PGL4.10 upstream the 
luciferase2 sequence using KpnI and HindIII (Promega). Mutagenesis was performed 
using QuikChange® (Stratagene, USA) site-directed mutagenesis approach. (Primer 
sequences in supplementary table II). 
 
Zebrafish maintenance 
Tg(mpo:GFP)i114 zebrafish line (20,21) was handled compliant to local animal 
welfare regulations and maintained according to standard protocols (www.ZFIN.org). 
 
Zebrafish embryo preparation and tumor cell implantation 
2 days-post fertilisation (dpf) dechorionized zebrafish embryos were 
anaesthetized with 0.003% tricaine (Sigma) and placed on a 10-cm Petridish coated with 
3% agarose. PC-3M-Pro4mCherry cells were transfected 48h before implantation. Single 
cell suspensions were re-suspended in PBS, kept at room temperature before 
implantation and implanted within 3 h. The cell suspension was loaded into borosilicate 
glass capillary needles (1 mm O.D. × 0.78 mm I.D.; Harvard Apparatus) and the injections 
were performed using a Pneumatic Picopump and a manipulator (WPI, UK). 
Approximately 400 cells were injected at around 60 µm above the ventral end of the 
duct of Cuvier (DoC), where the DoC opens into the heart. After implantation with 
mammalian cells, zebrafish embryos (including non-implanted controls) were 
maintained at 33°C, to compromise between the optimal temperature requirements for 
fish and mammalian cells (22). Data are representative of at least two independent 
experiments with at least fifty embryos per group. Experiments were discarded when 
the survival rate of the control group was less than 80%. 





Statistical analysis was performed with GraphPad Prism 6.0 (GraphPad software) 
using t-test for comparison between two groups. Data is presented as mean ± SEM. P-








miR-25 expression is down-regulated in normal and transformed prostate 
stem cells (PCSC) and steadily increases upon luminal differentiation. 
To investigate the expression of miRs in prostate cancer stem cells (PCSCs), we 
used the ALDEFLUOR assay, which involves viable cell sorting based on ALDH enzyme 
activity (23,24). After viable sorting ALDHhigh and ALDHlow subpopulations of PC-3M-
Pro4Luc2 were used to identify the differential miR expression profiles of cancer stem 
cells (ALDHhigh) and committed non‐tumorigenic & non-metastatic (ALDHlow) cells (11). 
Real Time PCR-based miR expression profiling revealed that miR-25 was the most down-
regulated microRNA in cancer stem cells (ALDHhigh) compared to ALDHlow subpopulation 
of cells (LOG10-Fold change -2,76 p-value=0,05). (Fig. 1A).  
 
 
Figure 1. Differential expression of miR-25 in prostate cancer, prostate cancer stem-like cells, and 
benign prostate epithelial stem cells. A) miR-25 expression in ALDHhigh versus ALDHlow subpopulation 
isolated from PC-3M-Pro4Luc2 cells measured with real time PCR-based miRNA expression profiling; 
error bars, ±SEM (n = 2). B) relative array expression of miR-25 in BPH, PCa (prostate cancer), and CRPC 
samples isolated from patients. C) relative array expression of miR-25 in α2β1hi/CD133+, 




α2β1hi/CD133−, and α2β1low compartment, also referred to as stem-like cells, TA cells, and CB cells, 
respectively (12), isolated from BPH (n = 5 patients), PCa (prostate cancer; n = 5 patients; D), and CRPC 
(n = 3 patients; E); error bars, ±SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
 
We next investigated miR expression in subpopulations isolated from prostate 
tissue and primary epithelial cultures derived from patients with Benign Prostatic 
Hyperplasia (BPH), hormone-naïve prostate cancer (PCa, > Gleason 7) and castration-
resistant prostate cancer (CRPC) (12). First we quantified the expression of miR-25 in 
unfractionated soft tissue collected from BPH, PCa and CRPC and found increased miR-
25 expression upon tumor progression. (Fig. 1B). Then, after expansion of primary 
prostate cells in culture, we compared miR-25 expression in three cell populations: 
α2β1hi /CD133+ , α2β1hi /CD133-, and α2β1low , also referred to as stem-like cells (SC), 
transit amplifying cells (TA) and committed basal cells (CB), respectively (5,12,14,25). 
Interestingly, miR-25 is significantly and strongly down-regulated in the α2β1hi /CD133+ 
population compared to the α2β1hi /CD133- and α2β1low compartments, irrespective of 
their pathological status (i.e. BPH, PCa and CRPC) (Fig. 1C, D, E). 
Taken together, our data show consistent relative low expression levels of miR-25 in the 
cancer stem/progenitor subpopulation of cells in both human prostate cancer cell lines 
and the compartment defined as α2β1hi /CD133+ cells isolated from prostate cancer 
patients (12,25). The expression of miR-25 steadily and consistently increases during 
epithelial differentiation in patient-derived benign prostates (BPH) and malignant 
prostate samples. 
 
Identification and transcriptional analysis of miR-25 predicted target 
genes.  
Next Targetscan (Release 6.2) was used to identify novel miR-25 predicted target 
genes (26). Using this approach we identified 893 conserved putative target genes, with 
a total of 992 conserved sites and 211 poorly conserved sites. Among the list of 
predicted targets, 63 genes were mapped, using the database for annotation, 
visualization and integrated discovery DAVID (17,18), in processes linked to invasion and 
pathways related to prostate cancer and bone metastasis (Regulation of f-actin 
cystoskeleton, ECM-receptor interaction, TGF-β signalling pathway, MAPK signalling 
pathway and cell cycle). Interestingly, our in silico analysis showed that the regulation of 
F-actin cytoskeleton was one of the predicted pathways that is potentially affected by 
miR-25 (p-value = 2.1E-2). Mapping of the predicted miR targets to the regulation of F-
actin cytoskeleton, KEGG pathway identified multiple genes involved in important 








Figure 2. In silico analysis for predicted pathway identification and validation by RT-qPCR. A) 
interaction between miR-25 and predicted target genes overlaid on KEGG regulation of the actin 
cytoskeleton pathway. B) clustergram of mRNA expression assessed by RT-qPCR for selected target 
among those represented in A. Analysis performed in PC-3M-Pro4Luc2 and C4-2B cells (N = 3). Colors 
match with those represented in B, D, E, F, G, H (green, downregulation; red, upregulation). C) mRNA 
regulation of selected target genes on PC-3M-Pro4Luc2–overexpressing miR-25; regulation is 
highlighted in green (down) and red (up). Colors are matched with scatter plot (D) with threshold 
selected (threshold value = 2) and significant values are represented in volcano plot (E). F) mRNA 
regulation of selected target genes on C4-2B–overexpressing miR-25; regulation is highlighted in green 
(down) and red (up). Colors are matched with scatter plot (G) with threshold selected (threshold value = 
2) and significant values are represented in volcano plot (H). 
 
Strikingly, miR-25 was predicted to target IQGAP2 (a GTP-dependent protein involved in 
the cytoskeletal reorganization), WASL and CFL2 (involved in the actin polymerization 
and depolymerization), CDC42 (required for rounded/ameboid movements of single 
tumor cells), MYH9 (cellular myosin with a role in cytokinesis and cell shape), PIP4K2C 
and PIP5K1C (kinase which mediates RAC1-dependent reorganization of actin filaments 




(27)). RAC1 is involved in focal adhesion and is required for mesenchymal movements of 
single tumor cells (28)), PIKFYVE (which plays a role in endosome-related membrane 
trafficking), PPP1R12A (regulates myosin phosphatase activity), SLC9A1 
(sodium/hydrogen exchanger involved in focal adhesion), ITGA5 (a.k.a. fibronectin 
receptor, significantly down-regulated by miR-25 in both cell lines as shown by qRT-PCR 
analysis (Fig. 2 B,C,D,E and Fig. 2 F,G,H)) and ITGAV (a.k.a. vitronectin receptor), ITGA6 
(laminin-10/11 receptor) and Vinculin (VCL, however not affected by miR-25 as shown by 
western blot (Suppl. Fig. 1A) that are all involved in cell-matrix interactions and 
adhesion. Among the target genes involved in the regulation of the F-actin cytoskeleton, 
ITGAV and ITGA6 are members of the integrin family of transmembrane receptors that 
regulate cell adhesion, migration and remodelling of the ECM (29-31). Additionally, 
ITGAV and ITGA6 were also identified as miR-25 predicted targets using miRDB (15) and 
microTCDS (16). Moreover integrin-transmembrane receptors regulate the activation of 
Rho-GTPases, RAC1 and CDC42 (32). Interestingly, our mRNA analysis (Fig. 2B) revealed 
that miR-25 significantly down-regulated CDC42 and its effector proteins CDC42BPA and 
CDC42EP2 and decreased mRNA of RAC1 (Fig. 2 C,D,E and Fig. 2 F,G,H). Additionally, 
our RT-qPCR analysis revealed that miR-25 could significantly decreased PIP5K1C, 
kinase involved in RAC1 signaling and predicted target of miR-25 in both cell lines (Fig. 2 
C,D,E and Fig. 2 F,G,H). 
Previously we have shown that ITGAV is required for the acquisition of a 
stem/progenitor phenotype (31). Additionally, ITGAV and ITGA6 are highly expressed in 
prostate progenitor cells and ITGA6 has been established as maker for progenitor cells 
in prostate and breast cancer. These results suggested a functional link between miR-25 
and ITGAV and ITGA6 expression regulation in prostate cancer, for which no information 
is currently available.  
 
miR-25 overexpression down-regulates αv and α6 integrins in human 
prostate cancer cell lines and selected ALDHhigh subpopulation  
To investigate the functional interaction between miR-25 and the predicted 
target genes we isolated ALDHhigh and ALDHlow from PC-3M-Pro4Luc2 prostate cancer cell 
line by flow cytometry. As expected, the clonogenic and migratory potential of ALDHhigh 
vs ALDHlow cells was higher (11) (Suppl. Fig. 1B, C). Furthermore, ITGAV and ITGA6 
expression was also higher in ALDHhigh vs ALDHlow cells as expected, thus confirming the 
inverse correlation with miR-25 expression (11) (Suppl. Fig. 1D). We used ITGA2, an 
established prostate cancer stem cell marker, as positive control and confirmed its 
increased expression in ALDHhigh cells (5,11) (Suppl. Fig. 1D). 
The functional interaction between miR-25 and ITGAV and ITGA6 expression in human 





and ALDHlow committed cells) was evaluated by transfection with 60nM of pre-miR-25 or 
pre-negative control sequence.  
 
 
Figure 3. miR-25 overexpression decreases ITGAV and ITGA6 expression at mRNA and protein level 
in prostate cancer cells and selected ALDHhigh subpopulation of cells. A) PC-3M-Pro4Luc2– and C4-
2B–overexpressing miR-25; relative expression is compared with scramble negative control and all 
values were normalized to GAPDH; error bars, ±SEM (n = 3). B) mean intensity of ITGAV and ITGA6 
fluorescence in PC-3M-Pro4Luc2– and C4-2B–overexpressing miR-25 compared with scramble-negative 
control determined by FACS analysis; error bars, ±SEM (n = 3). C) histogram of flow cytometric analysis 
of ITGAV and ITGA6 protein expression. Expression levels in cells overexpressing miR-25 (continued line) 




are compared with scramble-negative control (dashed line). D) and E) mean intensity of ITGAV and 
ITGA6 fluorescence in ALDHhigh- versus ALDHlow-overexpressing miR-25 compared with scramble-
negative control determined by FACS analysis; error bars, ±SEM (n = 2). F) histogram of flow cytometric 
analysis of ITGAV and ITGA6 protein expression. Expression levels in ALDHhigh versus 
ALDHlow subpopulation–overexpressing miR-25 (continued line) are compared with scramble-negative 
control (dashed line). * and $, P < 0.05; ** and $$, P < 0.01; ***, P < 0.001. 
 
Overexpression of miR-25 significantly attenuated ITGAV and ITGA6 mRNA expression in 
PC-3M-Pro4Luc2 and C4-2B (ITGAV p-value = 0.05 and 0.001 respectively; ITGA6 p-value = 
0.01 and 0.001 respectively) (Fig. 3A). Interestingly, forced overexpression of miR-25 also 
led to a significant reduction in ITGA5 expression in both cell lines (p-value= 0.01 and 
0.001 respectively) and reduced levels of ITGA3, ITGB1 and ITGB4 in C4-2B (p-value= 
0.01, 0.001 and 0.05 respectively). (Suppl. Fig. 1E,F and Fig. 2B,C,D,E,F,G,H). As 
expected, no consistent inhibitory effect was observed on ITGA2 expression. 
Strikingly, upon transfection of PC-3M-Pro4Luc2 and C4-2B cells with pre-miR-25 (or pre-
negative control) for 72 hours ITGAV and ITGA6 protein expression were also 
significantly down-regulated not only in the bulk cell lines (Fig. 3B, C) but also in 
selected ALDHlow and highly aggressive ALDHhigh subpopulation of stem/progenitor cells 
transfected with pre-miR-25 (or pre-negative control) after viable cell sorting (Fig. 3D, E, 
F).  
 
miR-25 overexpression decreases migration of metastasis-initiating human 
prostate cancer cells and affects cytoskeleton dynamics 
Prostate cancer cell migration in both PC-3M-Pro4Luc2 and C4-2B cells was 
significantly attenuated upon miR-25 overexpression (PC-3M-Pro4Luc2, 88% decrease, 
p-value= 0.001; C4-2B, 49% decrease, p-value=0.01 after 72 hrs) (Fig. 4 A, B).  
Strikingly, miR-25 was able to strongly and significantly reduce migration also in 
selected highly migratory ALDHhigh subpopulation of stem/progenitor-like cells 
transfected after viable cell sorting (P<0.001) (Fig. 4 C,D). 
In contrast to migration, cell proliferation was not affected by forced miR-25 
overexpression compared to the scrambled negative control sequence (Suppl. Fig. 2A, 
B). miR-25 also induced a switch to a less invasive phenotype characterized by a 
dramatic change in cell morphology (Suppl. Fig. 2C). Phalloidin staining revealed an 
almost complete loss of actin filopodia and cytoskeletal reorganization associated with 
a strong decrease in the average F-actin fluorescence (p-value= 0.01) (Fig. 4E, F). 
Additionally, migration was monitored in ALDHhigh and ALDHlow subpopulation 4 days 
after sorting (i.e. 72 hours after transfection of selected subpopulation) and confirmed 
significantly higher conserved migratory potential in ALDHhigh cells compared to ALDHlow 





regulation of an invasive phenotype by modulating cytoskeletal integrity, organization 
and motility in humane prostate cancer cell lines and selected aggressive tumor- and 
metastasis-initiating ALDHhigh subpopulation (11).  
 
 
Figure 4. miR-25 overexpression affect cell morphology and decreases migration in prostate 
cancer cells and selected ALDHhigh subpopulation of cells. A) representative images of PC-3M-
Pro4Luc2 and C4-2B migrating in Transwell chambers after transfection with pre–miR-25 and 
prenegative control. B) mean number of migrated PC-3M-Pro4Luc2 and C4-2B cells per field transfected 
with scramble-negative control and pre–miR-25; error bars, ±SEM (n = 2). C) representative images of 
ALDHhigh and ALDHlow subpopulation of cells migrating in Transwell chambers after transfection with 
pre–miR-25 and prenegative control; error bars, ±SEM (n = 2). D) mean number of migrated ALDHhigh and 




ALDHlow subpopulation of cells per field transfected with scramble-negative control and pre–miR-25; 
error bars, ±SEM (n = 2). E) representative confocal images of PC-3M-Pro4Luc2 transfected with pre–
miR-25 and prenegative control stained for F-actin with phalloidin (green) and nuclei with TO-PRO 
(blue). F) corrected total cell fluorescent of PC-3M-Pro4Luc2 transfected with scramble and pre–miR-25 
measured with ImageJ and calculated as (integrated density − (area of selected cells × mean 
fluorescence of background readings)); error bars, ±SEM (n = 3 measurements). G) and H) mean number 
of migrated ALDHhigh and ALDHlow subpopulation of cells per field and representative images of the 
ALDHhigh and ALDHlow subpopulation of cells migrating in Transwell chambers; error bars, ±SEM (n = 2). 
**, P < 0.01; *** and $$$, P < 0.001. 
The miR-25 induced change to a less invasive phenotype does not coincide with major 
changes in the expression of epithelial markers, suggesting that the observed 
morphological changes are most likely due to altered integrin expression as we 
demonstrated previously for α v-integrins (31) (Suppl. Fig. 2D, E).  
 
miR-25 directly targets pro-invasive α6- and α v-integrins 
Next we investigated the putative direct functional interaction between miR-25 
and its predicted ITGA6 and ITGAV target genes. For this we cloned 497 bp and 485 bp 
nucleotide sequences corresponding to a portion of the 3’ UTR of ITGA6 and ITGAV 
respectively, including the conserved predicted binding site (seed sequence) for miR-25, 
downstream of the firefly luciferase2 sequence in a pGL4.10 vector background (see 
Materials & Methods) (Fig. 5A).  
To achieve high expression of the reporter system a 1184bp sequence corresponding to 
human elongation factor 1α (hEF1α) promoter was inserted into the multiple cloning 
site (MCS) of the pGL4.10 upstream to the luciferase2 sequence. The reporter constructs, 
containing mutant miR-25 binding site in the 3’ UTR of the descripted genes, were also 
generated and used as a control. Transfection of pre-miR-25 resulted in a significant 
reduction of luciferase activity in the wild-type but not in the mutant 3’ UTR of the ITGA6 
and ITGAV genes (p-value= 0.05 for both genes) (Fig. 5B, C). These results, combined 
with the transcriptional and translational analysis described above, show for the first 








Figure 5. miR-25 directly regulates ITGAV and ITGA6. A) portion of 3′-UTR of ITGAV or ITGA6 
containing the miR-25 predicted–binding site was cloned in PGL4-basic vector modified with hEF1α 
promoter. Scramble-negative control or pre–miR-25 was cotransfected with WT or MUT construct for 
ITGA6 (B) or ITGAV (C) together with CAGGS-renilla plasmid. RLU is calculated as ratio luciferase/renilla 
and normalized for scramble-negative control; error bars, ±SEM (n = 3). *, P < 0.05. 
miR-25 inhibits distant metastasis of human prostate cancer cells in 
zebrafish 
To investigate the ability of miR-25 to interfere with migration and invasion in the 
intact organism PC-3M-Pro4 prostate cancer cells, that stably express the NIRF protein 
mCherry, were injected into the circulatory system of zebrafish embryos and their tumor 
extravasation and distant metastasis formation was examined (33). The embryonic 
vascular system of zebrafish is fully functional and allows efficient detection of 
extravasating tumor cells (34). In addition, in the Tg(mpo:GFP)i114, the embryos are 
transparent and the immune system is not fully developed permitting successful 
xenotransplantation of human tumor cells (22). This makes the zebrafish model system 
highly appropriate for observing interaction between tumor cells and vasculature at the 
single cell level (35). We transfected PC-3M-Pro4mCherry cells to overexpress pre-miR-25 




(or pre-negative control) and inoculated the cancer cells into the duct of Cuvier (DoC) of 
2-day-old zebrafish embryos (100 embryos injected per group) (33). Disseminated cells 
were arrested in the host vasculature in the first hours, and extravasation was detected 
from 12hpi (hours post implantation). Perivascular tumor cells were observed in 
multiple foci, including the optic veins, the inter-segmental vessels, the dorsal aorta and 
the caudal vein. However, exclusively at the posterior ventral end of the tissue caudal 
hematopoietic (CHT, as indicated in Fig. 6) in the tail, perivascular tumor cells were able 
to invade into the neighboring tail fin. At day 1 post-implantation (1 dpi) miR-25 
overexpression caused a robust and significant reduction in the distal colonization and 
invasion from CHT into the tail fin compared to the scramble control cells (Fig. 6A). miR-
25 was able to completely abolish invasion which was detected in 20% of the embryos 
injected with cells transfected with pre-negative control. At day 2 post-implantation (2 
dpi), 40% of embryos injected with cells overexpressing the negative control showed 
invasion from CHT, compared to 20% of embryos injected with cells overexpressing miR-
25 (Fig. 6 B, C). In addition, miR-25 was able to significantly reduce the number of 
tumorigenic foci/embryo at 1 dpi while no significant difference was measured at 2 dpi 
(Fig. 7 A, B, C).  
Taken together, our experimental metastasis data support the findings in vitro and 
indicate that miR-25 negatively regulates the acquisition of an invasive, metastatic 









Figure 6. miR-25–overexpressing cells injected in zebrafish circulation show reduced 
extravasation. Of note, 100 embryos per group were injected and the percentage of embryos with 
invasion at CHT (invasion defined as >3 cells extravasating/embryo) was counted at day 1 post-injection 
(1 dpi; A) and day 2 postinjection (2 dpi; B); error bars, ±SEM (n = 2 experiments). C) representative 
confocal images of zebrafish embryos injected with PC-3M-Pro4mCherry cells overexpressing miR-25 or 
negative control. Cells overexpressing miR-25 were lodged into circulation, whereas cells 
overexpressing negative control started to show extravasation, full out of CHT and from CHT into the 
neighboring tail fin at 1 dpi. *, P < 0.05. 
 





Figure 7. miR-25–overexpressing cells injected in zebrafish circulation show reduced tumor foci 
(colonization). A) number of tumor foci is reduced in embryos injected with cells overexpressing miR-
25 compared with negative control at 1 day post-injection (1 dpi). B) no difference in the number of foci 
from embryos injected with cells overexpressing miR-25 and scr was measured at day 2 post-injection (2 
dpi). 100 embryos per group were injected; error bars indicate ±SEM (n = 2 experiments). C) 
representative confocal images of zebrafish embryos injected with PC-3M-Pro4mCherry cells 








In this study, miR-25 was identified as an important regulator of the invasive 
program in non-transformed and malignant human prostate epithelial tissues. In 
human prostate cancer cell lines and patient-derived primary prostate tumors, miR-25 
expression was low/absent in the α2β1hi /CD133+ (SC) cell subpopulation but its 
expression steadily increased during differentiation to α2β1hi /CD133- (TA) cells and 
α2β1low (CB) cells committed for terminal differentiation (12). Here we identified, for the 
first time, the pro-invasive αv- and α6-integrins as functional target genes of miR-25. 
Forced overexpression of miR-25 in human prostate cancer cells and in highly 
metastatic and aggressive subpopulation of cells (ALDHhigh) leads to a strong and 
significant decline in αv- and α6-integrin driven invasive behavior in vitro and blockage of 
metastatic colonization in the intact organism.  
Consistent with these observations, overexpression of miR-25 decreased migration and 
strongly affected cell morphology of prostate cancer cells through its direct effect on the 
cytoskeletal arrangement and dynamics. miR-25 may, therefore, represent one of the 
key regulators of the invasive program in the human prostate epithelium, in particular in 
the maintenance of an aggressive phenotype in human prostate cancer “driver” 
subpopulation of stem/progenitor-like cells.  
The results from this study support the notion that the stem/progenitor subpopulation 
in human prostate cancer displays increased clonogenic, migratory properties in vitro 
and stronger tumor- and metastasis-initiating properties in preclinical in vivo models 
(11).  
miR-25 is part of the miR-106b-25 cluster which was previously reported to be up-
regulated in primary tumors and distant metastasis in prostate cancer (36-40). A likely 
explanation for these apparent contradictory observations is that cancer cell lines and 
bulk tumor tissues are not homogeneous and consist of a mixture of heterogeneous 
subpopulations of cells (2). The findings reported here suggest that cellular 
heterogeneity may limit the appropriate interpretation of RNA expression-based 
analysis data obtained from bulk tissues. The cellular composition and proportion of 
α2β1hi /CD133+, α2β1hi /CD133- and α2β1low, also referred to as stem-like cells (SC), transit 
amplifying cells (TA) and committed basal cells (CB) (12) in the normal prostate 
epithelium vs prostate cancer epithelium is indeed generally very different (5). For 
instance, the “driver” stem/progenitor subpopulation in the human prostate often 
represents only 0.02% of all prostate epithelial cells (5,41). The increase in absolute 
expression levels of miR-25 in bulk tissues during prostate cancer progression may, 




therefore, be indicative of an increase in the proportion of more differentiated, less 
invasive, miR-25high luminal epithelial cells.  
Here we focused primarily on the differential miR expression in α2β1hi /CD133+ cells as a 
cellular subpopulation that “drives” tumorigenesis and metastasis (14). Our findings, 
indeed, confirmed that miR-25 is overexpressed in hormone-naive and castration-
resistant prostate cancer as previously reported by others (38,42). Intriguingly, we found 
that -despite the previously observed upregulation of miR-25 in bulk prostate cancer 
tissues (38) the expression of miR-25 in the α2β1hi /CD133+ cells isolated from prostate 
cancer patients matched its expression in the tumor- and metastasis-initiating ALDHhigh 
prostate cancer stem/progenitor subpopulation (11). Our analysis on the α2β1hi /CD133+, 
α2β1hi /CD133- and α2β1low cell compartment enriched from primary prostate cancer 
samples supports the notion that miR-25 is down-regulated in the stem/progenitor cell 
compartment and that its expression steadily increases during differentiation. 
Consistent with our findings, the expression of the miR-106b-25 cluster appears to 
mediate neuronal differentiation of adult neural stem/progenitor cells and, 
interestingly, induction of miR-106b-25 in hypoxic conditions was recently linked to 
increased expression of neuronal markers in prostate cancer cell lines (43,44).  
Thus, our work and these results suggest that lower miR-25 expression is needed to 
maintain stem/progenitor phenotype and its increase is associated with cellular 
differentiation.  
In line with the miR-25 data presented in this study, we previously found that αv-
integrins play a pivotal role in the acquisition of a migratory stem/progenitor 
phenotype, tumorigenicity and the formation of distant bone metastasis in vivo (31,45). 
Moreover, α6β4 integrin expression has already been associated with prostate cancer 
invasion, metastasis and disease progression (46-48). In addition, integrins provide a 
structural link between F-actin and the extracellular matrix and contribute to formation 
of focal adhesion points (49). Our confocal analysis showed that overexpression of miR-
25 dramatically affected cell morphology and impaired F-actin polymerization, reducing 
focal adhesion sites. It seems, therefore that miR-25 is a key player in the organization of 
the F-actin and exerts a crucial role in the regulation of an aggressive and migratory 
phenotype with its direct effect on integrin expression. In addition, organization of F-
actin is linked to activation of integrin-transmembrane receptor which regulates the 
activation of Rho-GTPases, RAC1 and CDC42 (32). Aberrant migration and invasion of 
cancer cells are key components of their invasive-metastatic phenotype. Individual 
tumor cells with an elongated, morphology like PC-3M-Pro4Luc2, often migrate in a 
“mesenchymal manner”, which requires activation of RAC1, decreased by miR-25 (28). In 
contrast, single tumor cells with a less mesenchymal phenotype, like C4-2B, migrate 





regulated after miR-25 overexpression (28). Our in silico analysis, revealed that PIP5K1C 
and PIP4K2C, kinases involved RAC1 signalling, are also predicted target of miR-25. In 
addition, our transcriptional analysis indicated that miR-25 down-regulates CDC42 
mRNA together with CDC42BPA and CDC42EP2 mRNA (CDC42 effector proteins). This 
information combined with the evidence provided by our mRNA and protein analysis on 
integrin expression in bulk cell lines and selected subpopulation of highly metastatic 
cells (ALDHhigh), suggest that miR-25 could be a central player in F-actin organization and 
cytoskeletal dynamics. However, the observed miR-25- induced loss of a migratory 
phenotype, confirmed in selected ALDHhigh subpopulation of stem/progenitor-like cells, 
could not be fully explained by the acquisition of more epithelial characteristics (or 
blockage of EMT-like processes), despite the fact that E-Cadherin is a validated target 
gene of miR-25 (50). 
Consistent with our in vitro observations, complete blocking of metastasis by prostate 
cancer cells overexpressing miR-25 at 1 dpi and a strong reduction at 2 dpi was found in 
embryonic zebrafish model (33). These observations indicate that the morphological 
alterations produced by miR-25 disrupt extravasation and colonisation at distant sites in 
vivo.  
In conclusion, we identified -for the first time- a direct functional interaction 
between miR-25 and integrins as key regulators of prostate cancer invasiveness and 
metastasis. Our in vitro and in vivo data indicate that miR-25 can have a suppressor role 
in aggressive human prostate cancer cells (cell lines and selected subpopulation of 
ALDHhigh cells) by blocking invasion, and metastasis by promoting prostate epithelial 
differentiation and by disrupting. From a therapeutic perspective, miR-25 seems an 
interesting small molecule for specific targeting of stem/progenitor-like cells in 
aggressive human prostate cancer. 
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Table I. Real time-qPCR primers 
GENE Forward Primer Reverse Primer 
ITGA2 TTTGGTAGTGTGCTGTGTTC GACTCTTCCTTCCTCTTTCTTTAG 
ITGA3 GCATCAACGTGACGAACACC TCTGGTTCCGTTTGAAGGGG 
ITGA5 AGTCCTCACTGTCCAGCTCA GCTCAGTGGCTCCTTCTCTG 
ITGA6 GCTGGTTATAATCCTTCAATATCAATTGT TTGGGCTCAGAACCTTGGTTT 
ITGAV GCTGGACTGTGGAGAAGAC AAGTGAGGTTCAGGGCATTC 
ITGB1 AGCAACGGACAGATCTGCAA GCTGGGGTAATTTGTCCCGA 
ITGB3 GTCTGCCACAGCAGTGACTT CTTGTAGCGGACACAGGAGA 
ITGB4 CTGTGTGCACGAGGGACATT AAGGCTGACTCGGTGGAGAA 
CDH1 TTGACGCCGAGAGCTACAC GACCGGTGCAATCTTCAAA 
CDH2 CAGACCGACCCAAACAGCAAC GCAGCAACAGTAAGGACAAACATC 
VIM CCAAACTTTTCCTCCCTGAACC CGTGATGCTGAGAAGTTTCGTTGA 
ZEB1 CCATATTGAGCTGTTGCCGC GCCCTTCCTTTCCTGTGTCA 
ZEB2 GACCTGGCAGTGAAGGAAAA GGCACTTGCAGAAACACAGA 
SNAIL1 ACCACTATGCCGCGCTCTT GGTCGTAGGGCTGCTGGAA 
SNAIL2 TGTGTGGACTACCGCTGC TCCGGAAAGAGGAGAGAGG 
PIP5K2C CATGCATAGCAACCTCTCCA ACTGACTCGGTACATCCCCA 
PIP5K1C CTGGAGGTACCGGACGAG ACAGAACCTCTGTTGGGGC 
RAC1 TCTCCAGGAAATGCATTGGT CTGATGCAGGCCATCAAGT 
CDC42EP2 GTCCAGCTCCTGAGACCTTG TCACCGAGGGTTACTTGTCC 
CDC42BPA CATTCTCGAATACCTAGAATGGG CAAAAGCTCCTCGACCAATC 
CDC42 CCCGGTGGAGAAGCTGAG CGCCCACAACAACACACTTA 
TWIST GCCGGAGACCTAGATGTCATT TTTTAAAAGTGCGCCCCACG 




Table II. Primers used for cloning and mutagenesis 
































Supplementary Figure S1. ALDHhigh prostate cancer cells display enhanced colony formation and 
migration compared to ALDHlow cells. A) Western Blot analysis for Vinculin (VCL) expression after 
miR-25 transfection. No effect on protein is detected. B) Number of colonies per 96-well plate in single 
cell diluted culture after 2 weeks. C) Mean number of migrated ALDHhigh and ALDHlow PC-3M-Pro4Luc2 
cells. Error bars indicate ±SEM D) qRT-PCR analysis on ITGA2, ITGA3, ITGA5, ITGA6, ITGAV, ITGAB1, ITGB4 
on ALDHhigh VS ALDHlow PC-3M-Pro4Luc2 cells. ITGB3 displayed very low expression (ct > 35, data not 
shown). E-F) qRT-PCR analysis on ITGA2, ITGA3, ITGA5, ITGAB1, ITGB4 in PC-3M-Pro4Luc2 and C4-2B 
transfected with pre-miR-25 and negative control. ITGB3 displayed very low expression (ct > 35, data not 









Supplementary Figure S2. miR-25 strongly changes cell morphology without affecting 
proliferation. A) MTS proliferation assay measured at 490nm 24-48-72 hours after miR-25 and control 
overexpression in PC-3M-Pro4Luc2 and B) C4-2B cells. C) Representative bright field picture of PC-3M-
Pro4Luc2 cells overexpressing miR-25 and negative control 72 hours after transfection. miR-25 induces 
dramatic change in cell morphology. D-E) qRT-PCR on EMT markers (E-Cad, N-cad, Vim, Zeb1, Zeb2, 
Snail1, Snail2, Twist) in PC-3M-Pro4Luc2 and C4-2B respectively. Relative expression is compared to 
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Prostate cancer is considered the most common cancer and represents the second 
leading cause of death from cancer in men in the Western world. Once that the tumor 
has metastasized to the bone, no cure is available. To date, the molecular mechanisms 
responsible for cancer relapse and metastasis formation have not yet been elucidated. 
However, epithelial-to-mesenchymal transition (EMT) has been established as one of 
the key events that lead to cancer invasion, the occurrence of distant metastasis and 
therapy resistance. Cells that undergo EMT acquire a more motile phenotype and 
become highly migratory. The functional role of the so-called non-canonical 
WNT/planar cell polarity (WNT/PCP) pathway in the acquisition and maintenance of a 
motile phenotype has been firmly established.  
In this paper we have studied a class of non-coding RNAs, the so-called microRNAs, 
that regulate gene expression and may play pivotal roles in carcinogenesis and tumor 
progression. We found that miR-25 that was shown previously to impair migration in a 
subpopulation of highly metastatic, cancer stem-like cells-, modulates the cross-talk 
between canonical and non-canonical WNT/PCP pathway. Our data show, for the first 
time, that miR-25 can modulate the expression of Dapper Homolog 1 (DACT1), an 
antagonist of β-catenin, thereby increasing canonical WNT signaling. TGF-β is 
considered to be one of the major drivers of EMT in various carcinomas, including those 
of the human prostate cancer. Our study, suggest that miR-25 might interfere with the 
cross-talk between WNT and TGF-β signaling and is capable to block the induction of 
migration produced by TGF-β in PC-3M-Pro4Luc2 human prostate cancer cells. Taken 
together, our observations suggest that targeting of non-canonical WNT/PCP pathway 
represents an interesting therapeutic strategy to block (or reverse) the acquisition of an 














Prostate cancer is the most common cancer in males and the second leading 
cause of death from cancer in the western male population (1). Occurrence of bone 
metastasis during the castration resistant phase represents one of the major problem 
for the patients, for which no therapeutic treatment is available at the moment. Despite 
the progresses in cancer biology, the mechanisms responsible for cancer relapse and 
metastasis formation have remained largely elusive. It is established that one of the 
critical event which precedes the formation of distant metastasis is the transition from 
an epithelial-like to mesenchymal-like state at the primary tumor (epithelial-to-
mesenchymal transition, EMT) (2). Cells undergoing EMT become more motile and 
invasive and also display therapy resistance (3,4). One of the signaling pathways that are 
involved in the modulation of motility is represented by the so-called non-canonical 
WNT/planar cell polarity (WNT/PCP) pathway (5,6). The role for canonical WNT signaling 
during the initial phases of cancer initiation is indeed established. However, 
accumulating evidence suggests a critical role of the non-canonical WNT/PCP pathway 
during the second phase of the disease, when cancer progress, invades and 
metastasizes (5). microRNAs are a small class of non-coding RNA molecules that 
regulates gene expression and for which the role in pathogenesis and progression of 
prostate cancer is established (7). Several studies have also highlighted the predictive 
value of measuring the levels of microRNA in urine and blood to monitor the progression 
of the disease (8). However, there is a remarkable lack of information about the role of 
microRNA in aggressive subpopulation of cancer stem/progenitor like cells, 
characterized by high invasiveness and capable of forming metastasis. According to this 
scenario, the non-canonical WNT/PCP pathway represents one of the important player 
in the maintenance of high migration and invasion in these cells. Recently we have 
shown that miR-25 is strongly downregulated in a subpopulation of highly migratory 
and metastatic ALDHhigh cells in human prostate cancer (9).  
In this study, we investigated whether miR-25 can interfere with the non-canonical 
WNT/PCP pathway in human prostate cancer cells. Our results indicate that miR-25 
represents an interesting player in the maintenance of the balance between canonical 
and non-canonical WNT/PCP pathway. We show here -for the first time- that miR-25 
modulates the expression of Dapper Homolog 1 (DACT1), an antagonist of β-catenin 
(10), thereby interfering with WNT signaling. Moreover we provide evidence that miR-25 
interferes with the cross-talk between WNT and TGF-β signaling leading to attenuated 
TGF-β-induced migration of human prostate cancer cells. Together, our data highlight 
the role of miR-25 in prostate cancer progression, in particular the targeting of non-
canonical WNT/PCP pathways as critical mediators of tumor invasiveness.  




Materials and Methods 
 
Cell lines and culture conditions  
Human osteotropic prostate cancer cell lines PC-3M-Pro4 and PC-3M-Pro4Luc2 
cells were maintained in DMEM with 10% FCII, 1% Penicillin-Streptomycin (Life 
Technologies) and 0.8 mg/ml Neomycin (Santacruz, USA) for cells expressing Luciferase 
2. Human embryonic kidney HEK293T cells were maintained in DMEM with 10% FCS and 
1% Penicillin-Streptomycin (Life Technologies, USA). Cells were maintained at 37°C with 
5% CO2. 
 
Transient transfection with pre-miR-25 or pre-negative control and 
luciferase reporter assay 
For microRNA overexpression, transfection was performed with Lipofectamine® 
2000 (Invitrogen, USA) according to manufacturer's protocol with Pre-miR-25 (ID: 
PM10584; Life Technologies) and pre-miRNA negative control (scramble) (ID: AM17110; 
Life Technologies). Total RNA was collected after 72 hours to assess positive 
overexpression and target gene down-regulation.  
For luciferase reporter assay, PC-3M-Pro4, HEK293T or HEK293T knock-down cells were 
seeded 10,000 cells in 500 µL medium in a 24-wells plate and Lipofectamine® 2000 used 
according to manufacturer's protocol. For experiments in combination with miR-25 
overexpression, for each condition, 100 ng of BAT-luciferase (reporter for canonical WNT 
signaling (11)) or ATF2-luciferase (reporter for non-canonical WNT signaling (12-14)) or 
CAGA-Luc (TGF-β reporter) and 10 ng CAGGS-renilla were used. After 24 hours, medium 
was replaced and cells were treated with 0.6, 1.8, 3.0 µM SB216763 (Sigma-Aldrich, The 
Netherlands); 5, 12.5, 20 mM LiCl; 50, 75, 100 mM GIN (11) or 100 µM PNU-74654 (Sigma-
Aldrich) or 0.1, 0.5, 1, 5, 10 ng/mL TGF-β for 24 hours before assessment of Luciferase 
activity. The Photonis pyralis (firefly) luciferase (Fluc) and Renilla reniformis luciferase 
(Rluc) activities in the lysates were measured with Dual Luciferase Assay (Promega, 
USA). Data are shown as Relative Light Units (RLU, Fluc normalized for Rluc levels). 
 
RNA extraction and qRT-PCR 
RNA was extracted using Trizol (Invitrogen) and cDNA synthesized by reverse 
transcription (Promega, USA) according to manufacturer’s protocol. qRT-PCR was 
performed with Biorad CFX96 system (Biorad, The Netharlands). DACT1 (FW: 
GGCGACCTTGAGTCTCTCAG; RV: CTGAGGCCTGGTCTTCACAG) expression was normalized 
to GAPDH (FW: GACAGTCAGCCGCATCTTC; RV: GCAACAATATCCACTTTACCAGAG) and/or 





miRNA target prediction and bioinformatic analysis of cluster of genes 
Targetscan v6.2 and microT-CDS (15) were used to identify miR-25 predicted 
targets. Functional annotation was performed using DAVID Bioinformatics Resources 6.7 
(16,17) and KEGG database (18). 
 
ALDEFLUOR® assay 
Aldehyde Dehydrogenase (ALDH) activity was measured using the ALDEFLUOR® 
assay kit (StemCell Technologies, USA) according to the manufacturer's protocol (19). 
ALDH substrate was added to the cells and fluorescent product measured by 
flowcytometry. For sorting, FACS ARIA cell sorter (BD Bioscience) was used. After sorting, 
RNA was collected from ALDHhigh= highest 10% and gene expression compared to 
ALDHlow = lowest 10%). 
 
Migration assay 
To assess migration, cells were starved overnight in medium containing 0.3% 
serum and 60,000 cells seeded the day after in medium containing 0.3% serum in 
Transwell (8-μm) upper-chamber (Corning, The Netherlands). The lower chamber was 
filled with medium containing 10% serum. After 16-18 hours of incubation, cells on the 
upper side of the filters were removed and cells on the lower side were fixed with 4% 
paraformaldehyde and stained with 0.1% crystal violet for 30 min at RT (Sigma-Aldrich, 
USA). Cell migrated were subsequently counted. 
 
Statistical analysis 
Statistical analysis was performed with GraphPad Prism 6.0 (GraphPad software, 
USA). T-test was used for comparison between two groups. Data is presented as mean ± 
SEM. P-values ≤ 0.05 are considered to be statistically significant (* P < 0.05, ** P < 0.01, 
*** P < 0.001). 
  






miR-25 induces canonical-WNT signaling via a WNT-dependent mechanism 
To investigate the effect of miR-25 on WNT signaling pathway, we employed a 
canonical WNT signaling bioluminescent reporter, BAT-Firefly Luciferase (Fluc) (20,21) 
and CAGGS-Renilla luciferase (Rluc) as control for transfection efficiency. miR-25 
overexpression in PC-3M-Pro4 human prostate cancer cell line resulted in significant 
increase in BAT-Fluc signaling indicating up-regulation of canonical WNT signaling (Fig. 
1 A, B and C, Control=vehicle condition). Our group has previously shown that inhibition 
of GSK3-β produced increase in canonical WNT signaling in human prostate cancer (11). 
Interestingly, we found that treatment with different GSK3-β inhibitors (SB216763 (22), 
LiCl (11) and GIN (23)) combined with miR-25 overexpression resulted in significant 
enhancement of canonical WNT signaling, suggesting an additive effect of miR-25 on 
GSK3-β inhibition (Fig. 1 A, B and C respectively). To assess whether the observed effect 
of miR-25 was WNT-dependent, we used a downstream inhibitor of canonical WNT 
signaling, PNU-74654, and measured the activity of canonical WNT reporter upon miR-
25 overexpression alone or in combination with PNU-74654. We confirmed that miR-25 
was capable of inducing canonical-WNT signaling and found that simultaneous 
incubation with 100 µM of PNU-74654 led to complete reversal of the induction of WNT 
signaling in PC-3M-Pro4 cells (Fig. 1 D). Together, these suggest that the effect of miR-25 
on canonical WNT signaling is direct and can be reversed upon treatment with 







Figure 1. miR-25 overexpression directly induces canonical WNT signaling. A-C) Treatment with 
different concentration of GSK3-β inhibitor SB216763 (A), LiCl (B) and GIN (C) in combination with miR-
25 overexpression produced additive effect on canonical WNT signaling induction. D) Administration of 
downstream inhibitor of WNT signaling PNU-74654 (PNU) can reverse the induction of WNT signaling 
produced by overexpression of miR-25. Error Bars ± SEM. p < 0.05 (*), p <0.001 (***).  
 
miR-25 downregulates Dapper, an antagonist of β-catenin, Homolog 1 
(DACT1) 
To study whether novel miR-25 predicted target gene(s) involved in WNT 
signaling could be identified, we predicted gene targets of miR-25 by publically-
available tools in silico. Our analysis found that Dapper, an antagonist of β-catenin, 
homolog 1 (DACT1) was shown as miR-25 predicted target gene in two independent 
online bioinformatic tools, TargetScan (24) and microTCDS (15). 
Previously we have shown that miR-25 is strongly downregulated in a subpopulation of 
highly tumorigenic and metastatic, stem-like ALDHhigh cells compared to non-
tumorigenic and non-metastatic ALDHlow subpopulation isolated from PC-3M-Pro4Luc2 
human prostate cancer cell line (9). Therefore, we hypothesized that miR-25 and DACT1 
expression in ALDHhigh vs. ALDHlow subpopulation could be inversely correlated. To test 
this hypothesis, we measured the expression of DACT1 mRNA in subpopulation of 
ALDHhigh compared to ALDHlow, isolated after viable cell sorting from PC-3M-Pro4Luc2 
human prostate cancer cells with ALDEFLUOR kit (19). Our mRNA analysis showed that 
DACT1 mRNA is, indeed, significantly higher in ALDHhigh vs. ALDHlow subpopulation (Fig. 
2A). Next we evaluated whether transient overexpression of miR-25 could reduce the 




mRNA level of its predicted target gene DACT1 in two independent cell lines. 
Interestingly, we found that overexpression of miR-25 could significantly decrease 
mRNA expression of DACT1 in PC-3M-Pro4Luc2 cells (p<0.01) and similar trend was 
observed in HEK293T cells (Fig. 2B and C respectively). 
Taken together, miR-25 and DACT1 expression are inversely correlated in ALDHhigh 
compared to ALDHlow subpopulation as we hypothesized. Moreover, miR-25 
overexpression may directly inhibit the predicted target gene DACT1 as was found from 
the in silico analysis described above. 
 
 
Figure 2. DACT1 is elevated in ALDHhigh vs ALDHlow subpopulation and miR-25 overexpression 
downregulate its mRNA expression. A) qRT-PCR in ALDHhigh vs. ALDHlow subpopulation isolated from 
PC-3M-Pro4Luc2 human prostate cancer cell line show increased expression of DACT1 in ALDHhigh cells. 
B) mRNA analysis after 72 hours following miR-25 overexpression shows significant reduction in the 
level of DACT1 mRNA in PC-3M-Pro4Luc2 cells. C) mRNA analysis after 72 hours following miR-25 
overexpression shows reduction in the level of DACT1 mRNA in HEK293T cells. Error Bars ± SEM. p < 0.01 
(**).  
 
DACT1 knock-down partially recapitulates miR-25 overexpression 
phenotype 
To functionally evaluate the biological role of DACT1 we used two shRNAs direct 
against DACT1 and one shRNA control to perform stable knock-down of this gene in the 
two independent cell lines PC-3M-Pro4Luc2 and HEK293T cells.  
We found that DACT1 knock-down affected cell morphology and cellular density in both 
cell lines employed with both shRNA constructs (Fig. 3A). ShRNA#63 drastically reduced 
cellular density and ShRNA#64 induced a spindle-shape phenotype (Fig. 3A). Specificity 
of knock-down was confirmed by qRT-PCR for both shRNA and showed significant 
decreased DACT1 expression with shRNA#63 (ShDACT1_#63) and partial knock-down 





significant increase in BAT luciferase activity with both shRNAs construct against DACT1 
used to perform the knock-down (p<0.001 for both shRNAs) (Fig. 3C).  
Given the stimulatory effect on canonical WNT signaling upon miR-25 overexpression, 
these findings all together reinforce the hypothesis that miR-25 interferes with WNT 
signaling via DACT1. 
Previously we have demonstrated that miR-25 overexpression strongly inhibits cell 
migration in human prostate cancer (9). This led us to hypothesize that DACT1 knock-
down could result in a similar functional phenotype. We used transwell boyden 
chambers to measure migration in PC-3M-Pro4Luc2 and HEK293T cells with DACT1 
knock-down (Fig. 3D). Interestingly, we found a strong and significant inhibition of 
migration in HEK293T cells (p<0.001 for both shRNAs) (Fig. 3E). However, no decrease in 
migration was detected in PC-3M-Pro4Luc2 cells which showed a surprising increase in 
motility with shRNA#63 (p<0.001) and no effect with shRNA#64 (Fig. 3F). These data 
suggest that miR-25 overexpression and DACT1 knock-down result in a similar effect on 
WNT signaling activity. However DACT1 knock-down can only partially recapitulate, in 
the human prostate cancer cell line, the phenotype produced by miR-25 overexpression.  
 
 
Figure 3. DACT1 knock-down affects cell morphology and partially recapitulates the miR-25 
overexpression phenotype in human prostate cancer cells. A) DACT1 knock-down induces changes in 
cell morphology compared to shRNA control (NT, left panels, top = HEK293T and bottom = PC-3M-
Pro4Luc2 cells); effect on cellular density is observed for both shRNAs in both cell lines (central and right 




panels, top for HEK293T and bottom for PC-3M-Pro4Luc2); in PC-3M-Pro4Luc2 shDACT1_64 induces a 
spindle cell shape phenotype (left bottom panel) compared to a more epithelial-like morphology 
induced by shDACT1_63 (central bottom panel). B-C) qRT-PCR confirms DACT1 knock-down with both 
shRNAs in both the cell lines used D) Bioluminescent reporter for canonical WNT signaling (BAT-Luc) in 
HEK293T cells support knock-down of antagonist of β-catenin (DACT1) and shows increased 
bioluminescent activity for both shRNAs used. E) Representative pictures of HEK293T and PC-3M-
Pro4Luc2 cells with knock-down for DACT1 with two shRNAs. F) Both shRNAs for DACT1 significantly 
reduce migration in HEK293T cells. *** vs NT (ShRNA control) and $$$ vs shDACT1_#64. G) shDACT1_#63 
induce migration in PC-3M-Pro4Luc2 cells (*** vs NT, ShRNA control and $$$ vs shDACT1_#64). Error 
Bars ± SEM. p< 0.01 (**), p<0.001 (***, $$$). 
 
TGF-β modulates the cross-talk between canonical- and non-canonical WNT 
signaling and miR-25 interferes with TGF-β signaling 
One of the critical events during prostate cancer progression is represented by 
epithelial-to-mesenchymal transition (EMT) (25). In this process, TGF-β represents one 
of the major drivers of EMT and promotes migration (26). The notion that Wnt/PCP and 
canonical-Wnt signaling are both part of a negative feedback-loop where Wnt/PCP 
negatively regulates canonical-Wnt signaling and vice versa (27) led us to test whether 
TGF-β could modulate canonical and non-canonical WNT signaling in our model. To this 
aim, we transfected PC-3M-Pro4 human prostate cancer cells with canonical (BAT-Luc 
(11)) and non-canonical (ATF2 Luc (12)) WNT bioluminescent reporter. Treatment with 
different concentrations of TGF-β (1, 5, 10 ng/mL) induced a significant, dose-dependent 
decrease in both canonical WNT signaling (Fig. 4A) and non-canonical WNT signaling 
(Fig. 4B).  
Given the stimulatory role of miR-25 on canonical WNT signaling, and its inhibitory effect 
on cell migration, we hypothesized that the modulation of canonical and non-canonical 
WNT signaling produced by TGF-β could be modulated by miR-25. To test this, we 
transfected PC-3M-Pro cells with a bioluminescent Smad-dependent TGF-β reporter 
(CAGA-Luc) and simultaneously overexpressed miR-25 and a scramble negative control. 
24h after transfection, cells were treated with TGF-β (0.1, 0.5, 1 ng/mL) and assessment 
of bioluminescent activity revealed that miR-25 was capable of blocking TGF-β signaling 
(Fig. 4C). Interestingly, we found that overexpression of miR-25 abolished the pro-
migratory effect of TGF-β compared so scramble negative control (Fig. 4D). Taken 
together our results suggest that miR-25 might represent an interesting player in the 











Figure 4. TGF-β modulates canonical and non-canonical WNT signaling in a different manner (A,B) 
and miR-25 interferes with TGF-β signaling and cell migration under basal- and TGF-β stimulated 
conditions (C,D). A) Canonical WNT signaling activity measured by bioluminescent reporter (BAT-Luc) 
in presence of an increasing dose range of TGF-β (1, 5, 10 ng/mL) (* p<0.05 vs. Untreated). B) Non-
canonical WNT signaling activity measured by bioluminescent reporter (ATF2-Luc) in presence of an 
increasing dose range of TGF-β (1, 5, 10 ng/mL) (** p<0.01 vs. Untreated). C) miR-25 reduces the activity 
of TGF-β signaling and is capable of blocking the stimulation with an increasing dose range of TGF-β 
(0.1, 0.5, 1 ng/mL). (***, p<0.001 with two way ANOVA). D) miR-25 overexpression can block the 
induction of migration produced by 1ng/mL of TGF-β compared to scramble negative control. 
  





The role of the canonical WNT developmental pathway in tumorigenesis has been 
firmly established in several types of cancers (28). However, more recent oncological 
research has highlighted the critical contribution of the so-called non-canonical 
WNT/planar cell polarity (PCP) pathway in the progression phase of the disease, 
typically characterized by cell migration, invasion and formation of metastasis (5).  
Previously we have shown that miR-25 is downregulated in a subpopulation of highly 
migratory and metastatic cells (ALDHhigh) and this miR appears to be a critical player in 
the modulation of cell motility, migration and differentiation of human prostate cancer 
cells (9). Here we investigated the role of miR-25 in the modulation of canonical and 
non-canonical WNT signaling and identified Dapper, Antagonist of β-catenin, homolog 1 
(DACT1) as a miR-25 predicted target gene. Wnt/PCP and canonical-Wnt signaling are 
part of a negative feedback-loop where Wnt/PCP negatively regulates canonical-Wnt 
signaling and vice versa (27). One of the important mediator of this feedback mechanism 
is represented by Dishevelled (Dvl) which is considered to be the “Hub of Wnt signaling” 
(29). In this context, when canonical WNT signaling is active, the recruitment of Dvl by 
Frizzled prevents the constitutive destruction of β-catenin and results in its 
accumulation and subsequent nuclear translocation (29). DACT1 has been shown to 
negatively regulate canonical WNT signaling by promoting lysosomal degradation of 
Dvl, leading to degradation of β-catenin (30). Real-time measure of canonical WNT 
signaling by bioluminescent reporter in prostate cancer cells in which DACT1 was 
knocked down supported this notion. The WNT/PCP pathway is critically involved in 
cytoskeletal remodeling and cell motility (30). Interestingly, loss of DACT1 has been 
shown to disrupt WNT/PCP pathway, altering Dvl activity and leading to malformation in 
mice (30). Here we found that miR-25 might target directly DACT1 mRNA, suggesting 
that a regulatory role for this miR in the WNT/PCP pathway. Previously, we 
demonstrated that miR-25 can disrupt cell migration and identified several predicted 
target genes involved in the modulation of F-actin assembly and in the remodeling of 
the cytoskeleton (9). Our data show that miR-25 expression is capable of stimulating the 
canonical WNT signaling pathway. Given the negative feedback-loop between canonical 
and non-canonical WNT/PCP signaling, we speculated that miR-25-induced activation of 
canonical WNT signaling will result in the attenuation of the non-canonical WNT/PCP 
pathway leading to a reduction in cell migration. In support of this observation, 
transcriptional analysis revealed that DACT1 is significantly up-regulated in invasive, 
metastatic ALDHhigh vs sessile, non-metastatic ALDHlow subpopulation of prostate cancer 
cells. Moreover, we have previously demonstrated that miR-25 is strongly 





human prostate cancer cells (9). Taken together, our data show an inverse correlation 
between miR-25 and DACT1 expression in ALDHhigh cells, suggesting that WNT/PCP 
pathway might be directly involved in the maintenance of an invasive phenotype in this 
subpopulation of cells. DACT1 knock-down in HEK293T cells resulted in a complete loss 
of migratory properties and recapitulated the miR-25 overexpression phenotype. 
However, the fact that the knock-down of DACT1, in PC-3M-Pro4Luc2 cells, failed to 
interfere with migration, suggests the presence of additional mechanisms that might 
determine their malignant phenotype. For example, PC-3M-Pro4Luc2 cells express high 
levels of α6 and αv integrins, that are directly targeted by miR-25 and that are 
functionally involved in the activation of latent TGF-β, motility, invasion and metastasis 
(9). Moreover, one single microRNA can downregulate multiple genes at the same time, 
leading to a global functional effect that logically cannot be entirely reproduced by the 
downregulation of a single gene.  
Our group described previously that TGF-β increases the size of ALDHhigh stem-like 
subpopulation of human prostate cancer cells (31). Here we show that TGF-β negatively 
regulates canonical WNT signaling and positively regulates non-canonical WNT/PCP 
pathway. This reinforces the tumor supportive role of TGF-β and its involvement in EMT 
and cell migration. In the perspective of a reciprocal feedback-loop between canonical 
and non-canonical WNT/PCP signaling, DACT family proteins have been identified in 
mammals as multi-adapter molecules with the ability to modulate and integrate WNT 
and TGF-β signaling (10). Here we showed that miR-25 inhibits TGF-β signaling and 
strongly reduced the migratory effect induced by TGF-β. These data, combined with the 
notion in literature, suggest that DACT1 might represent an important player in the 
modulation between the cross-talk between TGF-β and WNT signaling and that miR-25 
might interfere with this balance. 
 
Finally, although additional experiments are required to elucidate the exact role 
of miR-25 in this process, we hypothesized a model in which non-canonical WNT/PCP 
pathway and TGF-β signaling maintain the highly migratory phenotype in PC-3M-
Pro4Luc2 human prostate cancer cells. It is remarkable indeed that our bioluminescent 
measurement of WNT reporters revealed that the order of magnitude difference 
between non-canonical WNT/PCP compared to canonical WNT signaling is 
approximately a factor of 10. This suggests that there is a basal disbalance between 
canonical and non-canonical WNT/PCP signaling that result in a shift toward WNT/PCP 
pathway and that functionally sustain motility and migration. PC-3M-Pro4Luc2 cells are 
indeed highly migratory and metastatic upon inoculation in mice. Furthermore, the fact 
that overexpression of miR-25 leads to downregulation of DACT1, coinciding with loss of 
migration and strong induction of canonical WNT signaling, indicates that DACT1 might 




regulate this process. Moreover, administration of TGF-β reduces canonical WNT 
signaling and augments non-canonical WNT/PCP signaling, which support the notion 
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Prostate cancer is the second most common cancer in men worldwide. Despite 
current therapies, when cancer progress, patient develop metastasis, mainly in the 
bones. Therefore, targeting the molecular pathways that underlie primary tumor growth 
and spread of metastases is of great clinical value. Bone morphogenetic proteins (BMPs) 
play a critical role in prostate cancer. BMP9 and the closely related BMP10 signal via the 
transmembrane serine kinase receptors Activin receptor-Like Kinase 1 (ALK1) and ALK2 
and the cytoplasmic proteins SMAD1 and SMAD5. The human ALK1 extracellular domain 
(ECD) binds BMP9 and BMP10 with high affinity and we show that a soluble chimeric 
protein consisting of the ALK1 ECD fused to human Fc (ALK1Fc) prevents activation of 
endogenous signaling via ALK1 and ALK2. We also show for the first time in prostate 
cancer that ALK1Fc reduces BMP9-mediated signaling and decreases tumor cell 
proliferation in vitro. In line with these observations, we demonstrate that ALK1Fc 
impairs angiogenesis and reduces tumor growth in vivo. Our data show that BMP9 
correlates with poor survival and is upregulated in high risk prostate cancer patients. We 
identify BMP9 as a putative therapeutic target and ALK1Fc as a potential therapy 
capable of targeting tumor cells and the supportive tumor angiogenesis. Together these 



















Prostate cancer is the second most common cancer in men worldwide (1). 
Currently prostate cancer, when still in its first phase of androgen dependency, can be 
successfully treated surgically. However, once the cancer develops in an androgen-
independent state, therapy is no longer useful or successful and lethality is almost 
invariably due to the consequences of metastasis. Therefore, understanding the 
molecular pathways that underlie the emergence and spread of metastases from 
primary tumors are of great biological and clinical value. 
Expression of several BMPs has been examined in prostatic tissue with benign prostatic 
hyperplasia (BPH), non-metastatic and metastatic prostatic adenocarcinoma and has 
been associated with cancer aggressiveness (2). However, little is known about the roles 
of BMP9 and BMP10 and their signaling receptors, ALK1 and ALK2, in prostate cancer 
and particularly in androgen independent and metastatic prostate cancer. Previous 
studies have highlighted the role of ALK1 as key regulator of normal as well as tumor 
angiogenesis (3, 4). BMP9 and BMP10 are high affinity ligands for ALK1, which is 
predominantly expressed in endothelial cells (5). Alternatively, BMP9 signals through 
the BMP type I receptor ALK2 (6-8). Binding of BMP9/BMP10 to ALK1/ALK2 results in 
phosphorylation and activation of downstream effectors SMAD1/SMAD4 and/or SMAD5 
(7-9). In ovarian cancer, BMP9 acts as proliferative factor, promoting human epithelial 
ovarian cancer and human immortalized ovarian surface epithelial cell proliferation 
through ALK2/SMAD1/SMAD4 pathway (8). Similarly, BMP9 stimulates proliferation of 
liver cancer cells (10) and osteosarcoma growth (11). Among the BMPs, BMP9 is the most 
recently identified (12) and least studied ligand. Current research has not only 
attributed a tumor-promoting role to BMP9 (8, 10, 11) but also tumor suppressing 
properties (13-15) in different types of cancer, including prostate cancer.  
Several studies have highlighted the role of BMP9/ALK1 in the genetics and 
development of blood vessel formation, outlining its critical involvement in pathological 
and tumor angiogenesis (16, 17). Interestingly, alterations of signal transduction 
pathways that are important for blood vessel formation, such as the NOTCH pathway, 
have also been associated with arterio-venous malformations (18, 19). Recently, BMP9 
and BMP10 signaling were linked to NOTCH signaling, one of the major pathways 
involved in prostate cancer development, progression and bone metastasis (20). 
Expression profiling studies have shown that members of the NOTCH pathway are 
characteristic of high grade (Gleason 4+4=8) micro-dissected prostate cancer cells 
compared to low grade (Gleason 3+3=6) (21). Moreover, inhibition of NOTCH1 reduces 
prostate cancer cell growth, migration and invasion (22). Interestingly, NOTCH signaling 
pathway activates ALDH1A1, a well-known marker of prostate cancer stem cells (23-26).  




In order to understand the role of BMP9 in prostate cancer tumor progression, we 
employed the soluble chimeric protein ALK1Fc (ACE-041) (27) which binds BMP9 and 
BMP10 with high affinity and blocks their signaling via ALK1 and ALK2 receptors by 
acting as a ligand trap (28, 29). BMP9 induces endothelial cell proliferation and vessel 
formation (30) while ALK1Fc has previously been shown to inhibit vascularization and 
tumor growth of breast cancer in vivo in an orthotopic transplantation model (28). 
ALK1Fc binds and neutralizes only BMP9 and BMP10 ligands and not TGFβ (28, 29), 
which also plays important roles in angiogenic processes. Phase I clinical trials have 
been completed using ALK1Fc as anti-angiogenesis therapy in myeloma 
(clinicaltrials.gov identifier NCT00996957).  
Here we show, for the first time in prostate cancer, that ALK1Fc reduces BMP9 signaling 
and decreases proliferation of highly metastatic and tumor initiating human prostate 
cancer cells in vitro. We further demonstrate that ALK1Fc impairs angiogenesis, affects 
tumor cell proliferation and reduces tumor growth in vivo. Taken together these data 
suggest BMP9 as a possible therapeutic target in prostate cancer and justify the 







Materials and Methods 
 
Cell line and culture conditions 
The human osteotropic prostate cancer cell line PC-3M-Pro4luc2 (31) was 
maintained in DMEM supplemented with 10% FCII, 0.8 mg/ml Neomycin (Santacruz, 
Dallas, USA) and 1% Penicillin-Streptomycin (Life Technologies, Carlsbad, USA). C4-2B 
cells were maintained in T-medium DMEM (Sigma-Aldrich, The Netherlands) 
supplemented with 20% F-12K nutrient mixture Kaighn’s modification (GibcoBRL), 10% 
FCS, 0.125 mg/ml biotin, 1% Insulin-Transferin-Selenium, 6.825 ng/ml T3, 12.5 mg/ml 
adenine and 1% penicillin/streptomycin. Cells were maintained at 37°C with 5% CO2.  
 
Luciferase reporter gene constructs  
PC-3M-Pro4Luc2 cells were seeded at a density of 50,000 cells in 500 µL medium 
in a 24-well plate. Transient transfection of reporter constructs was performed with 
Lipofectamine2000 (Life Technologies) according manufacturer’s protocol. For each 
well, 100 ng of NICD-ff-luciferase,10 ng CAGGS-Renilla luciferase, 100 ng BRE renilla and 
100 ng BREluc/well were transfected. After 24 hours, medium was replaced and cells 
were treated with BMP9 for 24h. The Firefly luciferase and Renilla luciferase levels in the 
lysates were measured using Dual Luciferase Assay (Promega, Madison, USA). 
 
RNA isolation and real-time qPCR 
Total RNA was isolated with Trizol Reagent (Invitrogen, Waltham, USA) and cDNA 
was synthesized by reverse transcription (Promega, Madison, USA) according to the 
manufacturer’s protocol. qRT-PCR was performed with Biorad CFX96 system (Biorad, 
Veenendaal, The Netherlands). Gene expression was normalized to GAPDH or β-actin. 
(For primer sequences see Supplementary Table I). Total RNA from frozen section (5µm) 
was isolated with Qiagen Mini Isolation kit (Venlo, The Netherlands) according to the 
manufacturer’s protocol. Primer sequences are listed in Suppl. Table 1.  
 
MTS assay 
Cells were seeded at density of 2,000 cells/well and treated with ALK1Fc or CFc 
(10ug/ml, Acceleron, USA) allowed to grow for 24, 48, 72 and 96 hours. After incubation, 
20 µl of 3-(4,5 dimethylthiazol- 2- yl)- 5 -(3 -carboxymethoxyphenyl)- 2 -(4 -sulfophenyl)- 
2 H-tetrazolium was added and mitochondrial activity was measured after 2 hours 
incubation at 37°C. MTS absorbance values are positively proportional to total number 
of metabolically active cells providing an indirect correlation with cell proliferation rate 
(50) (CellTiter96 Aqueous Non-radioactive Cell proliferation assay, Promega). 





Male 6-8 week-old athymic nude mice (Balb/c nu/nu), purchased from Charles 
River (L’Arbresle, France), were used in all in vivo experiments (n=15 per group). Mice 
were housed in individual ventilated cages under sterile condition, and sterile food and 
water were provided ad libitum. Animal experiments were approved by the local 
committee for animal health ethics and research of Leiden University (DEC #11246), and 
carried out in accordance with European Communities Council Directive 86/609/EEC. 
After the experimental periods, mice were injected with hypoxia probe (6mg/kg, 
Burlington, Massachusetts, USA) and lectin-Tomato (1 mg/kg, Vector Laboratories, USA) 
intravenously prior to perfusion and sacrified according to our mouse protocol. Tumors 
were dissected and processed for further histomorphological analysis as described 
below. 
 
Orthotopic prostate transplantation and ALK1Fc treatment  
25000 PC-3M-Pro4luc2 cells (10 ul final volume) were injected in the dorsal lobe of 
nude mice. In brief: After anesthetizing the mice with isoflurane, each mouse was placed 
on its back and a small incision was made along the lower midline of the peritoneum for 
about 1 cm. The prostate dorsal lobes were exteriorized and stabilized gently. A 30-
gauge needle attached to a 1-cc syringe was inserted into the right dorsal lobe of the 
prostate. 10 µl of the material was slowly injected. A well-localized bleb indicates a 
successful injection. After retracting the needle a Q-tip was placed over the injection site 
for about 1 min to prevent bleeding and spillage of material. The prostate was then 
returned to the peritoneum and the abdominal wall and skin layer was sutured. After 
establishment of the primary tumor, at 10 days after the orthotopic transplantation, 
mice were intraperitoneally injected with Control-Fc (CFc) or ALK1Fc compounds (1 
mg/kg) twice per week. Administration of compounds was performed for four weeks. 
ALK1-Fc is a fusion protein comprised of the extracellular domain of human ALK1 fused 
to the Fc region of IgG and was obtained from Acceleron Pharma, Cambridge, USA. The 
Fc domain of IgG1 was used as a control (MOPC-21; Bio Express, West Lebanon NH). 
 
Whole body bioluminescent imaging (BLI)  
Tumor growth was monitored weekly by whole body bioluminescent imaging 
(BLI) using an intensified-charge-coupled device (I-CCD) video camera of the in vivo 
Imaging System (IVIS100, Xenogen/Perkin Elmer, Alameda, CA, USA) as described 
previously (51). In the SD-208 in vivo treatment experiment the newer IVIS Lumina II 
(Xenogen/Perkin Elmer, Alameda, CA, USA) was used for BLI measurements. Mice were 
anesthetized using isoflurane and injected intraperitoneally with 2 mg D-luciferin (Per 





performed after definition of the region of interest and quantified with Living Image 4.2 
(Caliper Life Sciences, Teralfene, Belgium). Values are expressed as relative light units 
(RLU) in photons/sec. 
 
Immunofluorescence 
Immunofluorescence staining was performed as described previously (52). In 
brief, Immunofluorescence staining was performed on 5-μm paraffin embedded 
sections. For antigen retrieval, sections were boiled in antigen unmasking solution 
(Vector Labs, Peterborough, UK) and stained with CD31 (Sigma) or ALDH1A1 (Abcam) 
antibodies. Sections were blocked with 1% bovine serum albumin (BSA)-PBS-0.1% v/v 
Tween-20 and incubated with primary antibodies diluted in the blocking solution, 
overnight at 4°C or room temperature. Sections then were incubated with secondary 
antibodies labelled with Alexa Fluor 488, 555, or 647 (Invitrogen/Molecular Probes, 
Waltham, USA) at 1:250 in PBS-0.1% Tween-20. Nuclei were visualized by TO-PRO3 
(Invitrogen/Molecular Probes, 1:1000 diluted in PBS-0.1% Tween-20) or DAPI, which was 
included in the mounting medium (Prolong G, Invitrogen/Molecular Probes). 
 
Western immunoblotting  
Proteins were extracted by using RIPA buffer (Thermo Scientific) and protein 
concentrations were quantified according to manufacturer’s protocol (Thermo 
Scientific). Proteins samples (20 µg per sample) were separated by 15% SDS-PAGE 
followed by transfer to a blotting membrane. The membrane was blocked with 5% Milk, 
dissolved in PBS-Tween for 1 hour at room temperature. The membrane was incubated 
with 1:1000 primary antibody (anti-NOTCH1, Cell Signaling, catalogue number 3608) at 
4ºC overnight. Subsequently, the membrane was incubated with 1:10000 secondary 
horseradish peroxidase (HRP) antibody. All antibodies were dissolved in PBS-Tween. 
Chemi-luminescence was used to visualize the bands. 
 
Clonogenic assay 
Clonogenic assay was performed in 6 well plate. 100 cells were seeded in 2mL of 
medium and incubated at 37°C in presence of 5% CO2 for two weeks. Plates were 
washed with PBS and cells fixed for 5 min with a solution of 4% PFA. Colonies were 
stained with 0.1% crystal violet (Sigma-Aldrich, The Netherlands) and plates were 









Statistical analysis was performed with GraphPad Prism 6.0 (GraphPad software) 
using t-test or ANOVA for comparison between more groups. Data is presented as mean 
± SEM. P-values ≤ 0.05 were considered to be statistically significant (* P < 0.05, ** P < 








High expression of BMP9 and ALK1 correlates with poor survival  
We investigated the correlation of survival with BMP9 and ALK1 expression in an 
independent publically available PCa dataset (GSE21032). BMP9 and ALK1 expression 
were associated with poor prognosis (Fig. 1 A and B top; Hazard Ratio (HR)=2.38 and 
p=0.007 for BMP9 and HR=2.62 and p=0.007 for ALK1). Additionally, the expression of 
BMP9 and ALK1 in stratified risk groups was significantly higher in the high vs. low risk 
group (Fig. 1 A and B Bottom; p=1.3e-34 for BMP9 and p=3.46e-19 for ALK1). Taken 
together, these data demonstrate that BMP9 and ALK1 are selectively highly expressed 
in aggressive PCa and that their expression correlates with poor prognosis. 
 
Figure 1. BMP9 and ALK1 correlate with poor patient prognosis. A-B) Top panels: Kaplan-Meier 
survival curves of censored Cox analysis in Taylor-MSKCC prostate database stratified by maximized 
BMP9 and ALK1 expression risk groups. Red = high expression; Green = low expression. Bottom panels: 
BMP9 and ALK1 expression levels stratified by risk groups. Red = high Risk and high BMP9 and ALK1 








ALK1Fc reduces primary prostate tumor burden in vivo 
To investigate the role of BMP9 in prostate cancer progression, ALK1Fc was 
administered in a mouse model of prostate cancer. Orthotopic prostate tumor growth 
was induced by intra-prostatic inoculation of human prostate cancer PC-3M-Pro4luc2 
cells in Balb/c nude mice and tumor progression was followed by bioluminescence 
imaging (BLI) (31) (Fig.2A). Based on the BLI signal the mice were distributed between 
two treatment groups: ALK1Fc or CFc (n=15 per group). The compounds were injected 
twice weekly and tumor imaging and body weights were monitored weekly for 5 weeks 
(Suppl. Fig.1). Tumor burden was quantitatively assessed for each animal during the 
course of treatment. The group of animals that received ALK1Fc exhibit smaller tumor 
size compared to the animals that received CFc based on the size after resection (Fig. 
2B) and bioluminescence quantification (Fig. 2C, p<0.001).  
 
Figure 2. Effect of ALK1Fc in vivo. A) PC-3M-Pro4Luc2 cells were orthotopically injected in the anterior 
lobe of prostate glands of nude mice (n=15 per group). Detection of primary tumor burden was 
observed at 2 weeks after injection, with the time point designated as “week 1” at the start of treatment 
with ALK1Fc or CFc. Representative examples of bioluminescent images of tumor burden at the start of 





tumor size (in centimeters) from a recipient of CFc versus ALK1Fc treatment after 5 weeks. C) 
Quantification of bioluminescent signal (photons/sec) in mice treated with either CFc (n=14) or ALK1Fc 
(n=15) for 5 weeks. Error bars indicate ± SEM. P value <0.001 (***).  
 
Alk1Fc reduces vascular density of the primary prostate tumor  
The degree of tumor angiogenesis is critical for progressive tumor growth beyond 
a few mm3 in size. Intravenous lectin perfusion was used to map the perfused elements 
of the tumor vasculature in mice. Fluorescent-conjugated lectin (lectin-Tomato) was 
visualized in tumor tissue sections and quantified. Vascular density, indicated by the 
overall lectin presence, was decreased in the tumors treated with ALK1Fc compared to 
the CFc group (Fig. 3A, B). We evaluated the presence of endothelial cells in tumor 
sections by CD31 immunofluorescence. CD31 expression was decreased after treatment 
with ALK1Fc indicating fewer endothelial cells and vessels (Fig. 3C, D). Hypoxia is an 
important component of angiogenesis and critical for tumor formation. A hypoxia-
induced probe was injected in tumor bearing mice just prior to sacrifice and the hypoxic 
areas within the tumors were visualized after tumor resection (Fig. 3E, F). Hypoxic areas 
are found in both treatment groups; however, the overall amount of hypoxia is 
significantly higher (p< 0.05) in ALK1Fc-treated, tumor-bearing mice over the CFc-
treated groups. We assessed the presence of cell proliferation and cell death in these 
tumors by immunofluorescence for the mitosis marker phosphorylated histone 3 (PH3) 
and the apoptosis marker cleaved caspase 3 (CASP3). Dividing PH3 positive cells are 
predominantly located in normoxic areas (Fig.3E, left panel). Quantification of 
immunofluorescence signal shows that the number of dividing cells is lower in the 
ALK1Fc-treated animals (Fig. 3G; p<0.05). Detection of apoptotic cells (Caspase-3 
positive) is higher in the ALK1Fc-treated tumors (Fig. 3H; p<0.05) and occurs mostly, 
however not exclusively, in hypoxic areas (Fig.3E), suggesting a correlation between the 
hypoxia and tumor cell death. 
 
 





Figure 3. Effect of ALK1Fc on vascular density, cell proliferation and apoptosis in vivo. A) 
Representative images of lectin detection in primary prostate tumor samples after perfusion with 
fluorescent-labelled lectin-Tomato (red). TOPRO (blue) marks the nuclei. Treatment groups: ALK1Fc or 
CFc. B) Quantification of lectin positive surface area in all tumor samples of each group (n=6 for CFc, n=7 
for ALK1Fc). (C) Representative images of CD31 (red) immunofluorescence staining in primary prostate 
tumor samples after 5 weeks of treatment with either ALK1Fc or CFc. D) Quantification of CD31 positive 
surface area in all tumor samples of each group (n=6 for CFc, n=7 for ALK1Fc). E) Representative images 
of hypoxia immunofluorescence staining (red) in primary prostate tumor samples after 5 weeks of 
treatment with either ALK1Fc or CFc. Hypoxia probe was injected prior to sacrifice and was detected by 
a specific fluorescent antibody. Immunofluorescence images for colocalization of apoptotic or 





animals. pH3: PhosphoHistone 3 proliferation marker (green); cleaved caspase 3 apoptosis marker 
(green); Hypoxic probe-antibody; hypoxic area (red). F) Quantification of hypoxia positive area in all 
tumor samples of each group (n=6 for CFc, n=7 for ALK1Fc). G) Quantification of pH3 positive area in all 
tumor samples of each group (n=6 for CFc, n=7 for ALK1Fc). H) Quantification of cleaved caspase 3 
positive (apoptotic cells) in all tumor samples of each group (n=6 for CFc, n=7 for ALK1Fc). 
 
ALK1Fc decreases proliferation of human prostate cancer cells  
To investigate how ALK1Fc can decrease tumor growth, we investigated the effect 
of ALK1Fc on prostate cancer cells. We measured the mRNA levels of BMP9 type I 
receptors ALK1 and ALK2 in the PC-3M-Pro4Luc2 (31) human prostate cancer cell line 
and tested the response of these cells to BMP9. Consistent with what was previously 
reported in highly metastatic PC-3 and PC-3M prostate cancer cells (32), qRT-PCR 
analysis in osteotropic PC-3M-Pro4Luc2 cells revealed undetectable levels of ALK1 
mRNA but clearly measurable levels of ALK2 mRNA (Suppl. Fig. 2A). Treatment with 
BMP9 showed a dose-dependent induction of BRE-Renilla luciferase activity in PC-3M-
Pro4Luc2 cells (p-value=0.005 and 0.05 with 0.5 nM and 1 nM BMP9, respectively) 
indicative of conserved and active signaling machinery (Suppl. Fig. 2B). Using the 1nM 
BMP9 dose for subsequent experiments, we tested the combined effect of BMP9 with 
either ALK1Fc or CFc on BRE reporter assay. Treatment with ALK1Fc (10 ug/mL) 
completely abolished the BMP9-mediated BRE luciferase (luc) activity (Suppl. Fig. 2C; 
BMP9+ALK1Fc) to levels similar to the non-stimulated control (Untreated). Treatment 
with BMP9+CFc (10 ug/mL) led to induction of BRE-luc activity of similar level as the 
BMP9 treatment (Suppl. Fig. 2C; p-value <0.05). Taken together, these results indicate 
that ALK1Fc blocks ALK2-mediated BMP9 signaling in PC-3M-Pro4Luc2 cells. 
We further show that treatment of with 10 ug/mL ALK1Fc, but not control Fc (CFc), 
strongly reduced BMP9-induced PC-3M-Pro4Luc2 cell proliferation (p<0.001 at day 4 
comparing vehicle vs BMP9 or ALK1Fc treatment, respectively) (Fig. 4A). The effect of 
ALK1Fc on cell proliferation appeared to be specific since it had no effect on cell 
proliferation in the absence of BMP9 treatment (Suppl. Fig.2D). The proliferative effect 
of BMP9 was also tested in the C4-2B prostate cancer cell line; however no significant 
difference was observed (Suppl. Fig. 2E). When we treated PC-3M-Pro4Luc2 cells with 
BMP9 in combination with an ALK2 kinase inhibitor (LDN193189, LDN) (33, 34) we 
observed a complete loss of BMP9-induced proliferation (Fig. 4B). LDN treatment also 
blocked BMP9 stimulation of the BRE-luc reporter in PC-3M-Pro4 cells (Suppl. Fig. 2F) 
but had minimal impact on basal proliferation levels in the absence of exogenously 
added BMP9 (Suppl. Fig. 2G). Finally, we evaluated the clonogenic ability of PC-3M-
Pro4Luc2 cells after BMP9 treatment alone (Suppl. Fig.3A) and confirmed that BMP9 
affects cell proliferation, strongly increasing the size of the colonies (Suppl. Fig.3B, 




p<0.05). However, BMP9 showed no effect on colony formation/self-renewal ability of 
PC-3M-Pro4Luc2 since the total number of colonies formed is similar (Suppl. Fig. 3C). 
Together, these data indicate that ALK1Fc strongly reduces BMP9- induced proliferation 
of human prostate cancer cells. 
 
 
Figure 4. Effect of BMP9 and ALK1Fc on proliferation and ALDH1A1 expression. A) MTS assay (24, 48, 
72, 96 hours) was performed in PC-3M-Pro4Luc2 cells stimulated with recombinant BMP9 (1 nM), BMP9 
(1 nM)+ALK1Fc (10 ug/ml) or BMP9 (1 nM)+CFc (10 ug/ml). Accumulation of MTS was measured based on 
absorbance at 490 nm. Values are normalized to the basal measurements at 24 hours after cell seeding 
and treatments. Graph represents values for three independent experiments (n=3). Error bars indicate ± 
SEM. P value < 0.01 (**) BMP9 vs Untreated and P-value < 0.001 (***) BMP9+CFc vs Untreated. B) MTS 





treated with BMP9 (1 nM), LDN (BMP type I receptor inhibitor LDN193189, 120nM) or LDN+BMP9. (n=2). 
Error bars indicate SEM. C) Representative images of ALDH1A1 immunofluorescence in prostate tumor 
samples from ALK1Fc and CFc treated animals. ALDH1A1: red; TOPRO: blue nuclear dye. D) 
Quantification of ALDH1A1 mRNA by Q-PCR in tumor samples of each group (n=5 for CFc, n=5 for 
ALK1Fc). E) Expression of ALDH1A1 in PC-3M-Pro4Luc2 cells. Relative mRNA expression was measured 
by Q-PCR from cDNA obtained from PC-3M-Pro4Luc2 cells treated with BMP9, BMP9+ALK1Fc, BMP9+CFc, 
for 48, 72 and 96 hours. Values are normalized to β-actin expression. Error bars are ±SEM (n=3). 
 
Expression of BMP9, ALK1 and ALK2 in human and murine prostate tumor 
tissues  
We investigated the mRNA expression of BMP9, ALK1 and ALK2 in 48 benign 
prostate tumors and 47 malignant prostate tumors (35) using bioinformatics analysis 
and data mining platforms (R2: microarray analysis and visualization platform 
http://r2.amc.nl, source: GEO ID: GSE29079) (Suppl. Fig.3D, E and F). While levels of 
ALK1 transcripts are decreased in the malignant tumor group compared to the benign 
group (p<0.001), levels of ALK2 transcripts are significantly increased (p<0.01) in the 
malignant tumor group compared to the benign group. BMP9 mRNA expression is 
similar in both groups (p=0.28). Previously, Bacac et al. (36) performed cDNA microarray 
analysis using laser-micro dissected stromal cells from murine prostate intraepithelial 
neoplasia (PIN) and invasive prostate tumors. Analysis of ALK1, ALK2 and BMP9 (Suppl. 
Fig.3G, H and I) expression in this dataset indicated elevated mRNA expression of ALK1, 
ALK2 and BMP9 during the invasive stage of murine prostate cancer.  
 
ALK1Fc inhibits ALDH1A1 expression in vivo and interferes with NOTCH 
signaling 
Given its ability to reduce primary tumor burden and block BMP9-induced tumor 
cell proliferation in vitro we assessed the effects of ALK1Fc on the relative expression of 
the ALDH1A1 marker that is associated with cancer stem cell-like cells and poor patient 
prognosis (25, 26). Treatment of prostate tumor bearing mice with ALK1Fc affected the 
number of proliferative ALDH1A1 positive cells in the prostate tumor tissues both at 
protein (Fig. 4C) and mRNA level (Fig. 4D). In vitro stimulation with BMP9 of the same 
cell line used to induce tumors in the xenograft mouse model, confirmed that treatment 
with BMP9 or BMP9+CFc upregulates ALDH1A1 expression while BMP9+ALK1Fc 
treatments does not have any effect (Fig. 4E). 
ALDH1A1 is known to be regulated by NOTCH signaling (23-25) and NOTCH1 plays a 
prominent role in prostate cancer cell proliferation and migration (22, 37-40). Larrivée et 
al. have shown that ALK1 and NOTCH converge on common downstream pathways and 
that BMP9 treatment alone upregulates JAG1 expression in HUVEC non-transformed 




cells (41). To verify the effect of BMP9 on NOTCH signaling activation in our cancer 
model, we used qRT-PCR to quantify the expression of JAG1 after BMP9 stimulation in 
presence of ALK1Fc or CFc. Our transcriptional analysis showed that BMP9 and 
BMP9+CFc induce mRNA expression of JAG1 and that ALK1Fc reduces the BMP9-
mediated induction of JAG1 (Fig. 5A). To assess the clinical relevance of BMP9/ALK2-
mediated NOTCH pathway activation in human prostate cancer, we performed 
bioinformatics analysis using data mining platforms (R2: microarray analysis and 
visualization platform http://r2.amc.nl, source: GEO ID: GSE29079). Transcript levels of 
the NOTCH ligand JAG1 were significantly higher in the malignant tumor group 
compared to the benign group (Fig. 5B) and positively correlate with ALK2 expression 
and disease progression (Fig.5D). In addition, the prostate tumor microarray data 
indicate a positive correlation between the level of NOTCH1 receptor expression and 
human progression to malignancy (Fig. 5C) as well as ALK2 expression (Fig. 5E). In 
addition, overexpression of JAG1 in PC-3M-Pro4Luc2 human prostate cancer cells 
increases metabolic activity measured by MTS assay (Fig. 5F).  
We targeted expression of NOTCH1 in PC-3M-Pro4Luc2 using a specific shRNA 
(shNOTCH1) and assessed resulting NOTCH1 levels by western blot and by reporter 
assay (Suppl. Fig. 4A and B). NOTCH1 knockdown cells had decreased proliferation 
compared to cells transduced with non-targeting shRNA lentivirus (p<0.05 at 48h and at 
72h) (Fig. 5G). We observe that stimulation of shNOTCH1-cells with BMP9 increases their 
proliferation rate (Fig. 5H) and that shNOTCH1-cells display decreased levels of JAG1 
mRNA (Suppl. Fig . 4C). These data suggest that BMP9/ALK2 induces activation of 
NOTCH signaling (JAG1 and NOTCH1) and enhanced cell proliferation both of which are 









Figure 5. Effect of BMP9 and ALK1Fc on NOTCH signaling pathway and correlation study. A) 
Expression of JAG1 in PC-3M-Pro4Luc2 cells. Relative mRNA expression was measured by qPCR from 
cDNA obtained from PC-3M-Pro4Luc2 cells treated with BMP9, ALK1Fc, CFc, BMP9+ALK1Fc or BMP9+CFc 
for 96 hours. Values are normalized to β-actin expression. Error bars are ±SEM (n=3). B-C) Bioinformatics 
analysis of AMC OncoGenomics database (Sueltman transcript comparison) showing mRNA expression 
of JAG1 B) and NOTCH1 C) in prostate tissues among benign prostate tissues (n=48) versus tumor tissues 
(n=47). Values are expressed as 2log ratio tumor/ benign. ns: not significant. P value < 0.001 (***). D) 
Correlation analysis of JAG1 and ALK2 expression (p<0.0001) and E) correlation analysis of NOTCH1 and 
ALK2 expression (p<0.0001) in prostate tissues among benign prostate tissues (n=48) versus tumor 
tissues (n=47). Bioinformatic analysis was performed using the AMC OncoGenomics database (Sueltman 
transcript comparison), values are expressed as 2log ratio tumor/ benign. ns: not significant. F) MTS 
assay (24, 48 hours) in PC-3M-Pro4Luc2 cells transfected with 1ug JAG1 or Mock expression vector (n=2). 
G-H) MTS assay (24, 48, 72 and 96 hours) in PC-3M-Pro4Luc2 cells were transduced with short hairpin 
RNA against NOTCH1 (shNOTCH1) lentiviral vector or non-targeting (NT) shRNA vector (mock) and 




plated at low density. Treatment with BMP9 (1 nM) was done once at cell seeding (t=0) MTS absorbance 
was measured. Values are normalized to the basal measurements t=0 after cell seeding and treatments. 
Graph represents values for three independent experiments (n=3). Error bars indicate SEM. P value 








In this study, we find that BMP9 and ALK1 correlate with poor survival in prostate 
cancer patients and that BMP9 has a tumor-promoting effect on human prostate cancer 
cells both in vitro and in vivo. We demonstrate that blocking BMP9 signaling with ALK1Fc 
efficiently diminishes prostate cancer cell proliferation and substantially attenuates 
tumor growth in an orthotopic model of human prostate cancer.  
BMP9 was first identified in the liver (12) and active forms are present in serum (8). BMP9 
is a ligand for the ALK1 receptor in endothelial cells (5) and exerts stimulatory or 
inhibitory effects on endothelial cell growth and migration depending on the cellular 
context (30, 42). Aberrant regulation of TGF-β and BMP signaling often results in cancer 
progression (43, 44). In particular, BMP ligands, such as BMP9 as well as BMP type I 
receptors (e.g. ALK1 and ALK2) have been associated with tumor angiogenesis and 
cancer progression. BMP9 signals through ALK2 in non-endothelial cells such as in 
ovarian epithelium, where it has been shown to promote ovarian cancer cell 
proliferation (8). Similarly, in hepatocellular carcinoma BMP9 has been reported to act 
as proliferative and survival factor (10). Studies have also highlighted the role of BMP9 in 
reducing breast cancer cell growth and metastasis (45-47). However, the role of BMP9 
and ALKs in promoting or suppressing different cancer types remains controversial. 
Collectively, this indicates that the effect of BMP9 on tumor promotion vs tumor 
suppression could be context and cancer-type specific, thus providing the rationale for 
to elucidate the role of BMP9 in prostate cancer, for which no information is available to 
our knowledge.  
We searched publicly available databases of human prostate cancer specimens and 
found that ALK2 is significantly upregulated in malignant vs. benign tumor tissue 
samples whereas ALK1 has the opposite expression pattern, although shown to 
correlate with poor survival in other dataset (35). However, these data are consistent 
with our model in which the tumor-promoting effects of BMP9 are mediated by ALK2. 
Additionally, microarray analysis of data from mouse prostate intraepithelial neoplasia 
(PIN) versus invasive cancer in a multistage model of prostate carcinogenesis showed 
up-regulation of ALK2 and BMP9 at the invasive stage in the stromal compartment (48). 
Taken together, these data suggest a tumor-promoting role of BMP9 produced by the 
supportive stroma during prostate cancer progression. The fact that the BMP9 transcript 
levels registered in the selected dataset are similar in benign vs tumor stage in human 
prostate tumor samples, suggests a paracrine effect of BMP9 in human prostate cancer 
(35). Moreover, the significant increased expression of ALK2 in human prostate tumor 
tissue samples suggests that the BMP9 produced by the stromal compartment might be 
pro-tumorigenic as suggested by the anti-tumor effect of ALK1Fc that we have 




documented here. This hypothesis is reinforced by our survival analysis which shows 
that BMP9 correlates with poor survival in human prostate cancer patients. 
Our in vitro findings strengthen the afore-mentioned expression data and suggest that 
BMP9 increases proliferation of human prostate cancer cells. Moreover, our studies 
incorporating blockade of ALK2 activity by LDN193189 support the notion that ALK2 is 
critically involved in mediating BMP9-induced proliferation. As depicted in the 
supplementary data, treatment with ALK1Fc or LDN193189 alone did not affect 
proliferation of human prostate cancer cells suggesting a paracrine effect of stroma-
derived BMP9 on tumor cells. While BMP9 did not influence clonogenic ability of human 
prostate cancer cells, it elicited a significant stimulatory effect on colony size suggesting 
it influences colony expansion rather than colony formation.  
In our orthotopic model of human prostate cancer, ALK1Fc significantly reduced the 
prostate tumor burden compared to the control group and vascular density was also 
reduced in animals treated with ALK1Fc versus those treated with CFc. Interestingly, 
lectin distribution appeared to be less diffuse in ALK1Fc treated animals, suggesting an 
effect on vessel maintenance rather than angiogenesis. Strikingly, ALK1Fc treatment of 
tumor-bearing animals resulted in highly hypoxic tumors with a decreased number of 
CD31+ tumor capillaries suggesting that ALK1Fc may block BMP9-induced 
neovascularization.  
As expected, areas of tumor proliferation and apoptosis were found to be mutually 
exclusive in their distribution. Apoptotic regions overlapped with hypoxic areas, 
suggesting that blockade of BMP9 by ALK1Fc might have an effect on proliferation and 
apoptosis of human prostate cancer cells in addition to targeting vessel maintenance 
(28).  
SMAD1 and SMAD5 are intracellular effectors of BMP9 signaling that can directly interact 
with the JAG1 promoter following BMP9 treatment (49) and induce transcription of the 
NOTCH ligand JAG1 (41). Transcriptional analysis revealed that ALK1Fc systemically 
blocks the induction of JAG1 mRNA in the presence of BMP9 (49) supporting our 
hypothesis that the crosstalk between BMP9 and NOTCH signaling may have clinical 
implications in prostate cancer. Indeed, in silico analysis of a previously published 
dataset of human prostate cancer specimens confirms that both NOTCH1 and JAG1 are 
upregulated at the tumor stage (35). Our database analysis in a multistage model of 
prostate carcinogenesis on mouse prostate intraepithelial neoplasia (PIN) vs. invasive 
cancer further indicates that Jag1 is significantly upregulated in the stroma during the 
invasive cancer stage (48).  
Interestingly, NOTCH activates aldehyde dehydrogenase 1A1 (ALDH1A1) a well-known 
marker of highly tumorigenic prostate cancer stem-like cells (23-25). The ALDHhigh 





expressed in advanced-stage cancers correlates with poor survival in hormone-naïve 
patients (25). ALK1Fc-treated tumors showed significant reduction of ALDH1A1, which in 
combination with the data described above, suggests that ALK1Fc might potentially 
interfere with NOTCH signaling in the regulation of ALDH1A1.  
In conclusion, our findings provide novel information on the role of BMP9 in human 
prostate cancer and suggest the promising use of BMP9 targeting molecules for the 
treatment of tumor and supportive microenvironment in prostate cancer patients.  
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Suppl. Fig. 1 Body weight of animals used for in vivo experiment. Body weight (grams) of all the 









Suppl. Fig. 2 Characterization of dose response for BMP9 with luciferase reporter. A) Endogenous 
expression of ALK1, ALK2, ALK4 and ALK5 receptors in PC-3M-Pro4Luc2cells (mRNA level). Relative 
expression levels normalized to β-actin are shown. Error bars indicate +/-SD. B) Dose dependent 
response of PC-3M-Pro4Luc2 cells to recombinant BMP9 (0.01, 0.1, 0.5, 1 nM). Downstream activation of 
BMP signaling was tested by transfection of BRE-renilla construct and measured by reporter activity 
assay. Graph represents values from three independent experiments; error bars indicate ± SEM (n=3). P 
value < 0.05 (*) and P value < 0.01 (**). C) BRE reporter luciferase (BREluc) assay; Inhibitory 
concentration of ALK1Fc or CFc (10 ug/ml) was determined in cells stimulated with 1 nM BMP9. Graph 
represents values from two independent experiments; error bars indicate ± SEM (n=2). P value < 0.05 (*) 
and P value < 0.01 (**) compared to “untreated” control. P value < 0.01 (##) D) MTS assay (24, 48, 72 
hours) was performed in PC-3M-Pro4-luc2 human prostate cancer cell line treated with recombinant 
ALK1Fc (10 ug/ml), CFc (10 ug/ml). Accumulation of MTS was measured based on absorbance at 490 nm. 
Values are normalized to the basal measurements at 24 hours after cell seeding and treatments. Graph 
represents values from two independent experiments (n=2). Error bars indicate ±SEM. E) MTS assay (24, 
48, 72, 96 hours) was performed in C4-2B human prostate cancer cell lines stimulated with recombinant 
BMP9 (1 nM), BMP9 (1 nM)+ALK1Fc (10 ug/ml) or BMP9 (1 nM)+CFc (10 ug/ml). (n=3). F) BMP promoter 
assay (BRE-luciferase). PC-3M-Pro4 were seeded and, transfected with BRE-luc and renilla plasmid DNA. 
After 24 hours the medium was replaced with 0.3%, 5%, 10% FCII serum containing media and treated 
with BMP9 (1nM), LDN193189 (LDN, 120nM) and BMP9+LDN. Luc and Ren values were measured 24 hrs 
after treatment. RLU ratio values are shown (Luc/Ren). Error bars indicate ±SD. G) MTS assay (24, 48, 72 




hours) was performed in PC-3M-Pro4-luc2 human prostate cancer cell line treated with LDN inhibitor 
(LDN193189, 120 nM). (n=2). Error bars indicate +/-SEM. 
 
 
Suppl. Fig. 3 Effect of BMP9 and ALK1Fc on clonogenicity and ALK expression in human samples. A)  
Clonogenic assay of PC-3M-Pro4Luc2 cells. Low-density cultures (100 cells per well of 6well plate) were 
stimulated with BMP9, CFc, ALK1Fc, BMP9+CFc, BMP9+ALK1Fc. Colony formation was assessed after 10 
days by crystal violet staining. Representative images are shown. B-C) Quantification of surface covered 





surface normalized per condition (average of three independent experiments). P value < 0.05 (*). Error 
bars indicate SEM. D-F) Bioinformatics analysis of AMC OncoGenomics database (Sueltman transcript 
comparison) showing mRNA expression of ALK1, ALK2 and BMP9 in prostate tissues among benign 
prostate tissues (n=48) versus tumor tissues (n=47). Values are expressed as 2log ratio tumor/ benign. 
ns: non-significant. P value < 0.01 (**) G-I) Microarray cDNA analysis (adapted from Bacac et al., (36) of 
Alk1, Alk2 and Bmp9 expression in microdissected murine stroma derived from two tumor stages; 





Suppl.Fig.4. Characterization of NOTCH1 knock-down. A) Western immunoblotting for NOTCH1 
protein as validation of lentiviral shRNA-mediated knockdown of NOTCH1 intracellular domain 
(cleaved) in PC-3M-Pro4luc2 PCa cell line using five shRNA constrcuts. Based on the downregulation of 
cleaved NOTCH1 observed after lentiviral transduction and puromycin selection, the stable line 
expressing the shRNA #2 construct was selected for further experiments. NT; non-targeting shRNA 
lentiviral mediated transduction. Β-actin was used as loading control. B) NOTCH transcription factor 
RBP-Jk-luciferase reporter assay in non-targeting (NT) and NOTCH1 (shRNA#2) knockdown (KD) PC-3M-
Pro4Luc2 cells. RLU: relative luciferase units (signal of luciferase normalised to renilla values). n=3, P 
value < 0.01 (**) C) QPCR for JAG1 mRNA levels in non-targeting (NT) and NOTCH1 (shRNA#2) knockdown 
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Prostate cancer (PCa) is the most prevalent cancer in men and metastatic spread 
to bone is detected in up to 80% of patients with advanced disease at autopsy. PCa can 
progress from treatable androgen-dependent stage to castration-resistant stage with 
distant metastases for which novel therapeutic targets and strategies are urgently 
needed. Here we identify the cell surface/secreted oncoprotein Cripto as a potential 
target for the diagnosis and treatment of metastatic PCa. We show that high expression 
levels of Cripto correlate with poor survival in stratified risk groups of PCa patients and 
demonstrate that Cripto and its signalling partner Grp78 are highly expressed in PCa 
metastases. We find that Cripto and Grp78 are expressed at substantially higher levels in 
the metastatic ALDHhigh subpopulation of PC-3M-Pro4luc2 PCa cells compared to non-
metastatic ALDHlow. In order to mimic the bone metastatic niche in vitro, we cultured the 
highly osteotropic PC-3M-Pro4luc2 PCa cells with differentiated primary human 
osteoblasts. This strongly induces Cripto and Grp78 expression in the PCa cells and 
increases the size of the ALDHhigh subpopulation relative to the ALDHlow in PC-3M-
Pro4luc2. Additionally, Cripto or Grp78 knockdown decreases cell proliferation, 
migration, clonogenicity and the size of the metastasis-initiating ALDHhigh 
subpopulation. Significantly, we find that Cripto knockdown reduces the dissemination 
and invasion of PC-3M-Pro4luc2 cells in a zebrafish model and strongly inhibits bone 
metastasis in a preclinical mouse model. Taken together, our findings highlight a 
functional role for Cripto and Grp78 in PCa metastasis and suggest that targeting 
















Prostate cancer (PCa) is the second most common cancer in men worldwide (1). 
While current treatments of primary tumors are initially very effective, these beneficial 
responses are often followed by tumor recurrence and incurable bone metastasis. 
Therefore, identifying molecular mediators of PCa relapse and metastasis will aid in the 
development of therapies for this deadly phase of the disease. 
Cripto (TDGF1, Cripto-1) is a small, GPI-anchored/secreted foetal-oncoprotein that plays 
important roles in regulating stem cell differentiation, embryogenesis, tissue growth 
and remodeling (2). Cripto promotes transformation, migration, invasion and 
angiogenesis and its misregulation can contribute to cancer development and 
progression in multiple malignancies, including breast cancer and PCa, which are both 
characterized by osteotropism in their metastatic stage (3,4). Cripto modulates crucial 
pathways that regulate bone metastasis such as the TGF-β pathway (5) and functions as 
an obligatory co-receptor for Nodal, a TGF- β superfamily member that promotes 
epithelial to mesenchymal transition (EMT) in PCa (5-7). Glucose-regulated protein 78 
(Grp78) was identified as a Cripto binding protein and essential mediator of Cripto 
signaling (8-10). Grp78 is well established as a key survival factor in development and 
cancer (8,9) and, notably, up-regulation of Grp78 has been associated with the 
development of castration resistant PCa (CRPC) (11). While Cripto was reported to 
impact primary human prostate adenocarcinomas (6), its role in driving CRPC and PCa 
bone metastasis remains unknown.  
Here, we investigated the roles of Cripto and Grp78 in aggressive, metastatic 
human PCa cells both in vitro and in vivo using an embryonic zebrafish model and a pre-
clinical mouse model of experimentally induced PCa bone metastasis. We find that 
Cripto and Grp78 are upregulated in clinical samples of PCa metastases from human 
patients and in the highly metastatic ALDHhigh stem/progenitor-like subpopulation of a 
human castration resistant PCa cell line (12,13). We further demonstrate that 
knockdown of Cripto or Grp78 in these cells decreases the size of the stem/progenitor-
like subpopulation and also inhibits their extravasation following inoculation into 
zebrafish and their metastatic potential in a preclinical mouse model of bone metastasis 
in vivo. Together, these findings provide new evidence that Cripto and Grp78 may drive 
metastatic PCa and highlight the therapeutic potential of targeting the cell surface 
Cripto/Grp78 complex for the treatment of this deadly disease.  
 





Materials and Methods 
 
PCa Cell lines and culture conditions 
Human osteotropic PCa PC-3M-Pro4luc2 cells were maintained in DMEM with 
10% FCII, 0.8 mg/ml Neomycin (Santa Cruz, USA) and 1% Penicillin-Streptomycin (Life 
Technologies, USA). C4-2B cells were maintained in T-medium DMEM (Sigma-Aldrich, 
The Netherlands) with 20% F-12K nutrient mixture Kaighn’s modification (GibcoBRL, 
USA), 10% FCS, 0.125 mg/ml biotin, 1% Insulin-Transferrin-Selenium, 6.825 ng/ml T3, 
12.5 mg/ml adenine and 1% Penicillin/Streptomycin. Primary human osteoblasts were 
differentiated at confluence: ascorbic acid (50 mg/ml, MERCK, USA) was added in DMEM 
with 10% FCS, 1% Penicillin-Streptomycin and 1% MEM Non-essential Amino Acids 
(Gibco-Thermo Scientific, USA). Upon detection of nodules (day 11), medium was 
supplemented with β-glycerolphosphate (5mM, Sigma, the Netherlands) and 100 nM 
dexamethasone. After 3 weeks, cells were washed with phosphate buffered saline (PBS) 
and fixed with 4% paraformaldehyde (PFA). Culture was analyzed for osteogenesis with 
Alizarin Red staining (ICN Biomedicals, USA) (14). Cells were maintained at 37°C, 5% CO2 
 
Suppressing Cripto and Grp78 expression with shRNAs  
Short hairpin RNAi constructs for Cripto1 (TDGF1 clone# TRCN004889, 
TRCN004890 and TRCN004891) and HSPA5 (Grp78 clone# TRCN231123, TRCN218611) 
were obtained from Sigma’s MISSION library (Core Facility at LUMC). 500 µL of shRNA-
lentiviral vector and 8 µg Polybrene (Sigma, USA) were added to PC-3M-Pro4Luc2 and 
PC-3M-Pro4Luc2_dTomato cells and incubated for 2 hours. Scrambled shRNA (SHC002, 
non-targeted, NT or control) with lack of homology for any mammalian mRNA sequence 
was used as negative control. Cells were selected using puromycin (1µg/ml, Sigma, 
USA). 
 
Flow Cytometry and aldehyde dehydrogenase assay 
PC-3M-Pro4Luc2 were fluorescently labelled with PKH26 Red Fluorescent Cell 
Linker Kit according to protocol (Sigma-Aldrich, MO, USA). 900.000 cells were seeded in a 
10 cm petri dish on a layer of confluent and differentiated human osteoblast. After 48 
hours cells were washed with PBS, 1mM EDTA and harvested using trypsin. 
Fluorescently labelled PC-3M-Pro4Luc2 cells were separated from osteoblast with BD 
FACS ARIA (BD Biosciences, USA). Non-labelled PC-3M-Pro4Luc2 cells; labelled PC-3M-
Pro4Luc2 tumor only and osteoblast only cells were included as controls. Aldehyde 









Cells were washed with PBS and proteins were extracted with RIPA buffer. 
Proteins were quantified using Pierce Protein Quantification Assay (ThermoFisher 
scientific, USA) and 10µg of samples separated by 10% SDS-PAGE and transferred to a 
blotting membrane using standard techniques. Signal was detected after incubation 
with 1:1,000 primary antibody (anti-Cripto, #PBL6900, (15)) and with 1:10,000 secondary 
horseradish peroxidase (HRP) antibody (Promega, USA).  
 
Cripto overexpression 
Cripto construct was generated as previously described (16). PC-3M-Pro4Luc2 
cells were transfected with Lipofectamine2000 (Life Technologies, USA) and C4-2B cells 
with Fugene HD (Promega, USA) according to supplier’s protocol. Five hours after 
transfection, the culture medium was replaced. Before collection, cells were washed 
with PBS and RNA extracted using Trizol (Invitrogen, USA). 
 
RNA isolation and real-time qPCR 
After viable cell sorting with ALDEFLUOR Assay Kit (Stem Cell Technologies, USA) 
(12), total RNA was isolated with Trizol Reagent (Invitrogen, USA) and cDNA synthesized 
by reverse transcription (Promega, USA) according to protocol. qRT-PCR was performed 
with BioRad CFX96 (Biorad, The Netherlands). Gene expression was normalized to 
GAPDH, HPRT and Actin. Primers are listed in Supplementary Table 1. 
 
Proliferation assay 
Cells were seeded at density of 1,500 cells/well and allowed to grow for 24, 48, 
and 72 hours. Proliferation was assessed with 3-(4,5 dimethylthiazol- 2- yl)- 5 -(3 -
carboxymethoxyphenyl)- 2 -(4 -sulfophenyl)- 2 H-tetrazolium after 2 hours incubation at 
37°C. (CellTiter96 Aqueous assay, Promega, USA). Data were normalized for number of 
cells. 
 
Transwell migration assay 
Migration assays were performed using 24-well transwells (8 mm, Corning Life 
Sciences, The Netherlands) (13). For the experiments with conditioned medium from 
osteoblast, this was diluted in the lower chamber 1:2 with medium (50% condition) or 
administered un-diluted (100% condition). 





Colony formation assay 
Clonogenic assay was performed in 6 well-plate. 100 cells were seeded in 2mL of 
medium supplemented with 10% FCII. After 2 weeks, plates were washed with PBS, cells 
fixed with 4% PFA and colonies stained with 0.1% crystal violet (Sigma-Aldrich, The 
Netherlands). Plates were imaged before processing the data (17). 
 
Zebrafish maintenance, embryo preparation and tumor cell inoculation 
Tg(fli1:GFP)i114 zebrafish line (18,19) was handled and maintained according to 
local animal welfare regulations to standard protocols (www.ZFIN.org). 2 days-post 
fertilization (dpf) dechorionized zebrafish embryos were anaesthetized and injected 
with PC-3M-Pro4Luc2 cells fluorescently labelled as we previously described (13,20). 
Data are representative of at least two independent and blind experiments with equal or 
more than 30 embryos per group. Experiments with survival rate of control group lower 
than 80% were discarded. 
 
Mice 
Male 4-5 week-old athymic nude mice (Balb/c nu/nu n=10 per group) were 
purchased from Charles River (L’Arbresle, France). Animals were housed in individual 
ventilated cages under sterile condition, and sterile food and water provided ad libitum. 
Animal experiment has been approved by the local committee for animal health ethics 
and research of Leiden University (DEC #14226) and carried out in accordance with the 
European Communities Council Directive 86/609/EEC.  
 
Intracardiac PCa cell injection and whole body bioluminescent imaging 
(BLI) 
A single cell suspension (1x105 PC-3M-Pro4Luc2 Cripto knock-down (KD) or non-
targeted (NT) control cells per 100 µl PBS) was injected into the left ventricle of 
anesthetized 5-week old male nude mice (Balb/c nu/nu). Tumor growth and metastasis 
formation was monitored weekly by bioluminescent reporter imaging (BLI) using 
IVIS100 Imaging System (Caliper LifeSciences, USA) (12). Analyses of images was 









Immunofluorescence staining was performed on 5-μm paraffin embedded 
sections. For antigen retrieval, sections were boiled in antigen unmasking solution 
(Vector Labs, UK) and incubated in 3% H2O2 for sequestering endogenous peroxidase 
(21). Sections were stained with Cripto antibody (#PBL6900, (15)). After blocking with 1% 
bovine serum albumin (BSA)-PBS-0.1% Tween-20, sections were incubated with primary 
antibody (1:1000) overnight at 4°C. Detection of Cripto was enhanced using tyramide 
amplification (Invitrogen/Molecular Probes, USA) and by incubation of slides with 
horseradish peroxidase (HRP-conjugated secondary antibody (Invitrogen/Molecular 
Probes, USA), diluted 1:100), followed by incubation with tyramide-488 for 10 minutes 
(21). Nuclei were visualized by TO-PRO3 (Invitrogen/Molecular Probes, 1:1000 diluted in 




5 µm formalin fixed, paraffin embedded (FFPE) sections were dewaxed and 
rehydrated using xylene and ethanol, and endogenous peroxidase was blocked for 20 
minutes in 0.3% H2O2 in PBS. Heat-induced antigen retrieval was done in TRIS-EDTA 
buffer (pH=9, 4397-9001, Klinipath, The Netherlands) with a pressure cooker (1.2 bar). 
Antibodies (anti-Cripto, #PBL6900, 1:1,000 (15); Anti-Cytokeratin 18 (CK18) diluted 
1:1,000, Clone DC10, Dako, USA) were diluted 1:1,000 in PBS-BSA 0.1% and incubated 
overnight at 4°C. Envision (K500711, DAKO, USA) was used to visualize the antibody, 
followed by counterstaining with hematoxylin. 
 
Human Material 
Clinical prostate cancer bone metastasis (10 patients) were collected, stored and 
issued by the Erasmus MC Tissuebank under ISO 15189:2007 standard operating 
procedures. Use of these materials for research purposes is regulated according to the 
Human Tissue and Medical Research: Code of conduct for responsible use (2011). 
Confirmation that the Medical Research Involving Human Subjects Act (WMO) does not 
apply to the present study was obtained by the local ethics committee since the 
research was performed on “waste material” (3 patients) collected from Academisch 










Statistical analysis was performed with GraphPad Prism 6.0 (GraphPad software) 
using t-test or ANOVA for comparison between more groups. Data is presented as mean 
± SEM. P-values ≤ 0.05 were considered to be statistically significant (* P < 0.05, ** P < 








Cripto is highly expressed in metastasis from human PCa patients and 
correlates with poor survival 
Cripto and its signaling partner Grp78 have each been shown to play important 
roles in primary tumor development and bone metastasis (22). We investigated the 
correlation of survival with Cripto expression in two independent sets of publically 
available PCa datasets (GSE21032 and GSE10645 (23,24)). In both datasets Cripto 
expression was associated with poor prognosis (Fig. 1 A and B top; Hazard Ratio 
(HR)=1.87 and p=0.001 for GSE10645 and HR=2.2 and p=0.06 for GSE21032). Additionally, 
in both datasets, the expression of Cripto in stratified risk groups was significantly 
higher in the high vs. low risk group (Fig. 1 A and B Bottom; p=1.13e-103 for GSE10645 
and p=3.68e-23 for GSE21032). We further investigated the expression of Cripto and 
Grp78 in the Ramaswamy Multi-cancer dataset from Oncomine™ (Compendia 
Bioscience), which compares PCa metastasis to primary sites in 76 samples (25) and 
found that Cripto and Grp78 are significantly upregulated in metastasis compared to 
primary sites in human PCa (Fig. 1C, p=7.15e-4 for Cripto and p=0.03 for Grp78; 
1=primary site; 2=metastatic site). Given its expression in metastasis and its correlation 
with survival, we subsequently investigated the expression of Cripto in PCa bone 
metastasis by immunostaining of paraffin embedded sections of bone metastasis 
freshly isolated from patients. We detected significant expression of Cripto and co-
localization of Cripto with cytokeratin-18 in serial sections from each of the 13 
specimens analyzed (Fig. 1D). Moreover, immunostaining with the same antibody 
revealed that Cripto is also prominently expressed in experimentally induced bone 
metastasis tissue resulting from intracardiac injection of human castration resistant PC-
3M-Pro4Luc2 PCa cells in mice (Suppl. Fig 1). Taken together, these data demonstrate 
that Cripto is selectively expressed in aggressive and metastatic PCa and that its 
expression correlates with poor prognosis.  






Figure 1. Cripto is expressed in PCa metastasis from human patients and correlates with poor 
patient prognosis. A-B) Top panels: Kaplan-Meier survival curves of censored Cox analysis in 
Kollemeyer-Jenkins prostate and Taylor-MSKCC prostate database stratified by maximized Cripto 
expression risk groups. Red = high expression; Green = low expression. Bottom panels: Cripto expression 
levels stratified by risk groups. Red = high Risk and high Cripto expression; Green = low risk and low 
Cripto expression C) Cripto and Grp78 are significantly up-regulated in PCa metastasis. The 





for analysis. Colors are Z-score normalized and represent from lower (blue) to higher (red) expression. 1 
= primary site; 2 = metastasis. D) Representative images of serial sections of PCa bone metastasis 
stained for CK18 and Cripto and counter stained with hematoxylin (N=13) at lower (10X) and higher (40X, 
see inserts) magnification.  
 
Co-culture with primary human osteoblasts augments the size of the 
ALDHhigh subpopulation, increases Cripto and Grp78 expression levels and 
promotes the metastatic phenotype of PCa cells  
Human PCa cell lines (PC-3M-Pro4Luc2 and C4-2B cells) express detectable levels 
of Cripto and Grp78 mRNA (Fig. 2A). We previously reported that the ALDHhigh 
subpopulation of PC-3M-Pro4Luc2 cells displays stem/progenitor-like properties and is 
highly metastatic relative to their ALDHlow counterpart (12). Cripto and Grp78 are 
expressed in human PCa cell lines (PC-3M-Pro4Luc2 and C4-2B cells) (Fig. 2A) and given 
their known roles in regulating stem cell function and tumor aggressiveness, we tested if 
Cripto and Grp78 are selectively expressed in the ALDHhigh subpopulation. Indeed, qRT-
PCR analysis on selected subpopulation of cells isolated after viable cell sorting, showed 
that both Cripto and Grp78 are highly expressed in ALDHhigh vs. ALDHlow subpopulation 
(p<0.01 for Cripto) (Fig. 2B). This result is consistent with a role for Cripto and Grp78 in 
promoting PCa metastasis. 
In PCa and other cancers, the osteoblastic microenvironment functions as 
premetastatic niche by attracting bone-metastasizing tumor cells (26-28). We developed 
a model of the bone metastatic niche in which primary human osteoblasts are co-
cultured with PC-3M-Pro4Luc2 cells in vitro. Differentiation of the human osteoblasts 
was confirmed by Alizarin red staining (Suppl. Fig 2A). We find that in the presence of 
osteoblasts the size of PCa cell ALDHhigh subpopulation was dramatically increased 
compared to the size of the ALDHhigh subpopulation in PCa cells cultured alone (co-
culture=60% vs. control=15%, p<0.05) (Fig. 2C). Moreover, mRNA analysis after viable 
cell sorting of fluorescently labelled PC-3M-Pro4Luc2 cells (co-cultured cells compared 
to control), showed significant increase in Cripto (p<0.05) and Grp78 expression (Fig. 
2D). In addition, conditioned medium (CM) collected from osteoblasts positively 
influenced the migratory capability of PC-3M-Pro4Luc2 cells. The increase in migration 
was directly proportional to the concentration of the conditioned medium used in the 
experimental setting (p<0.001 for 50% CM + 50% not-CM vs. control; p<0.001 for 100% 
CM vs. control and p<0.001 for 100% CM vs. 50% CM) (Fig 2E). In line with these 
observations, administration of osteoblast conditioned medium led to the acquisition of 
a motile, mesenchymal phenotype in PC-3M-Pro4Luc2 PCa cells as indicated by a 
decrease in the mRNA expression of the epithelial marker E-Cadherin (p<0.05), a 




concomitant increase in the mesenchymal markers ZEB1 and ZEB2 (p<0.05 for both 
genes) (Suppl. Fig. 2B) and a significant reduction of the ratio E-Cadherin/Vimentin 
(p<0.05) and ratio E-Cadherin/N-Cadherin (Fig. 2E). Together, these data indicate that 




Figure 2. Co-culture with human osteoblasts increases expression of Cripto and Grp78 and cancer 
stem cell properties of human PCa cells. A) Cripto and Grp78 are expressed in PC-3M-Pro4Luc2 and 
C4-2B human PCa cell lines. Error bars ± SEM. B) Cripto and Grp78 are significantly up-regulated in 
highly metastatic subpopulation of ALDHhigh PCa cells vs. low metastatic ALDHlow in PC-3M-Pro4Luc2 
cells. Error Bars ± SEM C) Direct co-culture of fluorescently-labeled PC-3M-Pro4Luc2 human PCa cells (T) 
with differentiated human osteoblasts (OB) for 48h increases the size of the ALDHhigh subpopulation in 
PCa cells. Error Bars ± SEM. D) mRNA analysis shows increased Cripto and Grp78 expression after co-
culture. Error Bars ± SEM. E) Conditioned medium (CM) from human osteoblast enhances migration of 
PC-3M-Pro4Luc2 human PCa cells. Error Bars ± SEM. F) Co-culture of PC-3M-Pro4Luc2_dTomato PCa 
cells for 48h with human osteoblast induces a shift to mesenchymal phenotype as indicated by 






Cripto and Grp78 maintain stem cell-like properties of aggressive human 
PCa cells in vitro  
In order to test the function of Cripto and Grp78 in human PCa cells, we 
generated stable knockdown lines in PC-3M-Pro4Luc2 and C4-2B cells and validated 
reduced expression of Cripto and Grp78 by Western Blot and qRT-PCR (Fig. 3A, Suppl. 
Fig 3A and Suppl. Fig. 4A). As previously shown by others in PC3 cells and consistent 
with the extensive post-translational modification of Cripto, we detected two protein 
bands of approximately 17 and 25 kDa (5,29) (Fig. 3A). Cripto knockdown lines 
(shRNA#2 and #3) both show decreased cell proliferation (p<0.001 at 24h for shRNA#2 
and p<0.001 at 24, 45, 72h for shRNA#2 and shRNA#3) (Fig. 3B). No effect on cell 
proliferation was observed in the C4-2B Cripto knockdown cells (Suppl. Fig. 3B). The 
PC-3M-Pro4Luc2 Cripto knockdown cells also had a significantly reduced percentage of 
metastatic, stem cell-like ALDHhigh cells relative to non-targeted control cells (p<0.05 for 
shRNA#2 and p=ns for shRNA#3) (Fig. 3C). Grp78 knockdown similarly displayed 
reduction of the size of ALDHhigh subpopulation of cells (p<0.05 for shRNA#1 and p=ns for 
shRNA#2) (Suppl. Fig. 4B). 
We previously reported that the ALDHhigh subpopulation of PC-3M-Pro4Luc2 is 
enriched for cells with increased clonogenicity and migratory properties relative to the 
ALDHlow cell subpopulation (12). Here we show that PC-3M-Pro4Luc2 Cripto knockdown 
cells have significantly reduced clonogenicity relative to control cells as measured by 
the number and area of colonies produced (p<0.05) (Fig. 3D). This effect appeared to be 
specific since transfection of a non-targetable Cripto expression construct resulted in 
significant rescue of the loss of clonogenicity caused by the Cripto shRNA (p<0.001 for 
colony number and p<0.05 for colony area) (Fig. 3D). Grp78 knockdown in PC-3M-
Pro4Luc2 human PCa cells also resulted in a decrease in the number of colonies (p<0.05) 
and a similar trend was shown for colony area (Suppl. Fig 4C). Finally, Cripto 
knockdown significantly reduced the migratory capability of both cell lines (p<0.05 and 
p<0.01 respectively, Fig. 4A and B). Complete (PC-3M-Pro4Luc2) or partial (C4-2B) 
rescue of the effects of shRNA knockdown could be again achieved by the non-
targetable Cripto expression construct (Fig. 4C and D). Grp78 knockdown in PC-3M-
Pro4Luc2 cells also resulted in a significant reduction of migratory potential (p<0.001 for 
both shRNAs) (Suppl. Fig. 4D). Together, these data suggest that Cripto and Grp78 are 
required to maintain the stem cell-like phenotype of PC-3M-Pro4Luc2 cells. 
 
 





Figure 3. Cripto knock-down causes loss of the stem cell-like phenotype in PCa cells. A) Western 
Blot analysis of Cripto expression in control (scrambled shRNA, NT) PC-3M-Pro4Luc2 (first lane) and 
Cripto knock-down PC-3M-Pro4Luc2 cells with shCripto#1, #2, #3, derived from different shRNA 
constructs. Two bands of respectively 25 KDa (Native) and 17 KDa (Core) for Cripto are detected as 
previously shown (see Results). B) Knockdown of Cripto affects the proliferation in PC-3M-Pro4Luc2 . 
Error Bars ± SEM. C) Cripto knock-down leads to a decrease in the size of ALDHhigh subpopulation in PC-
3M-Pro4Luc2 cells. Error Bars ± SEM. D) Cripto knockdown affects clonogenic ability and Cripto 
overexpression is capable of reversing this phenotype in PC-3M-Pro4Luc2. Error Bars ± SEM. * and $ and 








Figure 4. Cripto overexpression promotes PCa cell migration and rescues the Cripto knock-down 
phenotype. A-B) Cripto Knock-down significantly reduces cell migration in PC-3M-Pro4Luc2 and C4-2B 
cells and Cripto overexpression (C-D) is capable of rescuing completely (PC-3M-Pro4Luc2) or partially 
(C4-2B) the phenotype. Error Bars ± SEM. E) mRNA analysis in PC-3M-Pro4Luc2 cells and C4-2B (F) after 
48h of Cripto overexpression shows decrease in E-Cad/Vim ratio supporting the switch towards a more 











Cripto promotes EMT and invasiveness of human PCa cells  
EMT is strongly associated with tumor cell invasion and Cripto was recently 
reported to promote EMT in human PCa (6). Consistent with this study, we found that 
Cripto overexpression in PC-3M-Pro4Luc2 and C4-2B cells (Suppl. 5A and B) causes a 
strong and significant down-regulation of the epithelial marker E-Cadherin (p<0.05) at 
the mRNA level in both cell lines and an increase in the mesenchymal markers Vimentin, 
SNAIL2 and TWIST in PC-3M-Pro4Luc2 cells (p<0.05, p<0.05 and p<0.01 respectively) and 
ZEB1 in C4-2B cells (Suppl. Fig 5C and D). Cripto overexpression caused a strong and 
significant decrease in the ratio of E-Cadherin/Vimentin (p<0.01) in both PCa cell lines 
(Fig. 4E and F). Together, these data support a role for Cripto in promoting EMT and the 
invasive phenotype in PC-3M-Pro4Luc2 and C4-2B cells. 
We have previously shown that zebrafish can be used to effectively evaluate 
migration and invasion of human PCa cells and the interaction between PCa cells and 
the vasculature at the single cell level in vivo (13,30). Clear detection of extravasating 
tumor cells in this system is facilitated by the fact that the vascular system of zebrafish 
embryos is completely functional and the embryos are transparent (31). We tested the 
role of Cripto and Grp78 in PCa cell extravasation and metastasis by injecting 
fluorescently-labeled PC-3M-Pro4Luc2 cells with Cripto or Grp78 knocked down into the 
circulatory system of zebrafish embryos (13). In the first hours disseminated cells 
arrested in the host vasculature and then we observed extravasation from 12 hpi (hours 
post implantation) and perivascular tumor cells in multiple foci including the 
intersegmental vessels, the optic veins, the dorsal aorta and the caudal vein. The 
perivascular tumor cells invaded the neighboring tail fin exclusively at the posterior 
ventral end of the caudal hematopoietic tissue (CHT). At day 4 post-implantation (4 dpi), 
Cripto knockdown caused a significant reduction in extravasation and metastatic tumor 
growth compared to control cells with scrambled shRNA (Fig. 5A, B and C). Similarly, 
Grp78 knockdown cells displayed a significant reduction in the tumor growth into the 
tail fin after invasion from CHT compared to control cells (Suppl. Fig. 6A and B). 
However, invasion was not significantly different in Grp78 knockdown cells compared to 
control (Suppl. Fig. 6C). Taken together, these data support our in vitro findings and 
reinforce the hypothesis that Cripto/Grp78 signaling plays an important role in the 








Figure 5. Cripto knockdown reduces invasion and tumor growth of human PCa cells in vivo. A) PC-
3M-Pro4Luc2_dTomato human PCa cells with scrambled shRNA control (NT) and ShCripto#2 shRNAs 
have been injected in the duct of Cuvier to monitor extravasation and formation of distant metastasis in 
vivo. 30 embryos injected/group. B) Cripto knock-down reduces whole-body tumor burden at 4dpi (days 
post injection). Error Bars ± SEM. C) Cripto knock-down reduces number of extravasated cells at 1 and 
4dpi at the caudal hematopoietic tissue (CHT). Error Bars ± SEM. **, P<0,01; *** P<0,001. 
 
Cripto knockdown decreases metastasis formation in vivo 
We previously demonstrated that intracardiac injection of luciferase-expressing 
PC-3M-Pro4Luc2 cells in mice results in bone metastasis (12). Here we used this 
preclinical mouse model to test the role of Cripto in mediating the metastatic activity of 
these PCa cells. Cripto knockdown cells or control cells with a scrambled shRNA were 
injected into the left cardiac ventricle of nude mice (Balb/c nu/nu) and bioluminescence, 
which reflects tumor size, was measured weekly for the course of the experiment. 
Quantification of bioluminescent images showed significant reduction in metastasis 
formation and the number of metastasis in mice inoculated with Cripto knockdown cells 
compared to mice injected with control cells (week 5, p<0.05) (Fig. 6 A, B, C). This result 
is consistent with the other findings outlined above and suggests that Cripto is required 
for bone metastasis in a mouse model of human PCa. 
 





Figure 6. Cripto knockdown inhibits bone metastasis of human PCa cells in vivo. A) PC-3M-Pro4Luc2 
human PCa cells with Cripto knock-down (ShCripto#2) and shRNA scrambled control (NT) have been 
injected in the left ventricle of nude mice. Formation of distant metastasis was monitored weekly with 
BLI measurements. Images are representative of 6 animals for Cripto Knock-down and 4 animals for 
non-targeted control. B) Quantification of BLI measurements. Difference is significant at week 5 (p<0.05 
with two way ANOVA). Cripto knockdown is represented in red, non-targeted control is represented in 
blue. Error Bars ± SEM. C) Total number of metastasis per mouse in mice injected with either Cripto 
knock-down (ShCripto#2, red) or control (NT, blue) PC-3M-Pro4Luc2 cells, (*, p<0.05; **p<0,01; with two 







This study presents evidence supporting a role for Cripto and Grp78 in the 
regulation of the invasive program of PCa cells that maintains stem cell-like and 
aggressive phenotypes in human PCa. Cripto/Grp78 signaling is known to regulate stem 
cells and tumor cells (32) and our results suggest that this signaling may promote the 
acquisition of a metastatic phenotype in PCa. This phenotype includes the ability of PCa 
cells to invade the supportive stroma and neighboring tissues to allow subsequent 
formation of bone metastasis at distant sites (33). Cripto/Grp78 signaling may also play 
a specific role in metastasis by facilitating initial colonization of the bone by PCa cells.  
Our demonstration that Cripto is strongly upregulated in high-risk patient groups 
compared to low risk groups and that it correlates with poor survival highlight the 
significance of these proteins in metastatic PCa. Importantly, the selective expression of 
Cripto and Grp78 in PCa metastasis was substantiated by analysis of publicly available 
datasets (25) and reinforced by our analysis on 13 samples of PCa bone metastasis 
derived from CRPC patients.  
The ALDHhigh subpopulation of PC-3M-Pro4Luc2 cells is enriched for tumor 
initiating cells with metastatic potential and generally accounts for a small percentage 
of all tumor cells (12,13). Here we show that these highly metastatic ALDHhigh cells have 
higher levels of Cripto and Grp78 expression compared to non-stem cell-like, non-
metastatic ALDHlow cells. This finding supports our hypothesis that Cripto and its cell 
surface signaling partner Grp78 are restricted to a small subpopulation of cells 
characterized by high metastatic ability, similar to what was recently shown in breast 
cancer (15). Our results also support the notion that Cripto signaling promotes EMT (6,7) 
and the migratory and invasive phenotype in PCa cells associated with a switch from a 
sessile, epithelial state to a motile, mesenchymal phenotype. Indeed, transcriptional 
analysis following Cripto overexpression reveals the emergence of an “EMT signature” 
characterized by a marked reduction in the expression of the epithelial marker E-
Cadherin paralleled by a significant increase in the expression of the mesenchymal 
markers Vimentin, Snail2 and Twist, again indicating the acquisition of the 
mesenchymal phenotype. 
The activation of the bone stroma by metastatic cells alters the physiological balance 
between osteoblast-mediated bone formation and osteoclast-mediated bone 
resorption during bone metastatic colonization (34). Strikingly, we found that co-culture 
of PCa cells with human osteoblasts, important cellular constituents of the bone 
metastatic niche (34), induced a significant increase in Cripto and Grp78 mRNA 




expression in the tumor cells. Osteoblasts have previously been reported to promote the 
aggressiveness of osteolytic human PCa cells in vitro (26). These findings, are in line with 
our data showing that osteoblasts promote the metastatic phenotype of PCa cells by 
causing expansion of the ALDHhigh subpopulation, increasing tumor cell migration and 
inducing expression of Cripto and Grp78. In light of previous studies demonstrating that 
Cripto binds cell surface Grp78 and that this interaction is required for Cripto signaling, 
our results suggest that Cripto and Grp78 function cooperatively to regulate the 
interaction between tumor cells and osteoblasts within the bone microenvironment. 
However, given the complexity of the bone metastatic niche, we focused primarily on 
the role of Cripto and Grp78 in the maintenance of an aggressive and metastatic 
phenotype in PCa cells. Additional experiments are required to elucidate the 
interactions between PCa cells and the different components of the bone 
microenvironment in mechanistic detail.  
 
Figure 7. Schematic representation of the proposed role of Cripto in the metastatic cascade in 
human prostate cancer. Cripto and Grp78 influence cell proliferation and are highly expressed in a 
subpopulation of highly metastatic stem/progenitor-like cells (ALDHhigh). Cripto and Grp78 knock-down 
impairs cell migration, suggesting a role of these genes in the acquisition of an invasive phenotype. 
Cripto- and Grp78-expressing cells are better adapted to surviving in the circulation and of forming 





In conclusion, we demonstrate that Cripto and it signalling mediator Grp78 may 
play pivotal, functional roles in the acquisition and maintenance of an invasive, 
metastatic phenotype in human prostate cancer (see schematic representation in Fig. 
7). Therefore, from a therapeutic and diagnostic point of view, Cripto and Grp78 
represent compelling molecules for targeting and monitoring of highly aggressive 
stem/progenitor-like prostate cancer cells in advanced human prostate cancer. 
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Suppl. Fig 1. Cripto expression in experimental bone metastasis. Cripto expression in experimental 
bone metastasis derived from intra cardiac inoculation of PC-3M-Pro4Luc2 human PCa cells in a 
preclinical mouse model of PCa bone metastasis. 
 
Suppl. Fig 2. Osteoblast differentiation and influence of direct co-culture of tumor cells with 
human osteoblast on EMT markers. A) Alizarin Red staining of differentiated osteoblast shows efficacy 
of the differentiation process (see materials and methods). B) Co-culture of PC-3M-Pro4Luc2 tumor cells 
with differentiated primary human osteoblast induces downregulation of E-Cad and strong 







Suppl. Fig. 3. Cripto knock-down in C4-2B cells. A) C4-2B with Cripto knock-down show significanly 
lower Cripto expression compared to control cells. B) Cripto Knock-down does not affect C4-2B 
proliferation. Error Bars ± SEM. *, P<0,05. 
 
Suppl. Fig. 4. Grp78 Knock-down, functional study. A) PC-3M-Pro4Luc2 cells with Grp78 knock-down 
by two different shRNAs. Error Bars ± SEM. B) Grp78 KD reduces the size of ALDHhigh subpopulation of 
cells in PC-3M-Pro4Luc2 human prostate cancer cells. Error Bars ± SEM. C-D) Grp78 KD significanlty 
reduces clonogenicity and migration of PC-3M-Pro4Luc2 human prostate cancer cells. Error Bars ± SEM. 









Suppl. Fig. 5. Cripto overexpression in two human prostate cancer cell lines. A-B) Tumor cells 
overexpressing Cripto show significanlty higher Cripto expression compared to mock transfected cells 
(control). Error Bars ± SEM. C-D) Cripto overexpresssion in PC-3M-Pro4Luc2 and C4-B cells induces 
significant decrease of E-Cad and upregulation of Vim in PC-3M-Pro4Luc2 cells. Error Bars ± SEM. *, 
P<0,05; **, P<0,01; ***, P<0,001. 
 
Suppl. Fig. 6. Grp78 KD reduces invasion and tumor growth in vivo. A) PC-3M-Pro4Luc2_dTomato 
human prostate cancer cells with Grp78 knock-down have been injected in the duct of Cuvier to monitor 
extravasation and formation of distant metastasis in vivo. 30 embryos injected per group. B-C) Grp78KD 
reduces extravasation and tumor growth significantly at 4dpi (days post injection) at the caudal 
hematopoietic tissue (CHT). No effect on tumor burden is observed. Error Bars ± SEM. (Blind 








Suppl. Fig. 7. Cripto Knock-down effect on proliferation and measurment of weight of animal 
injected with matching cells in vivo. A) MTS performed on PC-3M-Pro4Luc2 cells with Cripto KD and 
NT control to confirm KD effect on proliferation prior to inoculation in animals. Experiment performed 
on same cells injected in vivo. Error Bars ± SEM. B) Body weight of animals (shCripto = 6 animals, NT = 4 




























Prostate cancer consist of heterogeneous epithelial cell subpopulations of which 
prostate cancer cells with stem/progenitor-like characteristics (CSCs) have been 
increasingly recognized as the “driver” cancer cell subpopulation in tumor initiation, 
local and distant relapse, hormone refractory disease, castration, metastasis and 
chemotherapy resistance (1-4). Therefore, unraveling the molecular properties of 
malignant subpopulation of CSCs may represent a promising strategy to identify new 
attractive targets for therapeutic intervention. 
The work presented in this thesis covers two aspects of the molecular 
characteristics of CSCs: in the first part the identification of miRs as novel regulators of 
gene expression in CSCs are described; in the second part two studies are presented 
that focus on the identification of new potential markers and functional factors that are 
involved in prostate cancer pathogenesis, progression and bone metastasis. A 




Figure 1. Schematic representation of the metastatic cascade. The involvement of miR-25, αv, α6 
integrins, non-canonical Wnt signaling, ALDH, BMP9 and Cripto signaling pathways are highlighted in 






Molecular characteristics of highly aggressive prostate cancer stem-like 
cells 
Cellular heterogeneity is an important characteristic of many epithelial cancers, 
including prostate cancer. The major aim of this thesis was to identify the molecular 
properties of selected subpopulation of highly metastatic cancer stem/progenitor-like 
cells in human prostate cancer. In the first part of this thesis, we characterized the miR 
expression of two subpopulation of cells: the tumor- and metastasis-initiating ALDHhigh 
cancer stem/progenitor-like cells and the more differentiated, poorly 
tumorigenic/metastatic ALDHlow cells (5). In the past 10 years, high aldehyde 
dehydrogenase activity has been progressively established as a maker to identify highly 
aggressive and metastatic prostate cancer stem cells (5-8) also in clinical studies (5,9). 
However, to the best of our knowledge, none of the previous studies have systematically 
investigated the molecular characteristics (e.g. miR expression) of ALDHhigh vs. ALDHlow 
cells in human prostate cancer. 
In Chapter 3, microRNA expression profiling of cultured ALDHhigh and ALDHlow 
prostate cancer cells revealed a number of differentially expressed miRs (10). Our results 
are strengthened by clinical profiling data of a comparison of three subpopulations of 
transformed epithelial cells isolated from primary prostate tumors, namely: the stem-
cell subpopulation, the α2β1hi /CD133- transient-amplifying cells and the α2β1low cells 
committed for terminal differentiation (11). Our study shows that miR-25 is low/absent 
in the ALDHhigh subpopulation isolated from prostate cancer cell lines and in the α2β1hi 
/CD133+ basal stem-cell subpopulation isolated from patients and steadily increases 
during differentiation to α2β1hi/CD133- transit amplifying cells and α2β1low committed 
basal cells. miR-25 is part of the miR-106b-25 cluster (12). Consistent with our findings, 
the expression of the miR-106b-25 cluster appears to mediate neuronal differentiation 
of adult neural stem/progenitor cells and, interestingly, induction of miR-106b-25 in 
hypoxic conditions has been linked to increased expression of neuronal markers in 
prostate cancer cell lines (13,14). Moreover miR-25 has recently been identified in PC12 
cells (15,16) as regulator of neuronal differentiation, supporting the involvement of this 
microRNA in differentiation processes (17). 
The data of our study, highlight the limitations of molecular profiling approaches 
in cell cultures, heterogeneous cell lines and heterogeneous bulk clinical tissues. For 
example, it was found that the miR-106b-25 cluster was up-regulated in primary tumors 
and distant metastases from multiple solid cancers, including those of the human 
prostate (12,18-21). Importantly, none of this studies focus specifically on miR-25 
expression but solely on the expression of the miR-106b-25 cluster. Additionally, 




microRNAs within one cluster might be regulated differently by different transcription 
factors and miR-25 has been shown to be uncoupled from the MCM7 host gene (22,23). A 
likely explanation for these apparent contradictory observations is that cancer cell lines 
and bulk tumor tissues are not homogeneous and consist of a mixture of heterogeneous 
subpopulations of cells (24).  
Therefore, we speculated that the increase in absolute expression levels of miR-
25 in bulk tissues during prostate cancer progression may be indicative of an increase in 
the proportion of more differentiated, less invasive, “miR-25high” more differentiated, 
“luminal” epithelial cells. This is reinforced by the fact that, forced miR-25 
overexpression led to a decrease in α2-integrin and β1-integrin expression (Chapter 3), 
markers of epithelial basal stem cell (25). Our bioinformatic analysis revealed that αv-
integrin and α6-integrin are target genes of miR-25. The identification of these genes 
confirmed the results of previous studies showing a significant higher expression αv-
integrin and α6-integrin selectively in the ALDHhigh subpopulation compared to ALDHlow 
in prostate cancer and in high-risk prostate cancer patients (26,27). Such studies also 
demonstrated that knockdown (26) or targeting of αv-integrin (28) significantly 
diminished the acquisition of a metastatic stem/progenitor cell phenotype and reduced 
the formation of prostate cancer bone metastasis in preclinical in vivo models. 
Consistent with these data, miR-25 overexpression significantly reduced the migratory 
potential of both bulk cell lines and selected ALDHhigh subpopulation. 
The induction of dramatic morphological changes after miR-25 overexpression 
prompted us to study the underlying mechanism(s) of these phenotypic alterations. Our 
analysis showed that overexpression of miR-25 dramatically impaired F-actin 
polymerization, thus reducing focal adhesion sites. Integrins provide a structural link 
between F-actin and the extracellular matrix and contribute to formation of these focal 
adhesion points (29). Additionally, integrins (αv-integrin in particular), are also involved 
in the activation of latent TGF-β which represents one of the major driver during EMT 
(30-32). As already discussed in Chapter 3, organization of F-actin is linked to activation 
of integrin-transmembrane receptors which regulates the activation of Rho-GTPases, 
RAC1 and CDC42 (33). Given the ability of miR-25 to target αv-integrin and α6-integrin it 
seems likely that regulation of these integrins by miR-25 has a major impact of the 
cellular phenotype. Interestingly, cells with a stellate, mesenchymal morphology like 
PC-3M-Pro4Luc2, often require activated RAC1 for migration (34). These observations 
are in line our findings that show reduced RAC1 mRNA upon forced miR-25 expression 





of miR-25 as a non-coding RNA for the regulation of tumor aggressiveness by the 
regulation of cytoskeletal organization and motility.  
In Chapter 4 we describe a potential, other role for miR-25 in the modulation of 
the invasive program in human prostate cancer through modulation of canonical and 
non-canonical WNT signaling of which RAC1 is also a component (35,36). The WNT/PCP 
pathway is considered the β-catenin independent branch of WNT signaling. Beside the 
involvement of WNT signaling in the pathogenesis of prostate cancer and bone 
metastasis (reviewed in (37-41)), accumulating evidence revealed the role for non-
canonical WNT/PCP signaling in prostate cancer progression, invasion and metastasis 
(36). Interestingly, canonical WNT signaling and non-canonical WNT/PCP signaling are 
part of a negative feedback-loop in which WNT/PCP negatively regulates canonical WNT 
signaling and vice versa (42). This led us to hypothesize that a possible differential basal 
level of canonical and non-canonical WNT signaling could maintain the mesenchymal 
and motile phenotype in PC-3M-Pro4Luc2 human prostate cancer cell line. Therefore, 
we speculated that the highly migratory phenotype in this cell line is due to a imbalance 
between canonical WNT and non-canonical WNT/PCP pathway. Indeed, in Chapter 4 we 
describe that the non-Canonical WNT/PCP pathway is approximately 10-fold more 
active that the canonical counterpart in our model. Moreover, administration of TGF-β, a 
known inducer of EMT in prostate cancer, strongly increased non-canonical WNT/PCP 
signaling with a concomitant decrease in canonical WNT signaling. Using the Smad-3 
dependent TGF-β reporter (CAGA-luciferase) we demonstrated that miR-25 can 
attenuate the activation of TGF-β signaling in human prostate cancer and is capable of 
blocking TGF-β-driven invasiveness. Overexpression of miR-25 also produced a 
significant increase in canonical WNT signaling, suggesting a modulation of the 
crosstalk between canonical and non-canonical WNT signaling pathway. Although 
additional experiments are warranted to confirm a specific and direct effect of miR-25 
on non-canonical WNT/PCP signaling, we found that DACT1 knockdown recapitulated 
the induction of canonical WNT signaling on a bioluminescent reporter that we also 
detected upon miR-25 overexpression.  
Taken together, the data described in this thesis support a key role of miR-25 in 
the regulation of motility invasiveness and epithelial differentiation in human prostate 
cancer. Furthermore, our data are in line with the literature concerning an intriguing 
contribution of non-canonical WNT signaling in prostate cancer progression and 
emphasize that targeting of this pathway might represent an interesting strategy to 
restrain EMT, invasion and metastasis. 
 




In Chapter 2, we reviewed the established miR-gene interactions among TGF-β, 
Notch and Wnt signaling pathway and identified a miR signature that highlighted the 
crosstalk between these pathways. Beside the relevance of CREBBP and EP300 in EMT, 
which has already been addressed in Chapter 2, we wanted to test whether the list of 
genes identified could be linked to our findings about the role of miR-25 in 
aggressiveness of prostate cancer stem cells. 
Interestingly, we found that CREB1 is identified as predicted target gene of miR-25 in 
two independent bioinformatics online available tools: TargetScan and microT-CDS. 
Although direct evidence is (still) lacking one can speculate that miR-25 may be involved 
in CREB1 downregulation and, as a result, would have a functional impact also on 
CREBBP (CREB-binding protein) and on the interaction with its signaling partner EP300. 
The value of the signature identified in Chapter 2, is supported by multiple 
connections with pathways analyzed in other chapters of this thesis (e.g. Cripto and 
Notch signaling). In Chapter 6 we have discussed the role of Cripto as emerging gene 
whose expression turns out to be involved in the formation of bone metastasis in 
prostate cancer. Interestingly, two miRs identified in our signature, (miR-15 and the 
miR-16) have been previously shown to directly interact with Cripto (43). Given the 
documented role of Cripto in EMT in prostate cancer (44), and its interaction with 
multiple TGF-β, Wnt and Notch signaling networks (45), this observation supports the 
involvement of the miRs signature during EMT. Moreover, in Chapter 5 we show that the 
soluble chimeric protein ALK1Fc (ACE-041) (46) reduces BMP9 signaling and decreases 
proliferation of highly metastatic and tumor initiating human prostate cancer cells in 
vitro and in vivo. Interestingly miR-34a and miR-24, that were also identified in our miR 
signature, are shown to target BMP9 (GFD2) by TargetScan online predictive tool. Taken 
together, our observations emphasize the functional value of the miR signature and 
further strengthen the role of TGF-β family members and the Notch pathway in human 
prostate cancer. 
As already discussed, EMT represents a crucial process that characterize the early 
phase of tumor invasion and generate the basis for the metastatic spread of the tumor. 
The role of CRIPTO during EMT in prostate cancer has already been described (44), 
however, to the best of our knowledge, the involvement of CRIPTO in the formation of 
bone metastasis by prostate cancer has not been reported.  
Given the clinical problem of bone metastasis and the fact that Grp78 (i.e. Cripto 
signaling partner) has been associated with the development of castration resistance 
(47), in Chapter 6 we tested whether we could register an involvement of Cripto in the 





Immunohistochemic analysis of clinical bone metastases collected shows that 
Cripto is strongly expressed and co-localize with cytokeratin-18 positive prostate 
epithelial cells. This support our hypothesis and suggest a functional involvement of 
Cripto in the formation of bone metastasis. Our in vitro experiments support the role of 
Cripto and Grp78 in the maintenance of aggressive characteristics in prostate cancer cell 
lines. The knock-down of Cripto and Grp78 induced a decrease in invasiveness and self-
renewal properties in prostate cancer cell lines. Moreover, inoculation of Cripto and 
Grp78 knock-down cells in the circulation of zebrafish embryos via the duct of Cuvier 
(10,48), resulted in formation of significantly lower number of experimental metastasis 
compared to control cells. Finally, we demonstrated that Cripto knockdown significantly 
reduced the metastatic outgrowth in a preclinical mouse model of prostate cancer bone 
metastasis. 
Our results suggest that Cripto and Grp78 might represent novel markers that 
could predict the formation of bone metastasis and be indicative of the initiation of 
invasiveness. This could therefore be of great value for the identification of new 
therapeutic targets. 
 
miR-25 and Cripto in the landscape of new markers for prostate cancer 
monitoring and prediction 
Although the progress in the molecular diagnostic research for prostate cancer in 
the last years, there is still a urgent need for the identification of novel additional 
predictive markers for prostate cancer monitoring and progression. 
In this context, the AR has represented the major target for studies focused on prostate 
cancer treatment. Such studies have addressed the status of the AR and its modification 
in response to drugs (e.g. abiraterone and enzalutamide both resulted in increased 
expression of certain AR variants (49,50)). Given the fact that the distant relapse 
represents the lethal phase of the cancer progression, other approaches have focused 
on the identification of novel molecules involved in the interaction between the 
supportive stroma and the tumor cells (51). However, the identification of reliable, 
predictive markers for the castration resistant phase is still challenging. 
In the landscape of the emerging molecular markers for CRPC, recent studies 
have highlighted the role of small non-coding RNA miR-1247-5p and of its target gene 
myc-binding protein 2 (MYCBP2) (52). Other recent work has revealed that the tri- and 
tetra-antennary N-glycan might be associated with the castration resistant status, 
therefore representing a potential predictive biomarker for castration-resistant prostate 
cancer (53). Moreover, the TMPRSS2-ERG fusion gene is currently in clinical testing for its 




diagnostic and prognostic value, however ERG fusions have been reported to be positive 
or negative for clinical outcome (54). The data described in Chapter 3 and Chapter 6 of 
this thesis suggest that new approaches and new molecules respectively might 
contribute to the identification of new markers of interest in CRPC. In Chapter 3, we 
have identified miR-25 as novel microRNA downregulated in the stem-cell 
compartments isolated from CRPC patients (10) and our results presented in Chapter 6 
show that high expression of Cripto is associated with poor survival in prostate cancer 
and that Cripto is highly expressed in prostate cancer bone metastasis collected from 
CRPC patients. 
Many studies have already successfully measured proteins and noncoding RNAs 
in blood or urine collected from prostate cancer patients (reviewed in (55)). However, 
the findings presented in this thesis highlight the difference of analyzing miRs and gene 
expression in bulk tissues compared to selected subpopulation of cells. The 
manipulation of selected targets in specific subpopulation of cells introduce additional 
layers of complexity linked to the development of targeting strategies that can 
selectively hit those highly metastatic cluster of cells dispersed within the tumor.  
In other words, we prove here that miR-25 is crucial for prostate cancer cell 
migration and invasion, but we show that miR-25 is downregulated in aggressive 
prostate cancer subpopulation of cells which makes it a “negative marker”, thus difficult 
to apply in the clinical practice. However, our molecular studies could contribute to the 
identification of novel target genes, to be employed as therapeutic targets. This notion 
is supported by the fact that αv-integrin, that we prove here to be targeted by miR-25, 
has already been shown as interesting therapeutic target involved in the formation of 
bone metastasis in human prostate cancer (28). 
We believe that the discovery of specific molecules, selectively expressed on 
highly malignant clones might help in the development of new targeting strategies, 
especially if those malignant clones and cells are spread and under-represented in the 
bulk tumor mass (only few aggressive cancer stem/progenitor-like cells are detected 
(11,56)). From this perspective, the membrane-bound nature of Cripto makes it an 
interesting target for the development of new molecules capable of targeting highly 
metastatic cells for diagnostic and therapy purposes. Additionally, this strategy could 
also be employed in the development of probes capable of revealing the localization of 
Cripto expressing cells during surgical intervention. Moreover, the soluble nature of 
Cripto, makes it an interesting molecule for the development of diagnostic and 
prognostic test to monitor the progression of prostate cancer in patients. Soluble Cripto 





already available for research purposes. Interestingly, manipulation of Cripto signaling 
has already been shown to be successful in the modulation of the maintenance of 
mammary stem cells in breast cancer (57).  
 
Clinical relevance, possible therapeutic opportunities and future 
perspectives 
The study presented in Chapter 5, supports the role of BMP9 as a tumor-
promoting factor in human prostate cancer cells in vitro and in vivo, acting on the Notch 
signaling pathway. To our knowledge, our study represents the first functional evidence 
for a role of BMP9 and the functional evidence of its targeting in human prostate cancer. 
Several approaches have been described for therapeutic targeting of the Notch 
signaling pathway in various diseases, but the majority of these clinical studies failed 
due to significant adverse effects (58,59). Interestingly, current options to interfere with 
Notch signaling originate from Alzheimer’s disease research where γ-secretase 
inhibitors (GSI) are employed to prevent the accumulation of amyloid-β peptides (60). 
The γ-secretases enzymes contribute to the cleavage of the transmembrane portion of 
the Notch receptor and represent crucial players in the activation of the Notch signaling 
pathway. Unfortunately, animal and human safety trials revealed a significant toxicity 
involving gastrointestinal bleeding and immunosuppression following the 
administration of GSI applied to T-cell acute lymphoblastic leukemia (T-ALL) (58,59). 
Interestingly, promising results have been achieved in preclinical studies by combining 
GSIs with conventional chemotherapeutic agents (61) with minimal toxicity. In prostate 
cancer, administration of GSIs blocks tumor angiogenesis and enhances the docetaxel-
mediated antitumor response, indicating a causal role of Notch signaling in mediating 
therapy resistance in human prostate cancer (61).  
Our data in Chapter 5 suggest that ALK1Fc might impact on cellular proliferation 
via an indirect effect on Notch signaling pathway. Therefore, this indicates that ALK1Fc 
might represent an interesting molecule to contain prostate tumor growth. Given the 
combinatorial effect of GSIs and current therapies, these results support the 
development of studies to investigate whether employment of ALK1Fc could contribute 
to sensitize prostate cancer cells to current treatment. Given the fact that ALK1Fc has 
recently been shown to be well tolerated by patients with advanced refractory cancer 
(62), showing promising antitumor activity, this might represent a promising and 
alternative strategy to circumvent the toxic side effects produced by GSIs. Additionally, 
ALK1Fc has been shown to reduce the vascular density in various solid tumors (63). 
Considering that angiogenesis is a crucial process coupled to osteogenesis (51,64) in 
osteoblastic bone metastasis (such those originated from prostate cancer), the testing 




of ALK1Fc in preclinical bone metastatic models might be promising. Moreover, the 
recent experimental evidence that endothelial Notch activity promotes angiogenesis 
and osteogenesis in bone (65), reinforces the application of ALK1Fc in a metastatic 
setting (ALK1Fc interferes with Notch signaling see Chapter 5). However, a limitation of 
the animal models employed in the metastatic setting, is that osteoblast progenitors 
and hematopoietic stem cells (HSCs), responsible for the bone remodeling are tightly 
associated with “type H”, CD31high vessels (64). These vessels are at their highest peak in 
young 4-week-old animals compared to old 11-week-old mice (64). Thus, a possible 
strategy to evaluate the efficacy of ALK1Fc in a metastatic setting in murine models, 
could combine the treatment with ALK1Fc together with the stimulation of the bone 
growth.  
The results presented in Chapter 6 suggest that Cripto and its signaling partner 
Grp78 could be employed as novel target genes to identify selectively metastatic 
prostate cancer cells. Interestingly, Grp78 has been shown to be involved in therapy 
resistance (66) and Grp78-targeted nanotherapy has already been tested in human 
prostate cancer (67). Additionally, the development of new molecules capable of 
targeting Cripto has already been shown to be effective in breast cancer (57). Moreover, 
the availability of monoclonal antibody specifically targeting Grp78 support the 
developing of strategies targeting the Cripto/grp78 pathway (68,69). These together 
support the development of preclinical studies to investigate the application and the 
relevance of such molecules in prostate cancer treatment.  
The results in Chapter 3, support that the identification of new putative (up-
regulated) miR-25 predicted target genes, could help in the identification of new factors 
involved in the maintenance of the aggressiveness in prostate cancer. Such research 
could then be exploited to identify novel small molecules capable to target these 
factors.  
A direct translation of our direct findings would consist of an overexpression of 
miR-25 selectively in those highly migratory and invasive aggressive clones. Obviously 
this imply the application of selected targeting of specific cells which, up to date, is still 
under testing and development (2). Such targeting would require knowledge of the 
differences between normal and cancer stem cells. The latest developments in targeted 
therapy comprise the design of novel siRNA, miRNA, and antisense nucleotide therapy 
against CSCs. In this context, miR-25 could represent an interesting target for this type 
of new therapies and for nanotherapeutic approaches that have already investigated 






The targeting of CSCs might be achieved by four approaches: targeting component of 
the CSCs niche, targeting resistance mechanisms, inhibition of self-renewal signaling 
pathways and elimination therapy (2). The last one involve the eradication of CSCs 
based on specific characteristics of these cells for example the expression of specific 
molecules/antigens. In this context, the identification of new specific markers for these 
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In the past decade it became increasingly clear that tumor heterogeneity represents one 
of the major problems for cancer treatment, also in prostate cancer. The identification 
of the molecular properties of these highly aggressive cells (Cancer Stem Cells, CSCs) 
dispersed within the tumor represents a challenge for the identification of new efficient 
therapies. In most of the cases, current treatments are indeed successful in eradicating 
the primary tumor. However, the clinical evidence of relapse and the occurrence of 
therapy resistance, suggest the presence of subpopulation of cells within the tumor, 
that can survive such treatments and can perpetuate the cancer. 
In Chapter 1 we provide an overview of the general properties of cancer, with particular 
attention at the tumor heterogeneity. In this chapter we discuss the problem of prostate 
cancer and uncover specific aspects of tumor initiation and progression. The current 
diagnostic strategies are discussed and current therapeutic options for both localized 
and advanced disease are also addressed. Additionally we provide an overview about 
the molecular properties of prostate cancer stem cells and discuss the molecular 
pathways involved in prostate cancer progression and bone metastasis formation, with 
particular focus on the role of microRNAs (miR).  
In Chapter 2 we investigated the reciprocal established miR/gene interactions among 
the Notch, Wnt and TGF-β signaling pathways. With this approach, we identified a 
validated miR signature that is common to these three key signaling pathways in 
prostate cancer progression and bone metastasis formation. Our analysis support the 
cross-talk between TGF-β, Wnt and Notch signaling and their regulatory role during the 
process of epithelial to mesenchymal transition (EMT). 
In Chapter 3, miR-25 was identified as a key regulator of invasion and metastasis in 
human prostate cancer stem cells in vitro and in vivo. The expression of miR-25 steadily 
and consistently increases during epithelial differentiation in the human benign 
prostate hyperplasia (BPH) and prostate cancers. Forced miR-25 expression in the 
ALDHhigh subpopulation of highly tumorigenic and metastatic prostate cancer cells 
strongly reduced their invasive ability. Our research led to the identification of αv- and 
α6-integrins as direct target genes of miR-25. Furthermore, we found that forced miR-25 
overexpression in osteotropic human prostate cancer cells attenuated extravasation 
and subsequent metastatic colonization in vivo.  
In Chapter 4 we provide a follow-up study about the role of miR-25 in the maintenance 
of aggressive behaviour of prostate cancer cells. The acquisition of an invasive 
phenotype is key to cancer progression and characterized by enhanced motility and 
migration. In prostate cancer, a mesenchymal and migratory phenotype is induced by 





In addition, we identified DACT1 as a putative miR-25 target gene. DACT1 appears to 
modulate the reciprocal interaction of canonical and non-canonical WNT/PCP signaling 
that represents one of the key regulatory pathways involved in the acquisition and 
maintenance of a migratory phenotype. 
As previously discussed, one of the key signaling pathways involved in prostate cancer is 
the Notch signaling network. Notch signaling is a developmental pathway that has been 
shown to be involved in both prostate cancer initiation and progression, as well as in 
bone metastasis formation. 
In Chapter 5 we found that BMP9 supports the growth of prostate cancer and induces 
indirectly Notch signaling pathway activity. BMP9 expression correlates with poor 
prognosis and BMP9 signaling can be inhibited by administration of soluble chimeric 
protein (ALK1Fc), which is capable of retarding tumor growth in an orthotopic prostate 
cancer model in vivo.  
Together these findings suggest that ALK1Fc might represent an interesting molecule for 
prostate cancer treatment.  
Finally, in Chapter 6, Cripto and Grp78 have been identified as novel proteins that are 
involved in the formation of prostate cancer bone metastases. Knockdown of Cripto and 
Grp78 in human prostate cancer cells reduced extravasation of these cells when 
inoculated into the circulation of zebrafish embryos. Moreover, Cripto knock-down 
diminished bone metastasis formation in a preclinical mouse xenograft model. In line 
with these observations elevated Cripto expression was detected in clinical bone 
metastasis samples isolated from Castration Resistant Prostate Cancer (CRPC) patients. 
The results of this thesis are discussed in Chapter 7, where we evaluated and analysed 
the clinical relevance and the possible therapeutic opportunities of our findings. 
Collectively, the studies described in this thesis have increased our insights into the 
molecular properties of highly metastatic and tumorigenic ALDHhigh prostate cancer 
stem-like cells and provided new targets for possible diagnostic and therapeutic 
applications. 
  





De laatste jaren is duidelijk geworden, dat tumor heterogeniteit één van de grootste 
problemen vormt bij de behandeling tegen kanker, waaronder ook prostaatkanker. De 
huidige behandelingen zijn meestal succesvol in het vernietigen van de primaire tumor, 
echter terugkeer van de tumor en therapie resistentie zijn veelvoorkomende problemen. 
Deze klinische resultaten duiden op de aanwezigheid van een subpopulatie van cellen 
die de behandeling kunnen overleven en de tumor in stand kunnen houden. Deze zeer 
agressieve kankercellen, ook wel kanker stamcellen genoemd, liggen verspreid over het 
tumorweefsel en bemoeilijken de ontwikkeling van nieuwe efficiënte therapieën.  
Hoofdstuk 1 beschrijft de algemene kenmerken van prostaatkanker en het klinische 
probleem van de heterogeniteit. We bespreken de totstandkoming en progressie van de 
tumor en bespreken de huidige diagnostische strategieën en behandelopties voor 
prostaatkanker in een begin- en vergevorderd stadium. Bovendien wordt een overzicht 
gegeven van de moleculaire eigenschappen van prostaatkanker stamcellen. Daarnaast 
bespreken we de signaalroutes die betrokken zijn bij de progressie van prostaatkanker 
en uitzaaiingen (metastasen) naar het bot- en beenmerg, met daarbij specifieke 
aandacht voor microRNA’s (miRs).  
In hoofdstuk 2 is de wisselwerking tussen miRs en genen van de Notch, Wnt and TGF-β 
signaalroutes onderzocht. Hierbij hebben we een gemeenschappelijk signatuur van 
miRs geïdentificeerd die de progressie en metastasering van prostaatkanker 
beïnvloeden. Onze resultaten ondersteunen eerdere waarnemingen dat diverse 
interacties voorkomen tussen TGF-β, Wnt en Notch en tonen aan de mIRs een 
regulatoire rol vervullen in het verkrijgen van agressieve eigenschappen door het proces 
van een epitheliale naar een mesenchymale transitie (EMT).  
In hoofdstuk 3 is miR-25 geïdentificeerd als een belangrijke regulator van de invasie en 
metastasering van humane prostaatkanker stamcellen in vitro en in vivo. De expressie 
van miR-25 stijgt gestaag en consequent gedurende de epitheliale differentiatie van 
zowel niet-getransformeerde menselijke prostaatcellen (benigne prostaat hyperplasie, 
BPH) als prostaatkanker. Geforceerde miR-25 expressie in de ALDHhigh subpopulatie van 
agressieve prostaatkanker cellen resulteerde in sterk verminderde invasie. Ons 
onderzoek heeft geleid tot de identificatie van αv- en α6-integrines als directe doelwit 
genen van miR-25. Bovendien hebben we ontdekt dat overexpressie van miR-25 door 
humane prostaatkanker cellen de uittreding uit bloedvaten (extravasatie) en 
opeenvolgende metastasering sterkt remt in een intact organisme. 
In hoofdstuk 4 hebben we de rol van miR-25 bij het in standhouden van het agressieve 
gedrag van prostaatkanker cellen verder onderzocht. Het verkrijgen van agressieve 





karakteristieken en essentieel voor kanker progressie (uitzaaiing). Bij prostaatkanker 
kan dit proces (epitheliale-mesenchymale transitie of EMT) geïnduceerd worden door 
TGF-β. Onze bevindingen laten zien dat overexpressie van miR-25 de migratie, die 
geïnduceerd wordt door TGF-β, kan opheffen. Daarnaast hebben we vastgesteld dat 
DACT1 als doelwitgen fungeert van miR-25. DACT1 moduleert de wisselwerking tussen 
twee belangrijke manieren waarop wnt signalering plaatsvindt, t.w. “canonical” vs 
“non-canonical” wnt signalering, en speelt een belangrijke rol bij het verkrijgen van 
migratoire eigenschappen via “non-canocical” wnt signalering.  
De Notch signaleringsroute is in hoge mate betrokken bij de initiatie, progressie en 
metastasering van prostaatkanker. 
In hoofdstuk 5 laten we zien, dat BMP9 de groei van prostaatkanker stimuleert en 
indirect de Notch signalering induceert. BMP9 expressie correleert met een slechte 
prognose en kan geremd worden door het oplosbaar chimeer eiwit ALK1Fc (bindt en 
vangt BMP9 weg) dat de tumorgroei kan vertragen in een orthotoop prostaatkanker 
model in vivo. Deze resultaten laten zien dat ALK1Fc een potentieel interessant 
molecuul is voor de behandeling van prostaatkanker. 
In hoofdstuk 6 wordt het onderzoek beschreven over de rol van de signaaltransductie 
eiwitten Cripto en Grp78 bij invasief gedrag en skeletmetastasering van prostaatkanker. 
Knockdown van Cripto en Grp78 in humane prostaakanker cellen remt de uittreding 
(extravasatie) van tumorcellen na inoculatie in de bloedcirculatie van zebravissen. 
Bovendien resulteerde Cripto knockdown in verminderde botmetastasering in een 
model van botmetastasering in vivo (muis xenograft model). Onze bevindingen worden 
verder ondersteund, omdat Cripto verhoogd tot expressie komt in botmetastasen bij 
patiënten met gevorderd, castratie resistent prostaatkanker (bestaande klinische mRNA 
gegevensbestanden).  
De onderzoeksresultaten, de mogelijke klinische relevantie en therapeutische 
implicaties worden besproken in hoofdstuk 7. De onderzoeksresultaten, die beschreven 
zijn in dit proefschrift, hebben ons een beter inzicht gegeven in de moleculaire 
eigenschappen die ten grondslag liggen aan het agressieve gedrag van prostaatkanker 
stam/progenitor cellen en hebben bovendien geleid tot identificatie van potentiële 
nieuwe doelwitgenen voor diagnostische en therapeutische toepassingen. 
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